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Abstract 
Chronic lymphocytic leukaemia (CLL) cells are derived from mature B lymphocytes 
and are distinctive with respect to overexpression of the classical protein kinase C 
isoform protein kinase CβII (PKCβII), which is encoded by PRKCB. Expression of 
PKCII in CLL plays a vital role in the pathogenesis of the malignant cells in this 
disease, and within the microenvironment cells where it provides signals for the 
production of factors which support the survival of CLL cells. In CLL cells PRKCB 
transcription is stimulated by vascular endothelial growth factor (VEGF) through a 
mechanism involving activated PKCII. However, at the beginning of this thesis the 
molecular regulatory mechanism(s) governing expression of the PKC gene were 
poorly described. Thus, to characterise the factors regulating PRKCB transcription in 
CLL cells I used different approaches including mithramycin treatment, a drug which 
intercalates into GC-rich areas of DNA to inhibit binding of specificity protein 1 
(Sp1), specific Sp1 siRNA, promoter function assays and site directed mutagenesis 
and chromatin immunoprecipitation (ChIP). Experiments using these techniques 
showed that Sp1 has a direct role in driving expression of the gene coding for PKCβII 
in CLL cells. My results also show that Sp1 is highly associated with the PRKCB 
promoter in CLL cells compared to that in normal B cells, and suggest that this is 
likely because of the presence of histone marks permissive of gene activation. 
Examination of other transcription factors such as Sp3, MITF, RUNX1 and E2F1 that 
potentially bind the PRKCB promoter showed that they have static or indirect 
effects in regulating transcription of this gene. The exception to this is STAT3 which 
my data suggests plays a role in suppressing PKC gene expression in CLL cells. 
Exploration of the mechanism through which VEGF induces PRKCB transcription 
revealed that this growth factor stimulates increased association of Sp1 and 
decreased association of STAT3 with the PRKCB promoter. Thus, VEGF-stimulated 
activation of PKCII may play a role in this process. Taken together, Sp1 is the major 
driver for overexpression of PKCβII in CLL cells, and because this transcription factor 
is also overexpressed in these cells, the mechanisms I describe controlling PRKCB 
transcription potentially provide a foundation for further study of other genes 
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contributing to the phenotype of CLL cells that are regulated by this pleiotropic 
transcription factor. 
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 Chapter One: General Introduction 
1.1 Overview and aim of the study 
Protein kinase C II (PKCβII) overexpression is a distinctive feature of the malignant 
cells in chronic lymphocytic leukaemia (CLL) where it plays an important role in 
modulating B cell receptor (BCR) signalling [1], a key contributor to the 
pathogenesis of this disease [2]. Importantly, disruption of the gene coding for 
PKCII, PRKCB, in a mouse model of CLL suppresses development of the disease [3], 
suggesting that PKCII is also key to the pathogenesis of this malignancy. Therefore, 
understanding the mechanisms controlling (over)expression of the PKC gene may 
provide insight into the regulation of other genes important in the pathogenesis of 
CLL. Previous studies have been performed to investigate the control of PRKCB 
transcription, and have identified different transcription factors involved in this 
process [4-8].  However, at the beginning of this thesis the principle driver of PRKCB 
transcription was unknown, and how this transcription factor was regulated was 
undescribed. Thus, the main aims of this thesis are focused on identification of the 
principle driver(s) of PKC gene expression, and on understanding how these 
driver(s) are regulated in CLL cells. Chapter 3 of this thesis identifies a key role for 
Sp1 in regulating PRKCB transcription in CLL cells. In Chapter 4 I investigate the roles 
of other transcription factors, and find that they largely play minor or indirect roles 
in regulating expression of this gene. STAT3 is an exception, and my data show that 
it plays a major role in suppressing transcription of PRKCB. Chapter 5 explores the 
role of epigenetics in modulating PKCβ gene expression, and I show that high levels 
of PKCII expression are likely due to changes in chromatin landscape rather than 
gene methylation. Finally, Chapter 6 investigates the role of cell extrinsic factors, 
and I show that CLL cell stimulation with VEGF results in suppressed STAT3 and 
increased Sp1 binding to the promoter region of PRKCB. Taken together, the results 
I present in this thesis define a mechanism resulting in PKC gene overexpression in 
CLL cells, and are important to our understanding of cancer because this gene is 
found overexpressed in both the malignant and stromal support cells of other 
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neoplastic diseases. Furthermore, these results provide greater insight into the 
pathophysiology of CLL cells, and a strong foundation for further study of the 
mechanisms governing overexpression of other genes important for the phenotype 
of these malignant cells.  
1.2 Regulatory mechanisms of gene expression 
The genome is ultimately the key organizer for all cellular functions, and is largely 
responsible for regulating the distinctive phenotypic features of cells during their 
development and differentiation. Consequently, precise regulatory mechanisms, 
controlled by the genome, are in place at transcriptional, post-transcriptional, 
translational, and post-translational levels (Figure 1.1). 
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Figure 1.1: Regulatory mechanisms of gene expression. This diagram, adapted 
from Banks et al. 2000[9], illustrates the different regulatory levels of gene 
expression in cells (labelled in red font). The text enclosed by boxes indicates the 
processes that are majorly affected by epigenetic factors.  
      
 At the transcriptional level, numerous different mechanisms control both the rate 
of transcription as well as the time at which certain genes are transcribed. Initially, 
binding of transcription factors, known as trans-regulators, to specific consensus 
sequences within the regulatory region of DNA preceding a gene, known as the cis-
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regulator, is required to recruit the machinery required for transcription to begin 
[10]. The specificity of this interaction is crucial to this regulatory step, allowing 
expression of particular genes at particular times. For example, transcription factors 
involved in promoting cell mitogenesis induce expression of genes involved in this 
process only when the cell begins to replicate itself. Furthermore, the 
transcriptional control regions of many eukaryotic genes are known to harbour 
multiple enhancer or repressor elements, which, when bound by appropriate 
transcription factors, are able to regulate the rate of transcription to give fine 
control over high expression of particular genes as the need arises [11-13]. Finally, 
further complication and diversity is added because some genes have alternative 
promoters which regulate expression either in response to different cellular stimuli, 
or lead to initiation from different transcriptional start sites located either in the 
core promoter region or in the intronic regions of the gene [14, 15].   
     Gene expression is also regulated through a number of epigenetic mechanisms. 
Epigenetics is an umbrella term referring to heritable reversible changes that do not 
affect the DNA sequence of genes but nevertheless influence cellular phenotype in 
normal and diseased tissues diseases [16]. These mechanisms include DNA 
methylation [17], histone modification leading to changes in chromatin landscape 
[18], alternative splicing of RNA transcripts [19], and non-coding RNA species such 
as miRNA [20] (Figure 1.2). 
 
 4 
 
G
C
C G T A C T G C3` 5`
G C A T G A C G5` 3`
M M M
M
DNA MethylationA)
MM
mRNA
miRNA
mRNA translationmRNA degradation
miRNAD)
3’ 5’
5’
3’
Isoform A Isoform B
Alternative splicing 
Pre-mRNA 
mRNA 
Alternative splicing of RNA transcriptC)
Exon1
Exon1
Exon2
Exon2
Exon3
Exon4 Exon1
Exon4
Exon3 Exon4
Phosphorylation:            Acetylation:           Methylation:           Ubiquitination:
Posttranslational modifications of histones    B)
 
Figure 1.2: Epigenetic regulatory mechanisms for gene expression. This figure 
represents the epigenetic mechanisms that regulate gene expression at different 
levels of this process. A) DNA methylation. Methylation of the cytosine residues of 
the CpG islands within the promoter or gene body region causes silencing or 
activation of transcription. B) Posttranslational modifications of histone. Modifying 
the histone protein tails by acetylation (red star), methylation (blue pentacle), 
phosphorylation (yellow triangle), or mono ubiquitin (Purple small round circle) 
leads to alterations in chromatin structure. C) Alternative splicing of the initial RNA 
transcripts (pre-mRNA) results in various protein isoforms from the same gene but 
which may have different functions. D) miRNAs seed sequences recognize full 
complementary sequences within the target mRNA, which results in binding of both 
RNA species, and consequently gene silencing occurring by either blocking mRNA 
translation or by leading to mRNA degradation by miRNA-induced silencing complex 
(miRISC).     
 
     DNA methylation is a process whereby methyl groups are added to carbon #5 
within cytosine residues by methyltransferases. DNA methylation can act to silence 
or facilitate gene expression depending on the location of methylation. For 
instance, methylation of CpG islands within a promoter region results in gene 
silencing because transcription factor binding may be prevented, or because 
chromatin silencing complexes are recruited [21]. Alternatively, DNA methylation 
within the body of a gene can result in transcriptional activation because 
transcription factor binding to repressor elements is blocked [22, 23]. DNA 
methylation is a process that occurs naturally during cell development and helps to 
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maintain cell commitment to its overall phenotypic fate [24]. However, this process 
often becomes deregulated in cancer cells allowing phenotypic change away from 
that of its normal counterpart, and, in many types of cancer, DNA methylation is 
used as a biomarker to identify patients with progressive disease [25-27]. That DNA 
methylation changes in cancerous cells compared to their normal counterpart is 
because expression of the genes coding for and/or activity of the 
methyltransferases and demethylases that control this process becomes 
deregulated in these cells [28-30]. Importantly, DNA methylation cooperates with 
other epigenetic mechanisms, such as those involved in histone modification, to 
regulate chromatin structure [31, 32].  
     Histone proteins play an important role in regulating gene expression because they 
control the basic structure of DNA, condensing this linear molecule into chromatin 
so that it is able to fit inside the nucleus of a cell. Chromatin is comprised of basic 
structural units known as nucleosomes, each consisting of approximately 147bp of 
DNA wrapped around a core octamer histone complex of 2 each of H4, H3, H2A and 
H2B histone proteins. Nucleosome units are 10nm in diameter, and are arranged on 
the DNA fiber in a structure known as “beads on a string” where each nucleosome 
is separated from the other with a 10-80bp DNA linker.  Nucleosomes are further 
arranged around histone core H1 linkers that allow the condensation of helical 
chromatin into 30nm diameter structures. Further folding of these structures allows 
the formation of larger aggregates that are 300nm in diameter and result in overall 
chromosome structure [33]. The degree to which chromatin structure is condensed 
regulates gene expression. Thus, within the nucleus of a cell transcriptionally active 
regions of the genome (euchromatin) segregates from transcriptionally silent 
(heterochromatin) regions [34].  
     DNA wraps around the core octamer histone complex through interactions 
between the chargeable tails of histone proteins and phospho-groups in the DNA 
backbone. The chargeable tails of histone proteins can be post-translationally 
modified by acetylation, phosphorylation, sumoylation, ubiquitination, and 
methylation. These changes alter the charge associated with the histone tail, which, 
in turn, changes the interaction of the core octamer histone complex with DNA 
 6 
 
forcing either winding or unwinding of the beads on a string structure. Ultimately, 
overall chromatin structure is changed to either allow or disallow accessibility of 
transcription factors to gene regulatory regions. Histone post-translational 
modification is carried out by chromatin-remodelling enzymes, which are divided 
into three types depending on their function. Writers are enzymes that function to 
add chemical groups or small proteins such as mono ubiquitin and SUMO (all known 
as histone marks) to the amino acid residues in histone tails. Writers include 
enzymes such as methyl- /acetyltransfearases, enzymes involved in 
ubiquitination/sumoylation and kinases. Erasers are enzymes that function to 
remove histone marks, and include proteins such as demethylases, deacetylases, 
deubiquitinases and phosphatases. Readers are the third type of chromatin-
remodelling enzyme, and are not really enzymes at all. Readers function to recruit 
further proteins whose role is to energize the process of change in chromatin 
structure [18, 35, 36]. All post-translational modifications of histones are 
considered as simple modifications because they usually involve the addition of a 
single chemical group or small proteins to such as mono ubiquitin and SUMO to an 
amino acid residue within the histone tail. The exception to this is methylation, 
where lysine and arginine residues within histone tails can be  multiply methylated 
[37]. Chromatin-remodelling enzymes act as either activators or repressors of 
transcription, depending on the modifications they make to histone proteins, and 
on both the location and extent of these modifications relative to the gene regions 
[37]. Furthermore, the gene activator/repressor function of chromatin-remodelling 
enzymes operates within a cell-specific context [38]. For instance, within particular 
cells methylation of H3K9/H3K27 within core octamer histone complexes 
associated with DNA of gene promoter regions are markers for heterochromatin, 
whilst in other cells methylation of H3K4 in the same regions is a marker of 
euchromatin [37].  
     For the purpose of this thesis I will focus on the role of histone acetylation in 
influencing chromatin structure. Acetylation is an active reversible type of lysine 
residue modification, and affects histone and non-histone proteins [39]. This 
chemical modification is catalysed by histone acetyltransferases (HATs) which 
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transfer acetyl groups from acetyl-CoA to lysine residues of target proteins. In 
contrast, histone deacetylases (HDACs) reverse this modification and catalyse the 
removal of acetyl groups from the lysines of target proteins (Figure 1.3). The 
acetylation of histones is not exclusive for any particular lysine residue within the 
chargeable tail, and there is no consistent pattern in terms of position or extent. 
The role of acetylation is to neutralize the positive charge associated with the 
histone tails which consequently weakens the binding between histones and DNA 
to ultimately result in relaxing the chromatin structure so that it is open and  
permissive of transcription [40]. Histone acetylation often occurs with other 
modifications, either within the same histone tail, or between different histone tails 
within the core octamer histone complex [41]. For example, acetylation of H3K9/14 
is linked to methylation of H3K4, both of which are marks of euchromatin [42].   
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Figure 1.3: Histone acetylation/deacetylation which alters chromatin structure 
and regulates transcription is catalysed by HATs and HDACs enzymes. 
      
The next epigenetic phenomenon affects the transcribed product of gene 
expression. Genes are transcribed directly from DNA into pre-mRNA which includes 
gene intron and exon sequences. This pre-mRNA is then subjected to splicing 
whereby intron sequences are removed from exon sequences in order to produce 
the final mRNA from which the amino acid sequences of proteins are translated. 
However, in certain genes the way in which exons are spliced together can lead to 
the expression of different isoforms of the same protein from a single gene [19, 43]. 
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For example, the gene coding for PKC, PRKCB, can be differentially spliced to yield 
two isoforms; PKCI and PKCII [44]. These protein isoforms can have differential 
functions within the cell; PKCI is described to phosphorylate Bruton’s tyrosine 
kinase in monocytic cell lines [45], whereas PKCII is reported to phosphorylate 
p66shc [46].  
The process of translation of the final mRNA can be regulated by a class of non-
coding RNAs known as miRNA. miRNAs are short 21-25bp sequences which have a 
complementary sequence to the target mRNA species. Binding of miRNA to their 
cognate mRNA species leads to either blocked translation, or facilitated destruction 
through an ancient process which activates miRNA-induced silencing complex 
(miRSIC) complexes [20, 47]. Certain miRNA species are able to feedback to 
chromatin remodelling enzymes or to transcription factors themselves, thereby 
indirectly affecting transcription of genes in a specific cellular context [48].  
     The final step of regulation occurs at the post-translational level. This mainly leads 
to modifications in the structure of the end protein product, which can lead to a 
change in protein stability, its functional activity, and its ability to interact with 
other proteins [49].  
1.3 Chronic lymphocytic leukaemia (CLL) 
Chronic lymphocytic leukaemia (CLL) is a type of mature B neoplasm, where the 
malignant cells in this disease accumulate in the bone marrow as well as in the 
peripheral blood and lymphatic tissues [50]. This disease is the most common form 
of leukaemia affecting adults in America and Europe, and in the UK nearly 34% of all 
haematological cancers are CLL [51, 52]. The incidence of CLL is highest in people 
over the age of 65 years old [53], and favours males over females at a ratio of 2:1 
[54]. The aetiology of CLL remains unclear; however studies have identified risk 
factors contributing to the development of this disease. Genetic familial studies 
have suggested the risk of developing CLL is higher in persons who are the first 
degree relatives of CLL patients [55], or who have a family history of leukaemia and 
lymphoma [56, 57]. In addition, environmental work factors such as benzene or 
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pesticide use respectively in industry workers [58] and farmers have also been 
identified as potential risk factors [59]. Finally, the incidence of CLL is higher in 
people who have experienced multiple episodes of respiratory infection [60]. 
Phenotypically the malignant cells of CLL are distinguished from those of other 
types of leukaemia by their expression of the cell surface markers CD19, CD5, CD23, 
coupled with weak expression of CD20 and the surface immunoglobulins (Ig) IgM 
and IgD. Early studies using gene expression profiling have shown that CLL is distinct 
from other types of B cell malignancies, and that the phenotype of CLL cells is more 
closely related to memory than to naïve B cells [61, 62] . More recently, a study by 
Seifert et al. has shown the gene expression profile of CLL cells resembles that of 
normal CD5+ B cells in humans [63]. This latter description provides a solution to a 
long standing problem regarding the origin of CLL cells [64], and also provides some 
insight into the relationship between CLL and a clinical condition known as 
monoclonal B lymphocytosis (MBL).  Like CLL, the cells associated with MBL develop 
from CD5+ B cells and have similar genetic aberrations such as 13q14 deletion and 
trisomy 12, but do not have 17p or 11q deletions. The frequency of these cells 
increases with age, and are higher in elderly men than women, and in persons who 
have a familial history of CLL. In many ways CD5/CD23 positive MBL cells are similar 
to the malignant cells associated with the clinically indolent subtype of CLL. This 
similarity is important because it suggests that MBL cells may be a good model to 
study the transformational events that lead to CLL [65].  Here it is important to note 
that only a small proportion of patients with MBL develop CLL [66, 67]. 
B lymphocytes are part of the adaptive immune system in the body where they 
mediate humoral immunity against various foreigner invaders. The development of 
B cells begins during embryogenesis from a multipotent lineage of progenitor cells 
which divide to yield undifferentiated cells with self-renewal capacity known as 
haematopoietic stem cells (HSCs) [68]. Initially, the precursor cells of HSCs derive 
from the mesoderm of the embryo, and during embryogenesis differentiate to HSCs 
and migrate to the aorta-gonad-mesonephros region (AMG). The blood forming 
cells then migrate to the placenta, and finally to the fetal liver, thymus, omentum, 
 10 
 
and bone marrow during the late stages of fetal development. After birth, 
haematopoiesis, including B cell development, takes place in the bone marrow [69].  
The first stage of B cell development starts when HSC differentiate into common 
lymphoid progenitor cells (CLP) and requires the expression of the transcription 
factors Ikaros, fms-like tyrosine kinase 3 (FLT3) and low levels of PU.1. CLP cells 
then have the ability to further differentiate into natural killer cells, dendritic cells, 
B, or T lymphocytes depending on the expression of certain transcription factors 
and stimulatory factors (e.g. cytokines) received from surrounding stromal cells. 
CLP cells develop into precursor B cells (pro-B) when they activate the expression of 
genes (TdT and RAG) involved in immunoglobulin production. TdT and RAG are 
under the control of the transcription factors E2A, early B-cell Factor (EBF), and 
paired box protein (PAX5), which are important in carrying the development of CLP 
to pro-B cell and then the latter Pre-B cell stages. The pro-B cell stage is divided into 
two sub-stages, early pro-B stage is where the first Ig loci of the heavy chain, known 
as DH (diversity) and JH (joining) are joined, followed by the late pro-B cell stage 
where DH-JH segments are joined to VH (variable) gene segments. Late pro-B cells 
express accessory proteins for BCR proteins Igα and Igβ on their surface supported 
with chaperon protein, Calnexin. The pre-B cell stage proceeds causing VDJ 
segments rearrangement and results in the expression of heavy chains joined with 
surrogate light chains composed of VpreB and Vλ5 comprises the pre-BCR receptor. 
At the end of the pre-B cell stage joining of the VL and JL segments of the λ and κ 
light chain loci takes place which allows differentiation to immature B cells. During 
the immature B cell stage the rearrangement of VL segments occurs and results in 
the formation of a mature BCR receptor that able to act as immunological 
checkpoint (Negative selection) [70, 71]. The Ig gene rearrangements that take 
place to produce mature BCR on B cells result in a diverse repertoire of B cells with 
the ability to recognize different antigens. Clones which show strong self-reactivity 
are negatively selected by apoptosis, and those that show weak self-reactivity 
become anergic whereby the BCR no longer responds to antigen stimulation. The B 
cell clones which do not show any form of self-reactivity are able to migrate from 
the bone marrow environment as naïve B cells [71].  
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The next stage of B cell development continues mainly in secondary lymphoid 
organs such as the spleen and lymph nodes. Here B cells are exposed to foreign 
antigen. Those B cells that experience strong antigen stimulation subsequently pass 
through a gene rearrangement phase whereby Ig heavy chain sequences can be 
switched from IgM/IgD to IgG, IgE, or IgA, and through a stage involving somatic 
hypermutation of the antigen binding regions [71]. This latter process allows 
increased antigen binding affinity and antibody avidity and is known as affinity 
maturation. The end point of these processes is the development of antibody-
producing plasma cells, or retention of immunological memory by differentiation of 
mature B cells into memory B cells. Two other types of B cells that can develop are 
marginal zone (MZ) and peritoneal (B-1) B cells. The former develop in the spleen 
while the latter develop in the peritoneum, and result from B cells which 
experience weak antigen stimulation [72]. Here it is important to note that B-1 cells 
also develop during embryogenesis and are present at birth. Both MZ and B-1 cells 
only differentiate into plasma cells, and are largely responsible for innate antibody 
production [70, 73, 74] (Figure 1.4). 
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Figure 1.4: Stages of normal B cell development. (adapted from pieper et al., [74] 
and cambier et al., 2007, [75]). 
 
The multiple rearrangements of Ig genes that take place during B cell development 
make these cells susceptible to genetic abnormalities such as chromosomal 
translocations resulting in expression of protein chimaeras which may lead to 
malignant cell transformation [76]. Additionally, misdirected somatic mutation can 
lead to critical deletions as well as epigenetic alterations [77]. In the first instance, a 
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number of chromosomal translocations have been identified and linked to specific 
types of leukaemia (when these translocations occur in the bone marrow) or 
lymphoma (when these translocations occur in the spleen or lymph node) [78]. 
Particular point mutations are also known to lead to the development of 
lymphoma. For example, in diffuse large B cell lymphoma a mutation within CD79a 
can lead to constitutive BCR signalling and malignant transformation [79]. However, 
with respect to CLL cells it seems that neither of these genetic abnormalities is 
responsible for neoplastic transformation. The frequency of chromosomal 
translocation in patients with CLL is very rare [80]. Certain subsets of CLL patients 
have malignant cells with chromosomal deletions occurring at 17p, 11q, or 13q as 
well as other genetic aberrations (Table 1.1), and mutations within genes coding for 
p53, NOTCH1, splice factor3B1 (SF3B1), myeloid differentiation primary response 
protein 88 (MYD88) and  nuclear export protein (XPO1) [81-83]. However, these 
chromosomal deletions/gene mutations are only linked to disease 
prognosis/progression and are not causative of the disease. For example, deletions 
at 17p and 11q are typically associated with poor disease prognosis in CLL (Table 
1.1) [81, 84, 85]. Therefore, the key genetic events that lead to CLL development 
remain undefined. 
Table 1.1: Percentage (incidence), overall survival time and genes linked to 
genetic aberrations in chronic lymphocytic leukaemia patients [81, 84]. 
Genetic aberration Percentage (%) Overall survival 
time (years) 
Linked genes  
13q deletion only 55 11 miRNA 15a/16 
11q deletion 18 7 ATM 
17p deletion 7 2.5 TP53 
12q Trisomy 16 10 unknown 
Normal karyotype 18 10 None 
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Clinically CLL patients can be divided into two subsets. Patients who show no 
symptoms or disease progression are described as having indolent disease and have 
a median survival time of 20 years. In contrast, the second subset of patients show 
rapid progression as well as suppressed bone marrow and immune function, and 
have a median survival time of 7 years despite receiving intensive therapy [86, 87]. 
The first clinical systems devised to differentiate between these subsets of CLL 
disease were stablished by Rai [88] and Binet [89] (Table 1.2). These systems staged 
the extent of disease and related this to patient survival, but have limited 
application because when CLL is detected at an early stage it is impossible to know 
whether the patient has indolent or progressive disease [90, 91].  
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Table 1.2: CLL classification and survival time according to Rai and Binet staging 
system[92]. 
System Staging and risk Definition Survival time 
(Years) 
Rai System 
 0 (Low risk) Lymphocytosis only >10.0 
 I (Intermediate risk) Lymphocytosis and 
lymphadenopathy 
9.0 
 II (Intermediate risk) Lymphocytosis in blood 
and bone marrow with 
splenomegaly/or 
hepatomegaly 
(with/without 
lymphadenopathy) 
 
7.0 
 III (high risk) Lymphocytosis and 
anaemia 
5.0 
 IV(high risk) Lymphocytosis and 
thrombocytopenia 
5.0 
Binet system 
 A (Low) Enlargement lymphoid 
area of <3 (cervical, 
axillary, inguinal, spleen, 
liver) 
>10.0 
 B (Intermediate) Enlargement lymphoid 
area of >3 
7.0 
 C (High) Anaemia or 
thrombocytopenia 
5.0 
 
There have been many attempts at distinguishing indolent from progressive disease 
in CLL, and to this effect prognostic biomarkers such expression of zeta-chain 
associated protein kinase 70 (ZAP-70), CD38 and CD23, serum β2-microglobulin and 
thymidine kinase levels have all been related to disease prognosis [93]. However, 
none of these biomarkers give information regarding the factors which drive 
development/progression of the disease. With respect to this latter point, in 1999 
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somatic mutation of the immunoglobulin heavy chain variable region gene (IgVH) 
was discovered to relate to CLL disease prognosis by two different groups [86]. 
Thus, patients where IgVH sequences remained similar to germ line sequences were 
termed as unmutated CLL (UM-CLL), whilst those who had IgVH sequences with 
significant deviation from germ line sequences were termed mutated or M-CLL [80]. 
Importantly, patients with UM-CLL disease had poorer disease prognosis than 
patients with M-CLL disease. The reason why this discovery is important to our 
understanding of CLL is because it led to insights regarding the role of the BCR in 
driving disease progression in CLL [94]. Thus, in-vivo BCR engagement is thought to 
drive proliferation and survival of the malignant clone in CLL, and this paradigm has 
recently been exploited for the therapy of CLL. Two new drugs, ibrutinib and 
idelalisib, which respectively target Bruton’s tyrosine kinase (Btk) and 
phosphatidylinositol 3-kinase  (PI3K) are now approved for clinical application in 
the treatment of CLL [95-97].  
Figure 1.5 illustrates the BCR pathway and shows a key role for PKC in potentiating 
signalling within this pathway. Importantly, targeted deletion of the gene coding for 
PKC does not affect adaptive immunity, rather the B cells responsible for innate 
antibody production (MZ and B-1 cells) are missing [98]. This suggests that PKC 
plays a role in fine modulation of the BCR signalling pathway, a notion that is 
supported by work in this Department showing that transgenic overexpression of 
PKCII leads to favoured development of MZ and B-1 cells in mice [99]. With 
respect to CLL, work from this Department has shown that CLL cells overexpress 
PKCII and that it affects BCR signalling strength when it is active [1]. Furthermore, 
work by others using a mouse model of CLL where transgenic expression of the 
gene product of TCL1 results in the development of a CLL-like disease shows that 
this does not happen in mice where PKC expression is knocked out [3]. Taken 
together, these observations justify a need to investigate the mechanisms 
regulating PKCII overexpression in CLL. 
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Figure 1.5: BCR signalling pathway and structure of BCR receptor. A) Antigen 
engagement triggers phosphorylation of the tyrosine residues within the ITAM 
(immunomodulatory tyrosine activation motifs) of CD79a/b by Lyn. This attracts Syk 
which phosphorylates BLNK and BCAP, the latter of which attracts and activates 
PI3Kδ. Generation of phosphatidylinositol trisphosphate at the plasma membrane 
attracts Btk and phospholipase Cγ2 (PLCγ2), which when bound to BLNK, are 
subsequently phosphorylated by Syk. This activates Btk, which, in turn, 
phosphorylates and activates PLCγ2 leading to the generation of diacylglycerol 
(DAG) and intracellular Ca2+ release (through the production of inositol 
trisphosphate). DAG and Ca2+ activate PKCβ which then acts to augment MAPK 
activation, stimulate NFκB and JNK pathway activation, and downregulate BCR 
signalling by phosphorylating Btk (not shown) and inducing its relocation away from 
the plasma membrane. (adapted from Slupsky, J.R., 2014[100]). B) Structure of BCR 
receptor. (adapted from Gold, 2002 [101]). 
 
1.4 Protein kinase Cβ  
1.4.1 Protein kinase C (PKC) family overview 
Protein kinase C (PKC)s are a family of serine/threonine kinases [102, 103] that 
were initially described in extracts of rodent brain [104-106]. Further work after this 
initial discovery showed that this family of protein kinases is comprised of 11 
isoforms which are distributed into three subgroups depending on their structure 
and activation requirement factors: Classical / conventional PKC isozymes include 
PKCα, PKCγ, PKCβI and PKCβII and are activated by the presence of diacylglycerol 
(DAG), Ca2+ and phosphatidylserine (PS) [107]. Novel PKC isozymes include PKCδ, 
PKCε, PKCη, and PKCθ which are activated by the presence of DAG [108]. Atypical 
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PKC isozymes include PKCι, PKCζ, and PKCλ and activation of these kinases is both 
DAG and Ca2+ independent [109, 110].  
The PKC family of proteins is structurally conserved within eukaryotic organisms, 
and belong to a larger super family of protein kinases known as ABC (for protein 
kinase A, protein kinase B and protein kinase C) kinases [111]. These proteins all 
require phosphorylation of critical serine/threonine residues within a conserved 
domain known as the activation loop [111]. PKCs are composed of two main 
domains, the catalytic domain located in the C-terminus of the protein, and the 
regulatory domain located in the N-terminus. Each of these domains is further 
divided into functional regions. Within the catalytic domain there is the C3 region 
which is responsible for ATP binding, and the C4 region which contains the 
activation loop and is responsible for substrate binding [107, 111]. The regulatory 
domain contains the regions responsible for controlling activity; classical isoforms 
contain regions for binding DAG and Ca2+ whereas novel isoforms contain only a 
region for binding DAG [107, 111]. In contrast, atypical isoforms have neither of 
these DAG/Ca2+ binding domains. Importantly, the regulatory domain of all PKC 
isozymes contains a pseudosubstrate which acts to bind the catalytic domain and 
restrict its access to phosphorylation targets. Thus, upon binding of regulatory 
factors, such as DAG and Ca2+, a structural change occurs in the regulatory domain 
that disengages the pseudosubstrate from the catalytic domain to allow it to hinge 
away and gain ability to recognise and phosphorylate target sequences [106, 110, 
111] (Figure 1.6). 
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Figure 1.6: Schematic representation of PKC isoforms structure and their 
activation cofactors (adapted from Newton 2010[111] and Cosentino-Gomes et al., 
2012[112]). The catalytic domain contains conserved regions for ATP (C3) and 
substrate binding (C4). In particular, the C4 region contains the activation loop 
which requires phosphorylation of conserved T/S residues for full kinase activity 
(enclosed box). The regulatory domain of PKC contains regions required for 
DAG/membrane association (C1A and C1B) and Ca2+ binding (C2 region in classical 
isoforms). The variable regions (V1-V5) connect the conserved regions of PKC. The 
hinge V3 region allows protein folding so that the pseudosubstrate region (PS) 
interacts with the catalytic domain to block kinase activity. When PKCs come into 
contact with their agonists, structural changes within the regulatory domain force 
the PS away from the catalytic domain so that the active kinase is free to 
phosphorylate its target substrates.  
 
PKC isoforms phosphorylate a wide variety of protein substrates within cells, and 
are involved in an array of cellular processes such as proliferation [113, 114] and 
differentiation [115], cell-death [114], regulation of gene expression [116], 
mediating intracellular signalling related to the immune response [117, 118], cell-
cell adhesion and  migration [110, 119, 120]. Remarkably, only one PKC isozyme, 
PKC, is important for embryogenesis [121].Targeted disruption in expression of 
the other isozymes in mice show mild effects on phenotype. Disruption of PKC 
leads to hypercontractility of cardiac tissue [122] whereas disruption of PKC 
affects the development of MZ and B-1 B cells [98]. Knockout of PKC expression 
results in the development of a lupus like syndrome because B cells are able to 
emerge from anergy [123], whereas knockout of PKC alters macrophage 
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functioning due to defects in early stage response to lipopolysaccharide [124]. 
Finally, disruption of PKC leads to defects in the development of Peyer’s patches 
and spleen because of the role it plays in the NFB pathway [125]. The mild 
phenotypes observed associated with mice having disruption of PKC isozymes 
suggest functional redundancy. However, PKC isoforms show specificity with 
respect to certain functions in particular contexts: PKCδ is key in cellular senescence 
[126],PKC  is involved in artery constriction of the lung [127], and PKCβ plays a key 
role in mediating Toll-like receptor (TLRs) and BCR signalling in B cells [128, 129]. 
These functions depend on their cellular localization [111], their expression levels in 
certain cell contexts [111], the nature of the cellular stimuli and the nature of the 
substrate downstream of the activated isoform [111, 130].  
1.4.2 Expression and functional role of PKCβ in CLL cells and other 
types of cancer cells 
CLL cells express a unique profile of PKC isoforms, which likely plays a role in the 
pathogenesis of this disease. For example, CLL cells show low expression of PKC, 
and this may lead to increased tumourgenicity because of a recent demonstration 
showing that disruption of PKC function facilitates the development of a CLL-like 
disease within an in-vitro model of B cell differentiation [131]. Furthermore, 
inhibition of PKC with rottlerin results in CLL cell death possibly by affecting the 
expression of pro-survival proteins such as Mcl-1 and XIAP [132, 133]. Finally, work 
from this Department regarding the expression profile of PKCs in CLL cells showed 
that PKCβII is overexpressed in these cells, and that this overexpression could 
distinguish CLL cells from other types of haematological tumour cell [1]. 
PKCβII is a key mediator of BCR signalling in B cells as illustrated in figure 1.5. 
Overexpression of PKCβII in CLL cells is reported to enhance the survival of these 
cells by acting to phosphorylate S473 within protein kinase B (Akt) leading to 
increased expression of Mcl-1 [134] and other anti-apoptotic proteins [135]. In 
addition, PKCβII can translocate to the mitochondrial membrane where it mediates 
phosphorylation of Bcl-2 at S70 to allow sequestration of Bim [136]. This same 
report also showed that PKCII catalysed increased degradation of BimEL by 
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targeting it for proteasomal degradation [136] (Figure 1.7). That PKCII is highly 
expressed in CLL cells has therapeutic consequences because depletion of PKCβII 
expression in these cells by treatment with bryostatin enhances the cytotoxic effect 
of an antibody targeted against CD22 (BL22) [137]. This suggests that high levels of 
PKCII protect CLL cells against CD22-directed immunological therapies. 
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Figure 1.7: Role of PKCβ in CLL cells. PKCβII is overexpressed in CLL which inhibits 
BCR signalling by phosphorylation of Btk on S180 that prevents its activation. 
Additionally, PKCβII augments anti-apoptotic signalling by inducing S69 
phosphorylation of BimEL and S
70 phosphorylation of Bcl-2. Phosphorylation of these 
two residues results in BimEL proteasomal degradation, and sequestration of BimEL 
by Bcl-2 respectively. PKCβII can also activate Akt which is an important mediator of 
CLL cell survival. 
 
There is a clear role for PKC within the BCR signalling pathway. As a facilitator of 
BCR signalling, PKCβ phosphorylates CARD-containing MAGUK protein 1 (CARMA1) 
within the CBM complex [(CARMA1/ B- cell lymphoma 10 (Bcl10)/ Mucosa 
Associated Lymphoid Tissue Lymphoma Translocation 1 (MALT1)], and this leads to 
stimulation of Transforming growth factor-beta-activated kinase 1 (TAK1) [138] 
[139] and eventually to NFB pathway activation. Such NFB pathway activation 
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then induces expression of anti-apoptotic survival proteins such as Bcl-2 and Bcl-xL. 
This is important with respect to CLL cells because overexpression of PKCβ and 
constitutive activation of the NFB pathway are features of these malignant cells 
[140]. Active PKC as a facilitator of BCR signalling can also phosphorylate RasGRP3, 
which is a Ras-guanine exchange factor that can generate GTP-Ras in response to 
the presence of DAG [141]. Phosphorylation of RasGRP3 enhances its enzymatic 
function allowing GTP-Ras to augment the function of son-of-sevenless (SOS) [142] 
and lead to the activation of Extracellular Signal-Regulated kinases (ERK) [141].  
In contrast to its role as a facilitator of BCR signalling, PKCβ can also act within a 
feedback mechanism to negatively regulate this process. This mechanism involves 
phosphorylation of Btk at serine 180, and this interferes with the PH (pleckstrin 
homology) domain within Btk so that it can no longer bind Phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3), and results in migration of this kinase away from the 
plasma membrane. Away from the plasma membrane Btk is unable to 
phosphorylate and activate its substrate PLCγ2 and this effectively shuts the BCR 
signalling pathway off [128]. How this negative feedback mechanism contributes to 
disease pathogenesis in CLL is unclear, but could possibly explain some aspects of 
BCR anergy that are observed with CLL cells. A previous report from this 
Department showed that VEGF stimulates PKC activity, and that this dampens the 
BCR signalling response in CLL cells [143]. 
Whether overexpressed PKCII acts as facilitator, inhibitor or both of BCR signalling 
in CLL cells has not been clearly demonstrated. Nevertheless, there is evidence to 
indicate that overexpression of PKC plays a role in CLL development (Figure 1.8). 
Within the Tcl1 mouse model of CLL, expression of PKC is important in the 
pathogenesis of the malignant CLL-like cells [3]. In this model, the CLL-like disease 
does not develop in mice where the gene coding for PKC has been disrupted [3]. 
Although subsequent work has indicated that PKC expression within stromal cells 
aids their ability to support malignant cell establishment and growth [144], there is 
also a possibility that malignant cells do not form because the subgroup of B cells 
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from which the CLL-like disease would develop are missing due to the effect of 
disrupted PKC expression on MZ and B-1 cell development [3, 98].  
A second model which indicates a role for PKC in CLL cell pathogenesis is 
suggested in a recent study by Nakagawa et al., who show that PKCβII expression is 
upregulated in the malignant cells which form in their model of this disease. 
Importantly, the same study showed that targeting PKC activity with a specific 
inhibitor (enzastaurin) resulted in induced apoptosis and growth inhibition of the 
malignant cells [131]. Finally, work from this Department showed that B cell-specific 
overexpression of PKCβII leads to favoured development of MZ and B-1 cells while 
follicular B cell development is reduced [99]. Although disease was not observed to 
develop within this model, it may still be relevant because virtually all mouse 
models of CLL develop from a lymphocytosis of B-1 cells [145-147].  
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Figure 1.8:  In vivo studies support the key role of PKCβ in CLL. Mouse models 
illustrate the importance of PKCβ in CLL cell development. A) CLL-like disease does 
not develop in TCL-1 transgenic mice that have been crossed with PKCβ knockout 
mice. (Adapted from Holler et al. 2009[3]). B) In this model fetal liver 
haematopoietic cells (HPCs) are transduced to express kinase-dead PKCα-KR and 
then induced to differentiate into B cells. The resultant cells become neoplastic and 
are phenotypically similar to human CLL cells (Adapted from Nakagawa et al. 
2006[148]). Moreover, these cells behave similarly to CLL cells when injected into 
Rag-/- neonatal mice. C) B cell-specific transgenic overexpression of PKCβII shows 
favoured expansion of marginal zone (MZ) and B-1 cells (Adapted from Azar et al. 
2011 [99]). 
 
Although PKCII overexpression is a phenotypic characteristic of CLL cells, 
overexpression of this PKCβ isoform is also observed in other B-lymphocyte 
malignancies such as diffuse large B cell [149] and mantle cell lymphomas [150]. 
Further, overexpression of PKCβII is observed in epithelial tumours such as 
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carcinoma of the colon where development of this disease is intrinsically linked 
with expression of this PKC isozyme [151], and in tumours of the breast where 
overexpression of PKCβII has been linked to disease progression [152, 153]. 
Therefore, understanding the regulatory mechanisms governing expression of 
PKCβII may give insight into the pathogenesis and the progression of CLL and other 
cancers. 
1.4.3 Overview of the mechanisms regulating PKCβ gene expression 
within different cellular contexts  
PKCβII and PKCβI are encoded by the PRKCB gene, which is located on the long arm 
of chromosome 16 at position 11.2. Thus, PKCβII and PKCβI are alternative splice 
variants of this gene which differ from each other within, respectively, the last 52 
and 50 C-terminal amino acids [154, 155]. How this difference in the C-terminus of 
PKCβI and PKCβII is functionally manifested is unclear because systematic 
investigation into the individual roles of these isoforms has not been performed. 
Nevertheless, one early study has indicated that this region influences the Ca2+ 
requirement of each isoform for full activation; PKCβII requires Ca2+ in greater 
amounts for full activation than does PKCβI [156]. Moreover, the difference in C 
termini may influence the ability of PKCβI and PKCβII to associate with different 
target proteins. For example, PKCβI has been shown to associate with and affect 
the function of Btk in mast cells [157]. In CLL and other malignant cells it is 
predominantly PKCβII that is overexpressed [1, 149-152]. It is unclear why the 
splicing mechanism favours PKCβII over PKCβI in CLL and other malignant cells, but 
could be due to activated Akt2 as has been suggested in cardiac myocytes [158]. At 
a post-translational level it is thought that the protein phosphatases PHLPP1 and 2 
(PH domain and Leucine rich repeat Protein Phosphatase) and protein phosphatase 
2A (PP2A) play roles in mediating PKCβII deactivation and degradation following 
long term activation [159]. This may be important for PKCβII overexpression in CLL 
cells because these cells have been shown to have reduced expression of PHLPP1, 
and because PKCβII protein has a long half-life [160]. 
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The purpose of this thesis is to discover the mechanism(s) governing PKCII 
expression at the transcriptional level. In this respect, the promoter of PRKCB has 
been characterized by two groups who described the basal region responsible for 
driving gene expression [4, 161]. One of these studies identified a number of 
binding sites for potential transcription factors such as Sp1, Oct-1, and AP1 [4]. 
Later, Park et al., found that Microphthalmia-associated Transcription Factor (MITF) 
appeared to be involved in regulating the expression of PKCβ in melanocytes [7], 
while another study implicated a role for RUNX1 in U937 cells [6]. Recently, Farren 
et al. characterized a role for STAT3 as a suppressor of PKCβ gene expression in 
dendritic cells [8]. However, none of these studies described the major driver of 
PRKCB promoter activity within their cell system.   
With respect to the role of epigenetic modifications in regulating the expression of 
PRKCB, a single recent study by Hagiwara  et al. suggested that methylation of the 
PRKCB promoter played a role in transcription of this gene within a HeLa cell model 
[5]. However, the relevance of this observation to CLL is unclear because gene 
methylation studies of the malignant cells in this disease compared to normal B 
cells do not identify PRKCB as being differentially methylated [162]. 
Finally, work from this Department has shown that transcription of the PRKCB gene 
can be induced in CLL cells through a mechanism involving VEGF-induced 
stimulation of PKCβII activity [143]. This mechanism has also been reported in other 
cell systems [163, 164], but how this is mediated at the transcriptional level has not 
been described. Furthermore, the PKC agonist Bryostatin induces both 
differentiation of CLL cells [165] and reduction of PKCII expression [137]. While it 
is clear that bryostatin is likely to catalyse PKCII protein degradation through a 
mechanism involving PHLPP and PP2A [159], the mechanism inhibiting PRKCB 
transcription is still unclear.  
Thus, the main aim of this thesis is to investigate the regulatory mechanisms 
governing overexpression of PKCβII in CLL cells at the transcriptional level. At the 
beginning of this thesis, the only known transcription factors involved were MITF 
[7]and RUNX1 [6]. Therefore, I began this thesis with the aim to describe the role of 
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these Transcription factors, as well as that of Sp1 whose potential role was 
identified in the early descriptions of the PRKCB basal promoter [4]. Subsequently, 
STAT3 was also identified [8], and I have included this within this this thesis as well.  
1.5 Transcription factors regulating PRKCB expression. 
In this section I give an overview of the transcription factors known to regulate 
PRKCB transcription (RUNX1, MITF and STAT3) and of Sp1/Sp3 whose role in driving 
expression of this gene was implicated the early studies characterising the basal 
promoter region.  
1.5.1 Specificity protein 1 and 3 (Sp1)/(Sp3)                     
Specificity proteins 1 and 3 (Sp1)/(Sp3) are pleiotropic nuclear transcription factors 
which show a similar strong affinity to the GC-rich consensus binding sequence 
within regulatory regions of target genes [166-169]. These transcription factors are 
members of a family of proteins known as the Specificity protein (Sp)/Kruppel-like 
factor (KLF) family [170, 171], and are characterised by a structure that includes 
three zinc fingers which define their DNA binding domain [170] (Figure 1.9). There 
are 9 Sp type members of this family [172, 173], each one located on a different 
chromosome and contiguous with a homeobox (HOX) gene [174]. Sp1 and Sp3 
stand out from this family of proteins by targeting highly similar consensus 
sequences (Table, 1.3) [172, 175]. 
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Figure 1.9: Recognition and binding of Sp1 to DNA. Three specific amino acids 
(highlighted in red) within in each of the 3 zinc finger regions (F1 – F3) are 
responsible for nucleotide recognition within DNA containing the cognate binding 
site of Sp1/Sp3 (adapted from Bouwman and Philipsen, 2002[172]). 
 
Table 1.3: Sp protein expression and their DNA binding consensus sequences 
Sp protein members and their expression DNA binding consensus sequence 
Sp1 and Sp3 (pleiotropic)  / Sp4 (dominant in 
brain)[175] 
GC-box/ GT-box 
Sp2 (Various cell lines, tissue unidentified)[169, 170]  GT-box 
 
Sp1/Sp3 are involved in regulating constitutive as well as inducible expression of 
different genes related to various cellular functions such as growth, differentiation, 
apoptosis, metabolism, and chromatin remodelling enzymes [176]. The binding of 
Sp1/Sp3 to the promoter of these genes is modulated by different factors (Figure 
1.10). Firstly, the level of Sp1/Sp3 expression can be driven by the same 
transcription factors that modulate cell cycle phases and its related proteins such as 
E2F1 [177], and regulated post-transcriptionally by miRNAs such as miRNA29b that 
directly target Sp1 mRNA for degradation [30, 178, 179]. Secondly,  direct 
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interactions with other proteins such as the transcription factors E2F1 [180, 181], or 
with chromatin-remodelling enzymes like p300, histone methyltransferases [182] 
and histone deacetylases [183] can alter the function of Sp1. Thirdly, post-
translational modifications of Sp1 and Sp3 stabilize their expression, nuclear 
localization, and the interaction with other proteins [49, 176]. These modifications 
can influence the interaction of Sp1 with chromatin-remodelling enzymes and 
change the chromatin landscape structure from heterochromatin to euchromatin 
and affect the accessibility for other transcription factors [184, 185]. Finally, 
methylation of CpG sequences which contain the consensus binding sites for 
Sp1/Sp3 limits their accessibility to gene promoter regions to suppress transcription 
[186, 187] .  
Sp1/Sp3 play a crucial role in different types of cancers through their role in 
modulating the expression of genes responsible for tumour cell behaviour. For 
example, it is known that Sp1 regulates expression of the genes controlling 
vascularization in prostate, gastric and pancreatic cancers [188-190]. Sp1 is also 
known to regulate the genes responsible for apoptosis resistance in T cell 
lymphomas [191, 192], and for controlling growth and progression of disease in 
breast, gastric and lung cancer [193-196]. Sp1 is found overexpressed in multiple 
myeloma and acute myeloid leukaemia cells where it enhances their proliferation 
[179, 197]. This role of Sp1/Sp3 can be mediated either through direct interaction 
of these transcription factors with promoter regions of genes, or indirectly through 
Sp1-mediated expression of genes coding for enzymes involved in DNA 
methylation/demethylation [30, 198, 199].  
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Figure 1.10: Factors influencing Sp1/ Sp3 transcriptional activity.  
 
1.5.2 Runt-related transcription factor 1 (RUNX1) 
Runt-related transcription factor 1 (RUNX1, also known as acute myeloid leukaemia 
1 (AML 1)) and its isoforms RUNX2 and RUNX3 are encoded from a single gene but 
are regulated by different promoters and result from alternative splicing [200-202]. 
RUNX1, RUNX2 and RUNX3 are similar with respect to the runt-homology domain 
that is important for recognition and binding to their consensus sequence within 
DNA, but differ in their N-termini [200]. Interestingly, despite being coded by the 
same gene, knockout studies of the different promoters show clear function of 
these isoforms: RUNX1 is crucial for haematopoiesis [203], RUNX2 plays an 
important role in osteogenesis [204, 205], while RUNX3 is important in 
neurogenesis [206], development of cytotoxic T-lymphocytes [207] as well as 
development and differentiation of epithelial cells within the lung [208] and 
gastrointestinal system [209]. RUNX proteins have been found to play a role in 
carcinogenesis. It is well known that acute myeloid (AML) and B-acute 
lymphoblastic (B-ALL) leukaemias have high incidences of chromosomal 
translocations which create protein chimaeras of RUNX1 with ETO or TEL (ETV6) 
(respectively t(21;8) or t(21;12) translocations) [200]. Furthermore, the RUNX1 
gene in these leukaemias is often mutated in such a way that its ability to bind DNA 
is affected [210, 211]. Together, these two types of genetic aberration within the 
RUNX1 gene contribute to the development and transformation of the malignant 
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cells in AML [212] and B-ALL [213]. With respect to CLL, there are no reports 
implicating RUNX1, RUNX2 or RUNX3 in the pathogenesis of this disease.  
1.5.3 Microphthalmia-associated Transcription Factor (MITF) 
Microphthalmia-associated Transcription Factors (MITF) are basic helix-loop-helix 
(bHLH) leucine zipper transcription factors that are encoded from the MITF gene 
located at chromosome 3 [214]. These transcription factors belong to the MYC 
superfamily, and recognize either enhancer box (E-box) or M-box sequences within 
the regulatory regions of their target genes [215]. The helix-loop-helix and leucine 
zipper motifs within MITFs are important for complex (dimer) formation either with 
itself, or with other bHLH-related proteins such as TFEB, TFEC, and TFE3 [214]. MITF 
has nine isoforms (A, B, C, D, E, H, J, and M) generated by alternate splicing from a 
single gene whose expression is driven by four different promoters [216]. MITF-M is 
the most common isoform, and its expression is linked to melanocyte growth and 
differentiation [215]. Alteration in the expression or activity of this transcription 
factor due to genetic aberration or other factors leads to the formation of 
melanoma [217], and, as such, expression of MITF in melanocytes is used as a 
biomarker of this disease [218]. It is unclear whether expression or mutation of 
MITF has a role to play in cancer cells other than melanoma. However, I included 
this transcription factor in this study because of its described role in regulating 
PRKCB transcription [7]. 
1.5.4 Signal transducer and activation of transcription 3 (STAT3) 
Signal transducer and activation of transcription 3 (STAT3) is a cytoplasmic protein 
responsible for cell proliferation, differentiation and survival [219]. It belongs to a 
family of latent transcription factors that includes STAT1, STAT2, STAT4, STAT5a/b, 
and STAT6 [220]. The function of these transcription factors is stimulated by growth 
factors / cytokines which induce the phosphorylation of STATs either by Janus 
kinases (JAKs) [221] or Src-family kinases (SFKs) [222]. With respect to STAT3, it is 
activated by phosphorylation of tyrosine 705 / serine 727 which results in the self-
dimerization necessary for nuclear transport where it is able to bind its target 
genes[223]. The process of STAT3 activation is receptor-dependent, and is 
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stimulated by cytokines such as IL-6 and IL-21 [224], by growth factors such as 
granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte 
colony-stimulating factor (G-CSF) [225, 226], and by steroids [227]. Interestingly, 
STAT3 can also complex with NFB and become imported into the nucleus as an 
unphosphorylated protein to bind its consensus sequences within the regulatory 
regions of target genes [228].  
Constitutive activation of STAT3 is a phenotypic feature of solid tumours and 
leukaemias. Within this setting, constitutively active STAT3 can act as an oncogene 
where it controls transcription of genes involved in angiogenesis (VEGF) [229, 230], 
resistance to apoptosis (Bcl-family proteins and survivin) [231], invasion and 
metastasis (Matrix metalloproteinase 1/ 2 (MMP1 /2) [232, 233] and proliferation 
(Cyclin D1 [234], c-Myc [235], and pim-1/2 [236]). STAT3 activation in 
haematological cancers shows a correlation with disease stage. For example, in 
diffuse large B cell lymphoma (DLBCL) STAT3 activation is highly associated with the 
progressive activated B cell subtype [237]. Regarding CLL, the malignant cells in this 
disease are distinct in having a constitutive phosphorylation of STAT3 at serine 727 
[238]. The mechanism of this phosphorylation is unclear, but its presence seems 
important for the survival of the malignant clone in this disease because the extent 
of pS727-STAT3 in CLL cases correlates with cell resistance to apoptosis [239]. With 
respect to PRKCB, it was recently shown that active STAT3 acts as a repressor for 
transcription of this gene [8]. 
1.6 Hypothesis and aims 
PKCβII is overexpressed in CLL cells as well as other haematological and solid tumor 
cells. This overexpression plays a key role in the pathogenesis of the malignant 
clone in CLL. Understanding the mechanisms regulating the expression of the gene 
coding for PKCβII may provide insight into the pathogenesis of CLL cells, because it 
may provide a foundation for understanding how other genes important for the 
malignant phenotype of these cells may become deregulated.  
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In the early reports by Obeid et al., [4] and Niino et al. [161] the basal promoter 
region of PRKCB was shown to be dependent on a section of DNA containing 
binding sites for Sp1. Thus, we hypothesised that Sp1 is the major driver for the 
overexpression of PKCβII in CLL cells. To test this hypothesis I aimed to investigate 
the role of the following elements in regulating the expression of PRKCB expression 
in CLL cells: Sp1, other transcription factors (Sp3, RUNX1, MITF, and STAT3), 
epigenetic modifications (DNA methylation and histone modifications). Finally, I 
tested these findings within a functional setting to understand how VEGF and 
Bryostatin stimulated/inhibited PRKCB expression at the transcriptional level.   
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 Chapter Two: Materials and Methods 
This chapter principally is divided into five main sections of the methodology that 
generally have been performed during this study. The specific or optimized 
materials and methods for these techniques will be mentioned in each relevant 
section of the results in each chapter.  
2.1 Tissue culturing techniques 
2.1.1 Isolation, Purification, and storage of CLL and normal B 
cells 
2.1.1.1 Isolation and storage of CLL and normal B cells 
Peripheral blood samples were collected from CLL patients with informed consent, 
and with the approval of the Liverpool Research Ethics Committee (#06/Q1505/82).  
Blood samples were processed according to a standard operating procedure (SOP) 
developed by the Liverpool Leukaemia Biobank, University of Liverpool. Briefly, the 
whole blood sample was layered over Lymphoprep™ (Alis-Shield PoC AS, Oslo, 
Norway) with a volumetric relationship of 1 part Lymphoprep™: 2 parts blood, and 
then centrifuged at 800xg for 30 mins. Lymphocytes were collected from the 
plasma/Lymphoprep™ interface and then diluted to 50 ml with complete medium 
[RPMI-1640 + 10% Fetal calf serum (FCS), 100 U/ml penicillin, 100µg/ml 
streptomycin, 0.29 mg/ml L-glutamine (all from Sigma Aldrich, Gillingham, UK)] 
followed by centrifugation at 550xg for 5 mins. The cell pellet was resuspended 
with pre-chilled RPMI-1640 medium containing 10% FCS, and this was followed by a 
drop wise addition of an equal volume of pre-chilled RPMI-1640 medium containing 
20% Dimethylsulfoxide (DMSO) (Sigma Aldrich, Gillingham, UK). The volumes of FCS 
and DMSO containing media to be used in the previous step was determined using 
the total white cell count of the blood sample, and calculating an end concentration 
of cells of 2x107/ml. Finally, 1 ml of this suspension of cells was distributed to 
labelled cryovials held within a polystyrene holder, and then transferred to a -80ᴼC 
freezer for short-term storage, followed by long term storage at -150ᴼC.  
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2.1.1.2 Isolation, purification and storage of normal B lymphocytes 
from buffy coats 
Buffy coats were obtained from the British Transfusion Service (Liverpool, UK). 
Lymphocytes were first isolated over Lymphoprep™ using the above procedure 
(2.1.1). B cells were purified from mixed lymphocyte populations by negative 
selection using magnetic cell separation according to the manufacturer’s protocol 
(MACS®, Miltenyi Biotec Ltd, Surrey, UK). Purified B cells were stored frozen in 
RPMI-1640 + 10% FCS, 10% DMSO as above. 
2.1.2 Thawing, purification, and culturing of cells 
2.1.2.1 Thawing cryopreserved CLL cells 
The cryopreserved CLL samples vials were taken from the Liverpool Leukaemia 
Biobank freezer and were quick thawed at 37ᴼC. The thawed cells were then 
transferred into pre-chilled universal tubes placed in ice. Pre-chilled thawing 
medium (RPMI-1640 medium containing 1% BSA, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 0.29 mg/ml L- glutamine) was added in a drop wise fashion over 
the course of 30 mins with constant swirling of the tubes. Afterwards the 
suspended cells were centrifuged at 550xg for 5 mins at 4ᴼC. The cell pellet was 
further washed twice with 5 ml of complete RPMI-1640 medium. Finally, the cell 
pellets were resuspended with 5 ml of complete RPMI-1640 medium ready for cell 
counting. Cell concentration was adjusted to 1x107/ml with further addition of 
complete RPMI-1640 medium.  
Following the thawing procedure cells were left in an incubator with an atmosphere 
containing 5% CO2 at 37 ᴼC for 1h for recovery. Only samples which showed more 
than 75% viable cells were included in further experimentation. 
Clinical information regarding the samples that have been used in this study is 
mentioned in appendix A. 
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2.1.2.2 Analysis of CLL cell purity 
CLL cells were analysed for purity using flow cytometry. Thawed CLL cells (1x106) 
were incubated with PE-conjugated CD3 and non-specific control IgG antibodies 
(Becton Dickinson, Mountain View, CA) in order to identify T cells. When CLL cell 
samples contained greater than 5% T cells within the entire population they were 
excluded from study. 
2.1.2.3 Culturing of CLL cells 
Tissue culture plates were coated with non-toxic poly 2-hydroxyethyl methacrylate 
(poly-HEMA) (Sigma Aldrich, Gillingham, UK). 200 μl of 12 mg/ml poly-HEMA in 95% 
ethanol was added to each well of a 24 well tissue culture plate (Falcon, BD 
Biosciences, UK) that was then left to dry at 37 ᴼC overnight. This was done to avoid 
the potential effects of cell adhesion to the plate surface during culture of CLL cells 
[240]. 
CLL cells (1x107/ml) were seeded into prepared culture plates and kept incubated at 
37ᴼC in an atmosphere of 5% CO2 until used. For most experiments cells were 
cultured for at least an hour following the thawing procedure. 
2.1.3 Thawing, culturing, passaging and cryopreservation of 
human B lymphocytes cell lines MEC1 and Daudi cells 
2.1.3.1 Thawing and culturing of human B lymphocyte cell lines MEC1 
and Daudi cells 
 Cell lines were used in this thesis for functional experiments. Therefore, controlling 
the factors such as thawing, culturing, passaging, and cryopreserving that may 
affect their quality are fundamental. 
The MEC1 CLL cell line is derived from a 61 year old man with CLL that was 
undergoing prolymphocytoid transformation [241]. These cells were obtained from 
the Leibniz Institute (DSMZ) German Collection of Microorganisms and Cell Cultures 
(Braunschweig, Germany) and were used a low passage number. 
 36 
 
The Daudi cell line is a B lymphoblastoid cell line derived from a sixteen year old 
boy with Burkitt's lymphoma [242]. This cell line was obtained from ATCC (LGC 
Standards, Middlesex, UK).  
Cryopreserved vials of each cell line were rapidly thawed by immersion in a 37ᴼC 
water bath. Thawed cells were then transferred to pre-chilled universal tubes and 
treated in the same way as for CLL cells (section 2.1.2.1) with the exception that 
MEC1 cells were cultured in complete Dulbecco's Modified Eagle Medium (DMEM) 
(Sigma Aldrich, Gillingham, UK) and Daudi cells were cultured in complete RPMI-
1640 medium. Final cell culture was maintained in vented Nunc (T25) culture flasks 
(Fisher Scientific, UK) under standard conditions (37 ᴼC and 5% CO2). The cultured 
cell lines were tested regularly for mycoplasma infection by our department 
technician using an established protocol (see Appendix B). 
2.1.3.2 Passaging of human B lymphocyte cell lines MEC1 and Daudi 
cells 
Cell lines were passaged every three days to maintain optimal growth. MEC1 and 
Daudi cell lines were split using a 1:3 ratio of cell suspension to new appropriate 
media (see section 2.1.3.1).  The culture of cell lines was maintained until they were 
used in experiments, or the total number of passages exceeded 10. Cell lines were 
not used beyond 10 passages in culture.  
2.1.3.3 Cryopreservation of human B lymphocyte cell lines MEC1 and 
Daudi cells 
To minimize genetic and phenotypic changes of the cell lines I used in this thesis, 
and to ensure access to cell lines free from microbial infection it was necessary to 
cryopreserve stock cell lines with minimal number of passages.  
At the beginning of this thesis 1 vial each of MEC1 and Daudi cells was grown and 
tested to be free of mycoplasma. The cultured cells were then expanded to a 
density and volume that would achieve at least 20 vials each of 2x106 cells. The 
required number of cells was centrifuged at 550xg for 5 mins, and the cell pellet 
resuspended into ice cold appropriate media containing 10% FCS. An equal volume 
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of ice cold appropriate media containing 20% DMSO was gradually added in a drop 
wise fashion over the course of 30 mins. 1 ml aliquots of cell suspension (2x106 
cells) was placed into cryovials and frozen at -80ᴼC overnight in a polystyrene 
holder to ensure constant temperature change for each vial. The next day, or as 
soon as possible afterwards, the vials were deposited in a -150ᴼC freezer until they 
were needed. 
2.1.4 Preparing growth-arrested MEC1 and Daudi cells 
Some experiments required the use of growth-arrested cells in order to mimic CLL, 
which are arrested in G0/G1 phase of the cell cycle.  Twenty four hours prior to 
starting such an experiment the cultured cell lines were placed into appropriate 
serum free medium (section 2.1.3.1) by first washing the cells with phosphate 
buffer saline (PBS) twice, and resuspending the cells in serum free medium. Viability 
and growth arrest was assessed by cell counting before and after this procedure.  
2.2  In vitro Treatment 
2.2.1 Cell Counting 
CLL cells and B cell lines were counted for experimental purposes by using a 
haemocytometer after mixing the cells 1:10 with a 0.1% Trypan blue dye solution. 
The following equation was used to calculate the volume of cell suspension 
required to obtain desired cell density for each experiment as indicated in the 
relevant sections. 
 
 
 Equation 2.1: Where V = total volume of cell suspension, CDdes = desired cell 
density of suspension, CDobt = obtained cell density of suspension and n = number 
of treatments.  
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2.2.2 Different treatments of CLL and B lymphocyte cell lines 
2.2.2.1 Determination of the effective concentration of mithramycin 
to use in experiments with human B lymphocyte cell lines and CLL 
cells 
CLL cells were used at a cell density of 1x107/ml (section 2.1.2.3). The cells were 
incubated with different concentrations (50, 100, 200, 400 nM) of mithramycin 
(Sigma Aldrich, Gillingham, UK) dissolved in methanol. As an untreated control cells 
were treated with the equivalent volume of methanol needed to add the maximum 
concentration of mithramycin. Cells were harvested following for 24h culture.  
For the MEC1 and Daudi cell lines a cell density of 2x106/ml was used. Culture 
conditions were varied between serum free (section 2.1.4) and 10% FCS within 
DMEM and RPMI1640, respectively. Mithramycin or methanol was added in the 
same amounts as above, and the cells cultured for 24 h. 
2.2.2.2 Determination of the optimal time point for cell harvesting 
following treatment of human B lymphocyte cell lines and CLL cells 
with 200 nM mithramycin 
Cultures of CLL cells and growth-arrested MEC1 and Daudi cells were treated with 
200 nM of mithramycin or with an equivalent volume of methanol. The cells were 
then harvested at the following time points; 3, 6, 9, 12, 15, 18, 21, and 24 h. The 
initial time (T0) sample is cells untreated in any way, and harvested at the beginning 
of the experiment. 
2.2.2.3 Treatment of CLL cells with Vascular Endothelial Growth Factor 
(VEGF) 
CLL cells (1x107/ml) were cultured under standard conditions (section 2.1.2.3) in the 
presence or absence of 100 ng/ml vascular endothelial factor (VEGF) (Calbiochem, 
UK) for 24 h. This concentration of VEGF and incubation was chosen based on a 
previous report [143]. 
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2.2.2.4 Treatment of CLL cells with Bryostatin    
 CLL cells (1x107/ml) were cultured under standard conditions (section 2.1.2.3) in 
the presence of 50 nM Bryostatin (Sigma Aldrich, Gillingham, UK), a PKC agonist, or 
an equivalent volume of DMSO (as control). Following 24 h the cells were 
harvested. 50nM of Bryostatin was chosen as optimal based on previous reports 
using this compound with CLL cells [243] and [137].   
2.2.2.5 Treatment CLL and MEC1 cells with c-Myc inhibitor (10058-F4)  
CLL cells (1x107/ml) were seeded under standard conditions (section 2.1.2.3) either 
in the presence of 60 µM of the c-Myc-specific inhibitor 10058-F4 (Sigma Aldrich, 
Gillingham, UK)[244], or an equivalent volume of DMSO as control. For experiments 
involving MEC1 and Daudi cells, 2x106 cells/ml were seeded in serum free or 10% 
FCS media (section 2.1.4) and then cultured in the presence or absence of 60 M 
10058-F4 for 24h. 
2.2.2.6 Treatment of CLL and MEC1 cells with chromatin-remodelling 
enzyme inhibitors (Romidepsin and C646).   
Romidepsin is histone deacetylase inhibitors (HDACi), while C646 is a histone 
acetyltransferase inhibitor (HATi) specific for p300 [245]. Histone deacetylases and 
transferases are responsible for removal or addition of acetyl groups to histones, 
allowing change in the chromatin structure and landscape [246].  
CLL (1x107/ml) and MEC1 (2x106/ml) cells were seeded according to their optimal 
culture conditions. For romidepsin [(Celgene, San Francisco, CA United States of 
America (USA)], CLL and MEC1 cells were cultured in the presence of 10 nM of this 
compound, or an equivalent volume of DMSO. For C646 (Calbiochem, UK), a 
concentration of 10 M was used. In these experiments, CLL and MEC1 cells were 
cultured to 24 h with these inhibitors prior to further analysis. 
2.2.3 Cell Viability 
Cell viability for both CLL and B lymphoid cell lines was checked before and after the 
different treatments using trypan-blue exclusion. Using this method live and dead 
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cells can be distinguished; dead cells with disrupted plasma membranes will take up 
the dark blue dye, while live cells will appear shiny bright. As with the procedure for 
cell counting, cell suspensions were diluted 1:10 with 0.1% trypan blue dye 
solution, and dead and live cells were counted using a haemocytometer. Both live 
and dead cells were counted, and results reported as percent live cells within the 
total cell count.  
2.3 Molecular Biology Techniques 
2.3.1 Nucleotide Studies 
2.3.1.1 Total RNA Extraction 
Cells harvested from experiments were collected in 1.5 ml nuclease-free eppendorf 
tubes (Anachem Ltd, UK). Total RNA was isolated from these cells using a ZR RNA 
Midiprep™ kit (Zymo Research, UK) following the manufacturer’s instructions. In 
brief, the cell pellet was lysed with 400 μl RNA lysis buffer and then centrifuged at 
12,000xg for 1 min. The supernatant was transferred to a Zymo-Spin IIIC column, 
and this was centrifuged for 30 s at 8000xg. The flow-through was mixed with 320 
μl of 100% ethanol, and then transferred to a Zymo-Spin IIC column where it was 
centrifuged at 12000xg for 1 min. The column with attached RNA was washed once 
with 400 μl RNA prep buffer, once with 800 μl and then with 400 μl RNA wash 
buffer using 30 s pulses of centrifugation at 12000xg. An additional centrifugation 
step involved 2 mins at 12000xg in order to completely remove residual wash 
buffer. As a final step RNA was eluted from the column with 30 μl of elution buffer 
and centrifugation for 30 s at 10000xg. Isolated RNA was immediately stored at -80 
ᴼC following assessment for purity and quantity. 
2.3.1.2 Assessment of RNA purity and quantity 
The assessment of isolated RNA quality and quantity is essential for further 
molecular biology work. Quality of the isolated RNA from section 2.3.1.1 was 
assessed using a Nandrop 2000 spectrophotometer (Thermo scientific, UK). The 
isolated RNA was considered to be pure if the ratio light absorbance at 260 nm and 
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280 nm fell within the range 1.6-2; a value below 1.6 indicates extensive protein 
contamination. An additional ratio of light absorbance was taken, A260nm/A230nm and 
values between 2-2.2 were taken a pure; values outside this range indicate possible 
peptide or other contamination. 
Quantitation of RNA within the isolation preps was also performed with the 
Nanodrop 2000. To do this, the absorbance value at 260nm was taken and divided 
by 0.025 (the extinction coefficient for single stranded RNA) to obtain the 
concentration in ng/l. 
2.3.1.3 Synthesis of complementary DNA (cDNA) from RNA 
 To synthesize cDNA from isolated RNA, 1g of RNA was mixed with 1 µl of Oligo 
(dT) primer [500 ng/µl (Eurofins MWG Operon, Ebensburg, Germany)], and this was 
topped up with the addition of nuclease-free distilled water to a final volume of 14 
µl. This was incubated for 5 min at 37ᴼC, and afterwards chilled on ice. Meanwhile, 
the reverse transcription master mix was prepared; per reaction 5 µl 5xRT Buffer, 1 
µl (10,000U) Moloney murine leukaemia virus reverse transcriptase, 1 µl (10 mM) 
dNTP mix, 1 µl (2,500 U) RNase plus Rnase inhibitor (all from Promega, 
Southampton, UK) and 3 µl nuclease free water were mixed. To start the cDNA 
synthesis 11 µl of master mix was added to the 14 l of RNA/oligo dT mix. Synthesis 
was complete following incubation of the mixture at 42ᴼC for 1 h. Synthesized cDNA 
was kept in -20ᴼC until further used. 
2.3.1.4 Polymerase Chain Reaction (PCR) 
The basic RT-PCR  reaction contained 4 µL of Hot Fire pol EvaGreen qPCR master 
mix (newmarketScientific, Kennet, UK ), 1 µl DNA (cDNA (prepared in section 
2.3.1.3) or chromatin (prepared in section 2.3.6), 1 µl each (5 pmol/µl) of the 
forward and reverse primers (Eurofins MWG Operon, Ebensburg, Germany) needed 
to amplify the gene of interest, and 13 µl nuclease-free water to make a final 
reaction of 20 l. Amplification was performed using a DNA Engine® RPTC-200 
Peltier thermal cycler (MJ Research, Watertown, Massachusetts, USA), and the 
following thermal profile: An initial step of heating to 95ᴼC for 1 min. This was 
 42 
 
followed by 40 cycles of denaturation at 95ᴼC for 30 s, annealing for 30 s at a 
temperature specific for the primers being used (this information is tabulated for 
each primer pair in Appendix C), and extension at 72ᴼC for 30 s. A final step 
consisted of extension at 68ᴼC for 5 min. With each PCR reaction a control 
experiment was included where nuclease-free water was added in place of DNA. 
Each PCR reaction was verified to amplify a single product of the correct size by 
agarose gel electrophoresis.  
2.3.1.5 Quantitative Polymerase Chain Reaction (qPCR) 
Quantitative, or real time, polymerase chain reaction is a powerful molecular 
technique that allows either absolute or relative quantification of specific 
sequences of DNA. Generally, quantification of amplified sequences is achieved by 
measuring, in real time, the fluorescence signal that is released from a dye, such as 
SYBR green dye, as it binds to the minor groove of newly synthesised DNA double 
strands during the elongation phase of the PCR reaction. Relative quantification is 
performed using a reference gene, whereas absolute quantification is determined 
from a standard curve. This technique has been used in various applications such as 
gene expression analysis, gene amplification studies and chromatin 
immunoprecipitation (ChIP).  
The basic PCR reaction in this study is basically the same as is listed in section 
2.3.1.4. The exceptions are that amplification took place using a Stratagene 
MX3000P PCR machine (Agilent Technologies, Stockport, UK). The cycling 
conditions were slightly changed to include a fluorescence measurement step of 11 
s following the elongation step, and following the last cycle a melting curve was 
generated consisting of a final heat cycle of heating to 95ᴼC for 1 min, cooling to 
55ᴼC for 30 s and reheating to 95ᴼC for 30 s where fluorescence is measured. 
Generation of the melting curve assayed for purity and specificity of the amplified 
products by appearance of a narrow single peak.  
All PCR reactions had the same optimized cycling conditions with the exception that 
the temperatures for primer annealing and where the fluorescence data was 
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collected were different used. This information is listed for specific primer pairs and 
genes of interest in Appendix C.    
RNA polymerase II (For: 5’-CAAGACTGCTGAGACTGGATAC-3') and (Rev: 5'- 
CAAAGCGGAACTTCTTCTCAAAAG-3') was run as a reference gene for expression 
analysis of targeted genes in this study. RNA polymerase II was chosen because it 
showed a constant Ct value in qRT-PCR for all samples and different experimental 
conditions. As well, it is reported that RNA polymerase II expression is the most 
robust and constant reference gene within a comparison of all the classical 
reference genes (β-actin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
TATA-Box binding protein (TBP), hypoxanthine–guanine phosphoribosyltransferase 
(HPRT), Peptidyl prolyl isomerase A (PPIA), glucose 6-phosphate dehydrogenase 
(G6PDH), ribosomal protein L13(L13), β2-microglobulin (β2M), phospholipase A2 
(PLA), α-tubulin (Tub), albumin (Alb) and Porphobilinogen deaminase (PBGD); when 
measured in cells in different studies under diverse experimental conditions [247]. 
To normalize target gene expression to RPolII, the following equation was used: 
                                   
Equation 2.2: Normalization of the target gene to the reference gene by ΔCt method. 
Where Ct value represents the number of the cycles needed for the fluorescent 
signal to rise above baseline.  
2.3.1.6 Agarose Gel Electrophoresis 
Agarose gel electrophoresis is a technique used in molecular biology for separation, 
quantification and purification of DNA fragments based on their length as measured 
by base pairs. The procedure uses an electrical field to separate DNA fragments 
within agarose gels where high percentage gels are used for small DNA fragments, 
and low percentage gels for large DNA fragments. The DNA fragment size is 
determined by comparison to a DNA ladder which is composed of DNA fragments 
of known base pair length.  
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Agarose gels were prepared by weighing the desired amount of granular agarose 
(Web Scientific, UK) and adding 100 ml of Tris-borate- Ethyenediaminenetetraacetic 
acid (EDTA) (TBE) buffer (diluted from a 10X stock consisting of 0.445 M Tris borate, 
0.01M EDTA pH=8.2-8.4). The agarose is then melted by heating in a microwave, 
and therefore requires that the holding flask be suitable for use in this manner. 
Normally, the flask is heated for an initial 1 min, and then again in short bursts until 
all the agarose is melted. The melted agarose solution was left to cool down but not 
solidify. At this point 1 µl of Ethidium Bromide (EtBr) dye (Promega, UK) was added 
to the agarose solution before slowly pouring it into a gel tray in order to avoid air 
bubble formation. EtBr is added so that DNA can be visualised under ultraviolet 
(UV) light. With the well comb in place, the agarose solution is then allowed to 
solidify for at least 1 h.  
The solid agarose gel is placed in an electrophoresis tank. This tank is then filled 
with TBE buffer to which EtBr is added 1 µl for each 100 ml of TBE buffer) until the 
gel is covered. The comb is removed from the gel, and DNA samples, prepared by 
mixing DNA preparations with 6X DNA sample buffer (10 mM Tris-HCl pH 8.0, 50 
mM EDTA, 15% Ficoll-400 and 0.5% orange G), and then carefully pipetted into the 
wells.  
An electrical field was then applied (100V constant voltage) for 1 h, or sufficient 
movement of the tracking dye (orange G) was observed. At this point separated 
DNA fragments were able to be seen under UV light using a manual adjust system 
for exposure time (UVITEC, Alliance chroma system, Cambridge, UK) when 
obtaining images. 
2.4 Plasmid DNA preparation, transformation, and validation 
2.4.1 Plasmid DNA isolation and Transformation 
The generously gifted DNA plasmid constructs pGL3-pkcβ-1.2(wt), and three pGL3-
pkcβ-1.2 constructs containing mutated STAT3 binding sites used in this study were 
from Dr. Kelvin P Lee (Department of Immunology, Roswell Park Cancer Institute, 
Buffalo, USA). These constructs were provided blotted on to filter paper, and had to 
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be removed. Sterile scissors and forceps were used to carefully cut the circle of 
filter paper in which the DNA was blotted. DNA was then eluted from the filter 
paper with 100 – 500 µl nuclease-free water depending on the size of the circle. The 
concentration of the dissolved DNA was measured using Nandrop2000 
spectrophotometry. 100 ng of the DNA plasmid was then used to transform MAX 
Efficiency® DH5α™ Competent Cells (InvitrogenTM, Life Technologies, UK). Briefly, 
the competent cells were thawed on ice, and then 20 µl were transferred into a pri-
chilled 1.5 ml eppendorf tube containing the DNA plasmid. The tube was gently 
mixed, and then left on ice for 30 min. This was followed by heat shocking the 
bacteria by placing the tubes in a water bath set at 42ᴼC for 45 s. The tubes were 
again incubated on ice for 2 min, and then 500 l of Super optimal broth with 
catabolite repression (SOC) medium (Sigma Aldrich, Gillingham, UK) was added and 
tubes were then transferred to an incubator [C24 incubator shaker (New Brunswick 
Scientific, USA)] where they were left at 37ᴼC for 1 h with constant agitation 225 
Revelations per minute (RPM). 50 and 100 µl aliquots of this bacterial culture were 
spread onto separate pre-warmed Luria agar (LB) plates which contained 100 µg/ml 
ampicillin.  The plates were then incubated for overnight at 37ᴼC. The next day I 
picked a single colony and inoculated a 5 ml culture of LB medium containing 100 
µg/ml ampicillin within a 15 ml universal tube. This tube was further incubated with 
a loosened cap for 12-16 h at 37ᴼC with 225 RPM constant agitation. In some cases, 
500 µl of this final bacterial culture was added to a cryovial along with 500 µl of 
50% sterile glycerol in order to make a glycerol stock for long term storage at -80ᴼC. 
2.4.2 Plasmid DNA minimum-preparation (Miniprep) and Midi-
preparation (Midiprep) 
For mini-prep purification of plasmid DNA 3 ml of bacterial culture (like the one 
prepared above) was taken and processed following manufacturer’s instructions for 
the Zyppy™ Plasmid Miniprep Kit (Zymo Research, Cambridge Biosciences Ltd, 
Cambridge, UK). 
For midi-prep purification of plasmid DNA, I inoculated a larger culture 500 ml of LB 
broth with 100 µg/ml ampicillin with 100 µl of small bacterial culture (like the one 
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prepared above). This larger culture was incubated for a further 18-21 h with 
constant shaking. The entire culture was then processed according to the 
manufacturer’s instructions of the PureYield™ Plasmid Midiprep System (Promega, 
UK).  
Purity and quantity of both miniprep and midiprep prepared DNA was checked by 
Nanodrop 2000 spectrophotometry. 
2.4.3 Plasmid DNA digestion and validation 
To verify the identity of the plasmids I used in this study, single and double 
digestions using specific restriction enzymes was performed. For example, 500 ng of 
miniprep-prepared pGL3-pkcβ-0.5 plasmid was mixed with 1 µl of HindIII and/or 
with 1 µL XhoI restriction enzymes, as required for single/double digestion of the 
plasmid. 4 µL of digestion buffer 3 was added, 0.2 µl of molecular biology grade BSA 
solution, and the total reaction volume was topped up to 20 µl with nuclease-free 
water. The digestion was allowed to proceed for 1 h at 37ᴼC, and then the DNA 
fragments separated by electrophoresis using a 0.8% agarose gel (Figure 2.1). All 
restriction enzymes and buffers used in this thesis are from New England Biolabs, 
UK. 
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Figure 2.1: Validation of pGL3-pkcβ-0.5kb plasmid. The pGL3-pkcβ-0.5kb was 
validated for the PRKCB minimal promoter region (~0.5kb) insert in the basic pGL3 
plasmid by digestion method. Figure 2.1 A) shows the plasmid pGL3-pkcβ-0.5kb wt 
(lane 1). This plasmid was digested as single by either HindIII restriction enzyme 
(lane 2) or by XhoI restriction enzyme (lane 3) or as a double digest using both of 
these restriction enzymes in the same reaction (Lane 4). B) PGL3-pkcβ-0.5kb 
plasmid map shows the inserted 0.5kb of PRKCB promoter into the PGL3-Basic 
vector which drives the luciferase gene transcription in this vector by cutting the 
plasmid using digestion enzymes XhoI and HindIII. Arrows within the luciferase and 
Ampicillin gene boxes indicates the direction of the transcription. 
 
2.5 Loss of function Techniques 
2.5.1 Nucleofection of CLL and B cell lines 
Nucleofection is a technique that uses optimized voltage and an electrical 
conductive reagent to transfer nucleic acids into a target cell. To perform this 
procedure MEC1 and Daudi cells (2x106/transfection) or CLL cells (1x107/ 
transfection) were prepared by washing the cells twice with sterile pre-warmed PBS 
at 37ᴼC. The cells were finally suspended in 100 µl/transfection of nucleofection 
solution [nucleofection solution V (Lonza Group, Switzerland) for the CLL and MEC1 
cells, or Ingenio Mirus electroporation solution (Geneflow, Lichfield, UK) for Daudi 
cells]. When cells were in these solutions, they were kept in ice. The transfection 
procedure itself consisted of mixing 100 l of cells with different siRNA(s) or 
plasmids, transferring this mixture to a transfection cuvette and placing the cell 
within the Amaxa nucleofector (Lonza Biologics plc, UK). The following programs 
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were used for electroporation; U-13 for CLL cells, X-01 for MEC1 cells, and M-13 for 
Daudi cells. Directly following the electroporation the cells were transferred to 500 
µl of pre-warmed media within a 1.5 ml eppendorf tube, and maintained at 37ᴼC 
until all transfection procedures were complete. This was followed by transfer of 
the cells to more formal culture conditions (24 well plate) where they could be kept 
for 24 h under optimal conditions. Next day, the media was changed, and the cells 
were cultured for another 48 h before performing analysis for mRNA and protein 
levels.  
2.5.2 Knockdown studies by small interfering RNA (siRNA) 
Knocking down specific proteins in a highly precise fashion is one of the tools that is 
used to investigate the functional significance of these proteins under certain 
physiological and cellular conditions. This aim can be accomplished using different 
techniques such as siRNA, short hairpin RNA (shRNA), and, most recently, genomic 
editing using clustered regularly interspaced short palindromic repeats (CRISPR) and 
expression of the enzyme Cas9.    
For the purposes of this thesis siRNA was used. Table (2.1) lists the siRNA oligos 
used to target the genes of interest in this thesis. For many of the experiments in 
this thesis, pooled siRNA oligos were used. However, for some of the experiments 
single siRNA oligos were used. Where this was done is made explicit within the 
figure legends where illustrations of these experiments are presented. For 
specificity purposes, all experiments included a negative control where non-
targeted siRNA oligos were used. The amount of siRNA oligo solution used for 
particular target genes is made explicit within the figure legends where illustrations 
of these experiments are presented. Oligonucleotides siRNA for P300 was from 
[Santa Cruz technologies, Inc, Heidelberg, Germany, catalogue number (SC-29431)] 
while for E2F1 and c-Myc they were from Thermo scientific, MA, USA. 
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Table 2.1: siRNA duplex sequences of Sp1, Sp3, and MITF transcription factors 
Transcription 
factor 
siRNA duplex sequence Source 
 
Sp1 
 
D1 sense:5'-CCAAGGAAAUAAGGA-CAGUCUAGCT-3'  
  α-sense:3'-AUGGUUCCUUUAUUCCUGUCAGAUCGA-5'  
D2 sense:5'-CCCUCAACCCUAUUC-AUUAGCAUTA-3'  
   α-sense:3'-AUGGGAGUUGGGAUAAGUAAUCGUAAU-5'  
 D3 sense:5'-GGUGCAAACCAACAGAUUAUCACAA-3' 
   α-sense:3'-GUCCACGUUUGGUUGUCUAAUAGUGUU-5' 
 
TriFECTaRNAi 
Integrated DNA 
Technologies, 
Glasgow, UK 
 
 
Sp3 
 
D1 sense:5'-GCAAUGAAGAAAGUAAGUAGUCUTG-3' 
   α-sense:3'-UACGUUACUUCUUUCAUUCAUCAGAAC-5’ 
 
 D2 sense:5’-CCAGUAAAGUGUAACAUAUGCAAAC-3' 
   α-sense:3'-AUGGUCAUUUCACAUUGUAUACGUUUG-5' 
 
 D3 sense:5'-CCUAGAGUAAAUAAGAAUGAGCUTA-3' 
    α-sense:3'-AUGGAUCUCAUUUAUUCUUACUCGAAU-5' 
 
TriFECTaRNAi 
Integrated DNA 
Technologies, 
Glasgow, UK 
 
MITF 
 
D1 sense:5’-CCAAGUACCACAUACAGCAAGCCCA-3' 
   α-sense:3'-GUGGUUCAUGGUGUAUGUCGUUCGGGU-5' 
 
 D2 sense:5'-CCUAUGUAGACAAUAUAAGAGCUTC-3'  
   α-sense:3'-ACGGAUACAUCUGUUAUAUUCUCGAAG-5' 
 
 D3 sense:5'-GCCUAGAAUCAAGUUAUAAUGAGGA-3' 
   α-sense:3'-AUCGGAUCUUAGUUCAAUAUUACUCCU-5' 
 
TriFECTaRNAi 
Integrated DNA 
Technologies, 
Glasgow, UK 
 
2.6 Promoter Functional Study Techniques 
2.6.1. Dual Luciferase assay 
The dual luciferase assay is a technique that allows study of the naked promoter 
region of a specific gene in order to identify the factors, such as transcription 
factors, that affect its function.  
Promoter activity for the PRKCB gene was assessed using two different plasmid 
constructs. pGL3-pkcβ-0.5 is a 0.5kb construct consisting of the basal promoter 
region of the PRKCB gene upstream of the transcriptional start site inserted into the 
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pGL3 plasmid [A kind gift from Dr. A. P. Fields (Mayo Clinic College of Medicine, 
Jacksonville, Florida, USA]. pGL3-pkcβ-1.2 is a longer version (1.2kb) of the PRKCB 
containing the basal promoter region upstream of the transcription start site and 
including identified STAT3 binding sites within the promoter. This construct is 
cloned into the pGL3 plasmid backbone [a kind gift from Dr. K. P. Lee (Department 
of Immunology, Roswell Park Cancer Institute, Buffalo, USA)]. 
These plasmids were transfected into MEC1 and Daudi cells (2x106/experiment). 
Generally, 2 µg of either pGL3-pkcβ-0.5 or pGL3-pkcβ-1.2 was transfected with 100 
ng of pRL (a reference plasmid where expression of Renilla luciferase is driven by 
the CMV promoter). Luciferase activity was assessed 48 h following transfection, 
and was performed using the Dual Luciferase kit (Promega, UK) following the 
manufacturer instructions.  
In some experiments B cell lines transfected with pGL3-pkcβ-0.5 were treated with 
200 nM of mithramycin. Where this was done, mithramycin was added 24 h 
following transfection, and luciferase analysis carried out after an additional 48 h. In 
other tests investigating pGL3-pkcβ-1.2, transfected cells were treated with 100 nM 
PKCβ inhibitor (LY333531) (Cayman chemical company, Michigan, USA), 0.5 µM 
STAT3 inhibitor VII (Calbiochem, UK), 150 ng/ml Interlukin-6 (IL-6) (InvitrogenTM, 
Life Technologies, UK), 50 ng/ml Interlukin-21 (IL-21) (InvitrogenTM, Life 
Technologies, UK), or with 100 ng/ml VEGF. These reagents were added 2h 
following transfection, and analysis for promoter function performed after 48 h. 
2.6.2 Site- directed mutagenesis of Sp1 binding sites within the PRKCB 
promoter region 
Site-directed mutagenesis is a molecular technique whereby one or more 
alterations in a known nucleotide sequence of DNA is made. This methodology 
allows a precise understanding of the importance of certain nucleotide sequences 
on the activity of a gene promoter, or of an amino acid residue within a specific 
enzyme.  
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Alteration of the Sp1 binding sites within the PRKCB promoter was carried out by 
introducing mutations using a Stratagene QuickChange Site-Directed Mutagenesis 
kit (Agilent Technologies, Stockport, UK) following the manufacturer’s instructions. 
This kit uses a PCR-based protocol to achieve this purpose. Briefly, 25 ng of pGL3-
pkcβ-0.5 was used as a template in the PCR reaction. The PCR reaction consisted of 
pGL3-pkcβ-0.5 mixed with 5 µl of 10X reaction buffer, 1.25 pmol/µl each of forward 
and reverse primers (Table 2.2), 1 µl dNTP mix, and 10 µl of homemade 5X 
combinatorial enhancer solution (CES) (2.7 M betaine, 6.7 mM DTT, 6.7% DMSO, 
and 55 µg/ml BSA) which is used to solve the problem of PCR amplification of a GC-
rich region (>85%) within the template plasmid. The total volume was made up to 
50 µl with nuclease-free water. Finally, 1µl of PufoTurbo DNA polymerase (2.5 
U/µL) was added. The PCR reaction tube was briefly centrifuged and then put into a 
PCR machine where the following specific thermal profile was used to introduce the 
desired mutation: an initial denaturation step lasting for 30 s at 95ᴼC, 18 cycles 
whereby denaturation at 95ᴼC for 30s was followed by annealing at 70ᴼC for 1min 
and extension at 68ᴼC for 7 min. The PCR reaction was terminated with a final 
extension step at 68ᴼC for 7 min. Following the PCR reaction the parental plasmid 
template was digested with 1 µl of DnpI at 37ᴼC for 1 h. This digestion step was 
repeated. Then, 5µL of the PCR product containing the mutated promoter was 
transformed into 50 µl of XL1-Blue competent cells (section 2.4.1). Single colonies 
were picked and grown for miniprep preparations of the new plasmid. Introduced 
mutations were verified by commercial sequencing (Source BioScience plc, 
Nottingham, UK).  
Table 2.2:  Sequence of the primers used to introduce mutations for Sp1 binding 
site in PRKCB promoter region. 
Sp1 binding sites Primers sequence that used to introduce the mutations 
Sp1m1 Forward:5'-AGCAGCTGGCAGCGCTATGCTAGGCCTGGGCGCG-3' 
Reverse:5’-CGCGCCCAGGCCTAGCATAGCGCTGCCAGCTGCT-3' 
Sp1m2 Forward:5'TGGGCGCGATGCAAATGAGGAATGCTAGGCTGGCCCGGG-3'         
Reverse:5’CCCGGGCCAGCCTAGCATTCCTCATTTGCATCGCGCCCA-3' 
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2.6.3 Chromatin immunoprecipitation (ChIP) analysis 
Chromatin immunoprecipitation (ChIP) is a versatile tool in molecular biology 
because of its ability to define precise relationships between DNA and factors which 
regulate/affect gene expression/chromatin structure. Such factors can include 
transcription factors, chromatin remodelling proteins and histones, as well as DNA 
repair and replication proteins.   
In this thesis CLL and MEC1 cells were used to investigate the association between 
transcription factors and the PRKCB promoter. For each cell type 1x107 cells were 
washed twice with PBS and then treated with 0.5% formaldehyde solution (freshly 
prepared by dissolving paraformaldehyde in water with heating and in the presence 
of 7 mM KOH) for 5 min at R.T. to cross link proteins and DNA. The reaction was 
stopped with the addition of 1.35 M glycine to a final concentration of 135 mM, and 
then further kept at R.T. for 5 min. The fixed cells were washed twice with cold PBS, 
and then lysed with 1ml cold lysis buffer [(10 mM Tris-HCl pH 7.4, 10 mM NaCl, 5 
mM MgCl2, 0.2% IGEPAL
 CA-630, plus 1:100 diluted protease inhibitor 
(MerckMillipore, Watford, UK) and phosphatase inhibitor cocktails (200 mM 
Imidazole, 200 mM sodium fluoride, 100 mM Sodium orthrovanadate, 400 mM 
Sodium Tartrate, 100 mM β-glycerolphosphate, 100 Mm sodium pyrophosphate)] 
on ice for 15 min. Nuclei from the lysed cells were isolated by centrifugation at 
500xg for 5 min at 4ᴼC. These nuclei were washed once with 1 ml of cold MNase 
buffer [0.3 M sucrose, 10 mM Tris-HCl pH 7.4, 15 mM NaCl, 60 mM KCl, 5 mM 
MgCl2, 3 mM CaCl2, 0.5 mM spermidine, 0.15 mM spermine] using the same 
centrifugation conditions. This was followed by resuspending the pellet in 500 µl of 
cold MNase buffer to which 125 U micrococcal nuclease (New England Biolabs, UK) 
was added, and incubated the suspended nuclei for 20 min at 37ᴼC. The nuclease 
digestion reaction was stopped by with the addition of EDTA to a final 
concentration of 10 mM, and this was then sequentially followed by addition of 
IGEPAL CA-630, sodium deoxycholate and SDS to final concentrations of 1%, 0.5% 
and 0.1%, respectively. Nuclei were disrupted by sonication using a MS73 
 53 
 
sonication probe and two 30 s pulses at 40% power (Sonopuls ultrasonic 
homogenizer, BANDELIN GmbH & Co. KG, Berlin, Germany). This process released 
fragmented chromatin with an approximate size of 100-500bp (Figure 2.2). Finally, 
the tube was further by centrifuged at 12000xg for 5 min at 4ᴼC in order to remove 
insoluble material. 
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Figure 2.2: Sheared chromatin input sample from MEC1 cells. 1x107 cells of MEC1 
cell line were fixed with 0.5% paraformaldehyde to cross link DNA and associated 
proteins. The nucleus was disrupted by sonication for two 30sec pulses at 40% 
power. The cross link was   reversed and the size of 10µl purified DNA was observed 
by running it in 1% agarose gel. 
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The supernatant resulting from the above procedure contains protein/DNA 
complexes. This supernatant was initially precleared for 1 h with 20 µl Magna ChIP 
protein A+G magnetic beads (Millipore, Watford, UK), and then incubated overnight 
at 4ᴼC with either indicated ChIP-grade antibodies (Appendix D), or non-specific IgG 
control antibodies (Merck Millipore, Watford, UK) together with 20 µl Magna ChIP 
protein A+G magnetic beads (Millipore, Watford, UK). The immunoprecipitated 
complexes were then sequentially washed with 500 µl each  the following buffers in 
order: Low salt (0.1 %SDS, 1% Tritron-X 100, 2 mM EDTA, 150 mM NaCl, and 20 mM 
Tris-HCl pH=8.1), high salt (0.1 %SDS, 1 %Tritron-X 100, 2 mM EDTA, 500 mM NaCl, 
and 20 mM Tris-HCl pH (8.1), LiCL (0.25 M LiCL, 1% IGEPAL®CA-630, 1% sodium 
deoxycholate, 1 mM EDTA, and 10 mM Tris-HCl pH=8.1), and TE (10mM Tris-HCl 
pH=8.0 and 1Mm EDTA). Washed beads were then resuspended in 100 l elution 
buffer (1% SDS, 0.1 M NaHCO3, 0.2 M NaCl) to which 1 µl of RNAase inhibitor [248] 
was added, and then kept at 37ᴼC for 30 min with constant shaking using an 
Eppendorff thermomixer comfort (Humberg, Germany). The beads were removed 
by magnetic separation, and the supernatant taken and incubated at 65°C for 6 h in 
the presence of 10 µg of proteinase K to reverse cross links. The DNA contained 
within this eluate was purified using a DNA Clean & Concentrator™-5 kit (Zymo 
Research, Cambridge Bioscience Ltd, UK) according to the manufacturer’s 
instructions. DNA purified in this way was isolated in a total volume of 30 l.  
One microliter of purified DNA was used for PCR amplification using the following 
optimized thermal profile conditions: 20 s at 95ᴼC for denaturation, then annealing 
for 20 s and extension for 30 s at 72ᴼC, followed by an 11 s incubation to collect 
florescence data. The PCR reaction was performed using specific primers designed 
to cover the potential transcription factor binding sites within the PRKCB promoter 
(Figure 2.3) (Appendix C). Success of the immunoprecipitation step was confirmed 
by using primers for a gene known to be regulated by the transcription factor 
targeted by the antibodies used in this study (Appendix D).  
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Figure 1.3: Schematic diagram of the PRKCB promoter showing the location and 
sequence of the ChIP primers. This schematic drawing shows the binding sites for 
Sp1, E-box, E2F1, E47, RUNX1, and STAT3 binding sites within the PRKCB promoter 
and the ChIP primers that were used in this study covering the proximal and distal 
regions of this promoter. The transcription binding sites and the arrow for the 
proximal region of the promoter labelled in red while, for the distal region labelled 
with green. Underneath the schematic diagram is the sequence of the ChIP primers 
and labelled with same colour for each region as previously mentioned.  
 
2.6.4 PRKCB promoter methylation studies 
Promoter methylation occurs in different regions of a gene, including the gene body 
and the promoter region. This process is driven by DNA methyltransferases which 
add a methyl group to carbon number 5 within the pyrimidine ring of cytosine that 
are contained in CpG islands of DNA. Understanding DNA methylation is important 
because this is one epigenetic mechanism controlling gene expression, particularly 
when methylation occurs within the promoter region of genes.  
Study of the PRKCB promoter methylation status in this thesis was done using a EZ 
DNA Methylation-Gold™ Kit (Zymo Research, UK). This kit exploits the bisulfite 
conversion method which uses bisulfite to convert un-methylated cytosine within 
DNA sequences into uracil, and leaves methylated cytosine residues unchanged. 
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The product of this reaction is then studied following PCR amplification (in this 
thesis using primers specific for the PRKCB promoter) by sequencing. The 
percentage methylation in the CpG islands located within the DNA region of 
interest was measured relative to the ratio of T and C in the pyrogram. 
The protocol in brief, 1 μg of genomic DNA was sodium bisulphite treated using a 
EZ-DNA methylation gold kit (Zymo Research, Irvine, CA, USA).  A CpG-rich target 
region within the PRKCB promoter was selected for interrogation, and forward, 
reverse and pyrosequencing primers designed using Pyromark Assay Design 2.0 
software (Qiagen, Valencia, CA, USA) and synthesized by Eurofins MWG Operon: 
PRKCBmeth_fwd: 5’-GTTTGGGTATATTTTTTGAA-3’, PRKCBmeth_rev: 5’-Biotin- CCC 
TCCTCATTTACATC-3’, PRKCBmeth_seq: 5’-TTGGGTATATTTTTTGAA-3’.  PCR 
amplification was performed using 400 μM forward and reverse primers, 60 ng 
bisulphite-treated DNA, 200 µM dNTPs, 1 mM MgCl2 and 1.25 u GoTaq Flexi DNA 
polymerase (Promega, Madison, WI, USA). PCR cycling conditions were as follows: 
94°C for 3 min, followed by 40 cycles of 94°C for 30 s, 50°C for 30 s and 72°C for 30 s 
and an additional 72°C extension for 10 min. Specific PCR product quality and 
quantity were confirmed by agarose gel electrophoresis. PCR products were then 
immobilized on to Streptavidin Sepharose beads (GE Healthcare Biosciences, 
Pittsburgh, PA, USA) and sequentially washed in 70% ethanol, 0.2 M NaOH and 10 
mM Tris acetate, pH 7.5, using a PSQ96 Vacuum Workstation (Qiagen, Valencia, CA, 
USA).  PRCKBmeth_seq primer was then hybridized to the retained biotinylated 
DNA strand in annealing buffer and analysed using PSQ96 MA Pyrosequencer and 
PyroMark Gold Q96 reagents (Qiagen, Valencia, CA,USA).  Results presented as % 
methylation represent the mean average methylation of 8 CpGs within the analysed 
sequence. 
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2.7 Protein Electrophoresis and Blotting Analysis 
2.7.1 Preparation of cell lysate and protein determination 
2.7.1.1 Preparation of cell lysate  
Cell lines or CLL cells were harvested and washed once with cold PBS. Cells were 
lysed with 100 µl of 1% SDS lysis buffer (1% SDS, 125 mM Tris pH6.8, 5 mM EDTA, 
and 10% glycerol). The samples were kept in ice, and were sonicated for 30sec at 
40% power to disrupt released DNA. The samples were then heated at 95ᴼC for 10 
min, and finally centrifuged at high speed for 15 min to remove any debris. The 
lysates were kept at -20ᴼC until used.  
2.7.1.2 Protein determination 
The concentration of the total protein content for each sample was determined 
using the Bio-Rad DC protein assay kit (Bio-Rad laboratories Ltd, UK). Briefly, 5 µl of 
cell lysate was pipetted into wells of a 96 well plate in duplicate. In separate wells, a 
serial dilution of BSA standard (0-2 mg/ml) prepared in SDS lysis buffer was also 
applied. 1 ml of reagent A was freshly mixed with 20 µl of reagent S, and 25 µl of 
this mixture was then added to each well containing sample or standard. Then 200 
µl of reagent B was added per well, and the plate kept in dark for 15 min at room 
temperature. Absorbance readings were taken at 650 nm, and protein 
concentration within the samples was determined by comparison to the readings 
taken for the protein standards. The measurement was considered valid if there 
was a doubling of absorbance with each doubling of protein standard 
concentration, and the correlation coefficient value for the standard curve was 
0.99.  
For application to SDS gels, 10 µg of protein within the prepared cell lysates was 
used. The volume of each sample applied was equalised with SDS lysis buffer, and 
then 5X loading sample buffer (5% SDS, 625 mM Tris pH6.8, and 50% glycerol,  β-
mercaptoethanol and bromophenol blue) was added prior to gel loading.  
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2.7.2 Western Blotting 
2.7.2.1 Sodium Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis 
(SDS–PAGE) 
 SDS-PAGE is a chromatographic technique used to separate proteins based on size. 
Protein size in this technique is discriminated by changes in the percentage of 
acrylamide used to make the separating gels; low percentage acrylamide gels are 
better at resolving large molecular weight proteins, whereas high percentage gels 
are better at resolving low molecular weight proteins. Protein migration within gels 
is enabled by the application of an electrical field. So that all proteins migrate, the 
running pH of the separating gel is maintained at 8.8, and proteins are denatured in 
the presence of SDS which adds additional negative charge to facilitate protein 
migration. The final important feature of this system is the stacking gel, whose 
function is to focus (stack) proteins within samples by creating an ion gradient 
between faster running Cl- ions and slower running glycine by using a buffer whose 
ion strength is weaker than that used for the resolving gel, but has a pH of 6.8.  The 
molecular weight for any protein of interest can be determined by comparison with 
the migration of proteins with known molecular weights that are applied to run 
alongside the protein sample.  
The acrylamide composition of the gels used in this thesis is listed in the figure 
legends where this technique is used. For the purposes of this section I describe the 
preparation of a 10% acrylamide gel for a Bio-Rad minigel apparatus (Bio-Rad 
laboratories Ltd, UK): 4 ml resolving gel buffer (Geneflow, UK) was mixed with 5.3ml 
acrylamide solution (19:1 Acrylamide/Bisacrylamide, Geneflow, UK) and 6.7 H2O. 
Polymerisation of the gel was initiated with the addition of 75 µl 10% Ammonium 
persulphate (APS) and 15 µl tetramethylethylenediamine (TEMED). The amount of 
resolving gel solution made is ideal for casting 2 X 1.5mm PAGE gels, which were 
left to polymerize at R.T. for 1 h. A 5% polyacrylamide stacking gel was prepared by 
mixing 1.5 ml stacking gel buffer (Geneflow, UK) with 1 ml acrylamide solution and 
3.5 ml H2O, and then adding 10% APS and TEMED. 10 or 15 well combs were used 
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to create sample cells in the stacking gel. The gels were used immediately upon 
polymerisation.  
Samples were loaded into the prepared sample wells of the gels, and the 
electrophoresis apparatus was assembled and finally filled with 1X running buffer 
(25 mM Tris, 192 mM glycine, 0.1% SDS pH=8.3). For protein size Precision Plus 
Protein™ Kaleidoscope™ Standards (Bio-Rad laboratories Ltd, UK) were used. 
Protein separation was achieved with the application of 35V per gel constant 
voltage for 55 min.  
2.7.2.2 Protein Transfer   
Proteins separated by SDS-PAGE were transferred to polyvinylidene diflouride 
(PVDF) membranes for analysis by Western blot. PVDF membranes (0.45mm pore 
size, Roche Diagnostic Limited, UK) were cut to a 6X9 mm size, wetted with 
methanol, and placed into transfer buffer (25 mM Tris, 190 mM glycine, 0.1% SDS 
pH=8.3). A transfer sandwich was prepared, and was placed into the transfer 
apparatus along with chilled transfer buffer and a frozen cooling core. Finally, an 
electrical current 400mA (constant current) was applied for 1 h.  
2.7.2.3 Membrane probing and development 
To minimize non-specific interactions between membranes and probe antibody in 
Western blots the PVDF membrane was blocked using a blocking buffer consisting 
of T-TBS (25 mM Tris pH=7.6, 150 mM NaCl, 0.1% Tween-20) in which 5% (w/v) of 
advanced blocking agent (Fisher Scientific, UK) was dissolved for 1h with continues 
agitation at R.T. This blocking step was followed by probing the membranes for 
proteins of interest using primary antibodies; information regarding each of these 
including source and dilution is listed in Appendix D. Generally, membranes were 
incubated with primary antibodies diluted in blocking buffer overnight at 4ᴼC with 
continuous agitation. The next day the membranes were washed for 30 s, 5 min, 
and 10 min respectively with T-TBS, and then incubated with HRP (Horseradish 
peroxidase)-conjugated anti-rabbit/-mouse secondary antibodies diluted at either 
1:5000 or 1:10000 in blocking buffer for 1 h at R.T. with continuous agitation.  
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One exception to the above procedure was when membranes were probed for β-
actin. Here, membranes were probed with mouse monoclonal anti-β-actin antibody 
(Clone AC-74, product No. A 5316, Sigma Aldrich, Gillingham, UK) diluted 1:10000 in 
blocking buffer for at R.T. 30 min. The membrane was then incubated with HRP-
conjugated anti-mouse secondary antibody (1:10000) at R.T. for 30 min.  
Proteins of interest on the membranes were detected using either WESTAR® 
Supernova enhanced chemiluminescence (ECL) substrate reagent (Geneflow, UK) or 
Immobilon™ Western Chemiluminescent HRP Substrates (MerckMillipore, Watford, 
UK), and imaged using an LAS-1000 (Fujifilm, Japan). Densitometry was performed 
using AIDA image analyser software (v4.27.039).  
2.8 Immunoprecipitation (IP) 
Immunoprecipitation (IP) is a technique that allows isolation and concentration of a 
specific protein or a complex of proteins from a mixture, usually a cell lysate. This 
technique depends on the interaction of a specific antibody that recognizes a 
precise epitope on a protein of interest. For this study 1x107 CLL cells were lysed 
with RIPA buffer (10% Glycerol, 1% Triton X-100, 1% sodium deoxycholate, 0.1% 
SDS, 50 mM Tris pH=7.6, 2 mM EDTA, 2mM EGTA, 25 mM sodium pyrophosphate, 
50 mM sodium glycerolphosphate, 150 mM NaCl and 50 mM sodium fluoride) and 
centrifuged a 16,000xg for 15 min at 4C. The supernatant was then incubated with 
Sp1 antibodies overnight, and then precipitated with protein A/G magnetic beads. 
The beads were washed twice with RIPA buffer, and the attached proteins 
solubilised with SDS-PAGE sample buffer.  
2.9 Statistical Analysis 
The data in this thesis were analysed for statistical significance using either a 
Student’s t-test for paired data when comparisons between two connected 
variables were done, or a Mann-Whitney U-test for comparisons of data 
distributions such as expression of a particular gene between normal and CLL B cells 
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from different patients. The software used for these calculations was either 
Microsoft Excel, or IBM–SPSS (v22). 
 
Table 2.3: Sources for the chemicals that were used for the buffers preparations 
Name of supplier Chemical Name of supplier Chemical 
Sigma Aldrich, 
Gillingham, UK 
Betaine  Fisher Thermo 
Scientific, UK 
CaCl2  
β-glycerolphosphate  Glycine  
β-mercaptoethanol  KCl  
bromophenol blue dye  KOH  
BSA  MgCl2 
DTT  NaCl  
EDTA NaOH  
Ethanol  SDS  
Ficoll-400  sodium 
deoxycholate  
Glycerol  Tris acetate  
IGEPAL® CA-630 Tris borate  
Imidazole Tris-HCl  
LiCL  Tween20 
NaHCO3  paraformaldehyde 
 Orange G   
Sodium fluoride    
Sodium orthrovanadate   
Sodium pyrophosphate   
Sodium Tartrate    
Spermine   
spermidine   
Tritron-X 100  
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 Chapter Three: The key role of Sp1 in regulating 
PRKCB gene transcription 
 
3.1 Introduction and aim  
In 1992 the 5ˊuntranslated region of PRKCB, a region which includes the gene 
promoter, was cloned and characterized by Obied et al. [4]. They found that the 
PKCβ gene has a TATA-less promoter type with a high GC content. In addition, they 
showed that the 600bp region upstream of the transcriptional start site contained a 
number of potential binding sites for transcription factors (Figure 3.1). Interestingly, 
they found that a 100bp section immediately before the transcriptional start site 
was vital for basal promoter activity. Likewise, similar results were found in a 
different cellular system described by Niino et al. [161]. This 100bp section was 
noted to contain putative Sp1 binding sites. 
CLL cells are distinctive from normal B cells and other B cell malignancies by their 
ability to overexpress PKCβII [1]. Overexpression of this PKC isoform is regulated at 
the transcriptional level, and, as such, is markedly inhibited by mithramycin [143], a 
drug that inhibits gene transcription by intercalating into GC-rich areas of DNA 
particularly at Sp1 binding sites.  
Prior to beginning this thesis any role for Sp1 in PKC gene transcription was 
unknown. Therefore, a principle aim of this chapter was to investigate whether Sp1 
drove promoter activity and transcription of PRKCB in CLL cells. Secondary to this 
aim, was to determine the relationship between Sp1 and PKCII expression in CLL 
cells in order to understand whether Sp1 contributes to disease pathogenesis. 
However, using CLL cells in genetic manipulation studies is difficult. Therefore, a cell 
line model was used to develop these studies, which were then confirmed in CLL 
cells. 
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Figure 3.1: Schematic drawing of the basal PRKCB promoter. This schematic 
drawing shows the CG-rich region of the PRKCB promoter in pink, and lists potential 
transcription factor binding sites. The transcription start site is labelled by the red 
arrow and the translational site labelled by ATG in red. 
 
3.2 Results 
3.2.1 PKCβII mRNA levels are overexpressed and correlated with 
PKCII protein levels in CLL cells 
Previously, Abrams et al., 2007 reported that PKCβII protein is overexpressed in CLL 
cells compared to normal B and other types of mature B lymphoid malignant cells 
[1]. In addition, they showed that overexpression of this protein is due to the 
dominant transcript of PKCβII mRNA from the PRKCB gene. Moreover, they found a 
strong positive correlation between the mRNA of this isoform and its protein 
expression in these malignant cells. Therefore, I have started my investigations to 
understand the molecular regulatory mechanism(s) that control expression of the 
PRKCB gene in CLL cells by confirming these results. 
Using qRT-PCR and specific primers covering the coding region of PKCβII, I 
compared the relative expression of PKCII mRNA in normal B and in CLL cells. I 
found that PKCβII mRNA was expressed at significantly higher levels in CLL cells 
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compared to normal B cells (Figure 3.2A). Western blot analysis of PKCII protein 
levels in CLL and normal B cells showed that this PKC isozyme is overexpressed in 
the former (Figure 3.2B and C). In these experiments β-actin was used to indicate 
equal protein loading. Furthermore, as positive and negative controls I used Bcl2 
and ERK. It is well known that CLL cells overexpress Bcl2 protein compared to 
normal B cells, and Figure 3.2B confirms this in my results. In contrast, normal B 
cells and CLL cells showed equal amounts of total ERK protein (Figure 3.2B). Taken 
together, these results indicate that PKCII is overexpressed in CLL cells at both the 
transcriptional and protein levels, allowing reconfirmation of the strong correlation 
between PKCβII mRNA and protein levels in CLL cells (Figure 3.2D). 
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Figure 3.2: PKCβII is overexpressed in CLL compared to normal B cells. CLL and 
normal B cells were purified by positive selection and analysed for expression of 
PKCβII mRNA by qRT-PCR and protein by Western blot. A) PKCβII mRNA levels in CLL 
(n=23) and normal B (n=3) cells. Levels are reported relative to those of RNA 
Polymerase II, and are expressed as arbitrary units. B) PKCβII protein expression in 
CLL and normal B cells. Lysates of CLL and normal B cells were prepared and 10 µg 
protein was separated by SDS-PAGE, transferred to PVDF membrane, and probed 
for the indicated antibodies. C) Quantitative analysis of PKCβII, Bcl2, and total ERK 
protein expression in CLL and normal B cells depicted in part B. The Western blots 
prepared in part B were analysed by densitometry, and respective protein levels are 
reported relative to β-actin. Statistical significance was determined using a Mann-
Whitney U-test. D) Correlation analysis of PKCβII mRNA and protein in CLL cells. 
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3.2.2 Different leukaemia and lymphoma cell lines show different 
levels of PKCβII mRNA and protein expression 
Due to difficulty of using CLL cells in some of the functional experiments, it was 
important to determine and characterise a cell line for this purpose. Thus, I 
investigated the expression of PKCβII mRNA and protein levels in different 
leukaemic and lymphoma cell lines. qRT-PCR analysis showed variation in the 
relative expression of PKCβII mRNA level between the cell lines that were screened 
(Figure 3.3.A). Also, PKCβII protein level in these cell lines showed dissimilarity in 
the expression (Figure 3.3.B). For example, PKCβII protein was completely un-
expressed in KCL22 cells, a cell line derived from a chronic myelogenous leukaemia 
patient who is in blast crisis stage [249]. This is in contrast to the K562 cells which 
are also derived from a chronic myelogenous leukaemia patient in blast crisis stage 
[250]. The mRNA and protein levels of PKCβII expression in MEC1 cell line that 
represents a model of CLL cells showed the highest expression between these 
different malignant cells. In addition, Daudi cells showed a slightly lower level of 
PKCβII protein and this was in accord with its mRNA level in these cells. These 
results show that MEC1 and Daudi cells are the most suitable cells that I could use 
later in my functional experiments.  
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Figure 3.3:  Different cell lines show different levels of PKCβII mRNA and protein 
expression. Various leukaemia and lymphoma cell lines were screened for PKCβII 
mRNA and protein expression. A) qRT-PCR analysis of PKCII mRNA expression in 
the indicated cell lines. PKCβII mRNA levels are reported relative to RNA 
Polymerase II and are presented as mean ± SE of n=3 separate measurements. B) 
Western blot analysis of cell lysates prepared from the indicated cell lines. 10 µg of 
protein was separated on 10% acrylamide SDS-PAGE gels, and transferred to PVDF 
membranes, which were then probed with antibodies to PKCβII and β-actin. 
 
 
3.2.3 Sp1 mRNA is overexpressed and correlates with protein level in 
CLL cells 
As previously mentioned, overexpression of PKCβII is a distinctive feature of CLL 
cells where it likely contributes to the pathophysiology of this disease. Early studies 
of PRKCB promoter function suggested a potential role for Sp1 in transcription of 
the gene [4, 161]. To investigate this potential role it seemed logical to determine 
the level of expression of Sp1 in CLL cells.  
To study Sp1 mRNA expression three sets of primer pairs covering the entire coding 
region of Sp1 were designed (Table 3.1). First, a temperature gradient PCR for the 
primer sets was performed in order to optimize the suitable annealing 
temperature. I found that primer set number 3 amplified a single band without any 
formation of primer dimers at an annealing temperature of 64ᴼC (Figure 3.4A). qRT-
PCR was then used to amplify Sp1 from CLL samples, and this showed exponential 
amplification starting at cycle 26 (Figure 3.4B), with a single product as detected 
with a melting curve (Figure 3.4C). Thus, primer pair 3 was used to analyse Sp1 
mRNA expression in the cells used in this thesis. 
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Figure 3.4: Selection and optimization of PCR conditions for Sp1 primer pairs. A) 
An annealing temperature gradient of the three different primer pairs used to 
amplify Sp1. MEC1 cells were used as a source of cDNA, and the listed annealing 
temperatures were used as part of the PCR cycle. The cDNA template was amplified 
for 40 cycles using a DNA Engine RPTC-200 Peltier thermal cycler, and the products 
were separated using a 1% agarose gel. B) Amplification curve of the Sp1 amplicon 
using primer set 3 (blue) relative to that of the RNA Polymerase II amplicon 
reference gene (green). PCR was performed to 40 cycles using a Stratagene qRT-PCR 
machine. Nuclease free water was used as a negative control (Red and Grey). C) 
Melting curve of the final qRT-PCR products produced in part B. Single PCR products 
for the Sp1 (Blue) and RNA Polymerase II (green) amplicons were observed after 40 
cycles of amplification. 
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Table 3.1: Sequence of primer sets for measuring Sp1 mRNA 
Name of the primer Sequence of the primers 
Primer set 1 
   For: 5'-ACCACCTGTCAAAACATATCAAGACCCAC-3' 
   Rev: 3'-TGCCACCTGCATGACGTTGATGCC-5’ 
Primer set 2 
   For: 5'-TTTGCCTGCCCTGAGTGTCCTAAG-3' 
   Rev: 3'-GGTGGTAATAAGGGCTGAAGGAGTG-5’ 
Primer set 3 
   For: 5'-TCAAGACCCACCAGAATAAGAAGGGAG-3' 
   Rev: 3'-GACGTTGATGCCACTGTTGGCAAG-5’ 
 
 
I found that Sp1 mRNA levels were significantly overexpressed in CLL compared to 
normal B cells (Figure 3.5.A). Analysis of Sp1 protein levels showed a similar result, 
this protein being overexpressed in CLL compared to normal B cells (Figure 3.5.B 
and C). Finally, I showed that levels of Sp1 mRNA correlated with protein levels 
(Figure 3.5.D) indicating a potential relationship between Sp1 and PKCII that is 
investigated in section 3.2.5.  
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Figure 3.5: Sp1 mRNA and protein is overexpressed in CLL compared to normal B 
cells. Purified CLL and normal B cells were analysed for expression of Sp1 by qRT-
PCR and Western blot. A) qRT-PCR analysis of Sp1 mRNA levels in CLL (n= 9) and 
normal B cells (n=3). Sp1 mRNA expression is reported as arbitrary units relative to 
RNA Polymerase II as reference gene. Statistical analysis was performed using a 
Mann-Whitney U-test (p=0.014). B) Differential expression of Sp1 protein between 
normal B (n=3) and CLL cells (n=9). 10 µg protein from normal B and CLL cell lysates 
was separated by SDS-PAGE (10% acrylamide gel) and transferred to PVDF 
membrane, which was then probed with the indicated antibodies. C) Quantitative 
analysis of Sp1 protein expression relative to β-actin. Gel densitometry was used to 
analyse Sp1 and β-actin expression in the gels illustrated in part B. Statistical 
analysis was performed using a Mann-Whitney U-test. D) Correlation analysis of 
Sp1 mRNA with protein levels in primary CLL cells. Pearson coefficient was 
calculated using SPSS version 22 (R=0.65) and the correlation is significant at the 
0.05 level (p=0.05).  
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3.2.4 Differential expression of Sp1 mRNA and protein in different 
leukaemia and lymphoma cell lines   
 Given that cell lines were to be used in some of the experiments that relate to the 
functional studies, it was reasonable next to investigate Sp1 mRNA and protein 
expression levels in these different leukaemia and lymphoma cell lines. I found that 
the Sp1 mRNA levels are similar in MEC1, K652, Jeko-1 and Mino cell lines. 
Conversely, it was considerably lower in both KCL22 and Daudi cells (Figure 3.6A). 
Also, I found that Sp1 protein levels were similar in all of the cell lines examined 
(Figure 3.6B). Accordingly, I decided to use MEC1 cell line in the future studies 
because as mentioned earlier it is derived from CLL patient. In addition, I used 
Daudi cell lines because they showed reasonable level of Sp1 mRNA and protein. 
Also, previous work in our lab showed that these cell lines are easy to be 
transfected.  
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Figure 3.6: Different cell lines show different levels of Sp1 mRNA and protein 
expression. Various leukaemia and lymphoma cell lines were screened for PKCβII 
mRNA and protein expression. A) qRT-PCR analysis of Sp1 expression in the 
indicated cell lines. Sp1 mRNA levels are reported relative to RNA Polymerase II and 
presented as mean ± SE of n=3 separate measurements. B) Western blot analysis of 
cell lysates prepared from the indicated cell lines. 10 µg of protein was separated 
on 10% acrylamide SDS-PAGE gels, and transferred to PVDF membranes, which 
were then probed with antibodies to Sp1 and β-actin.  
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3.2.5 Sp1 protein levels correlate with PKCβII mRNA in CLL cells 
The data in section 3.2.3 demonstrates overexpression of Sp1 mRNA and protein 
levels in CLL cells. This observation suggests a correlation between PKCβII mRNA 
and Sp1 protein levels in CLL cells. Indeed, Figure 3.7 shows significant correlation 
between PKCβII mRNA and Sp1 protein levels in these cells, indicating that Sp1 
potentially plays a role in PKC gene transcription. The rest of this chapter is 
devoted to characterising this role.  
 
  
 
 Figure 3.7: Sp1 protein correlates with PKCβII mRNA in CLL cells. Sp1 protein 
levels were determined by Western blot and PKCβII mRNA expression was 
determined by qRT-PCR in purified CLL cells (n=9). The points associated with each 
individual case were plotted and linear regression applied. Pearson coefficient 
(R=0.817) was calculated by using SPSS version 22 software, and the correlation 
was considered significant at the 0.01 level (p=0.007). 
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3.2.6 Mithramycin inhibits PKCβ gene expression in B lymphoid cell 
lines and CLL cells in a concentration-dependent manner      
As a first step in elucidating the role of Sp1 in regulating PKCβ gene transcription in 
CLL cells I used mithramycin. Mithramycin is one of a family of antibiotics whose 
structure is based on aureolic acid. Mithramycin was isolated and characterized in 
the early 1950s, and is derived from fungus like bacteria such as Streptomyces 
plicatus that belong to the phylum actinobacteria. Accordingly mithramycin has also 
been named plicamycin owing to the organism from it was first isolated [251]. 
Mithramycin has a chemically distinctive feature that allows selective binding to 
GC-rich regions in the minor groove of DNA [252, 253]. These GC-rich regions of 
DNA are often found within the regulatory regions of genes and contain binding 
sites particularly for Sp group transcription factor members. Interaction of 
mithramycin with GC-rich regions of DNA can therefore block the binding of Sp 
group transcription factors, and this can lead either to down-regulation, or to up-
regulation of gene expression. An important member of the Sp group of 
transcription factors is Sp1, and many cancers, including CLL, show high expression 
of this protein. Thus, mithramycin was investigated as a therapeutic strategy to 
target Sp1 in different types of cancer cells [254, 255], and is recently approved in 
phase II clinical trials for the treatment of osteosarcoma [256]. 
I first established the optimal concentration of mithramycin to use. This was done 
by treating CLL as well as MEC1 and Daudi cells with different concentrations (0, 50, 
200, and 400 nM) of mithramycin. Figure 3.8 show that the presence of 
mithramycin reduced PKCβII mRNA levels in these cells in a concentration-
dependent fashion. As previously shown by our group [143], the presence of 
mithramycin with CLL cells had no effect on their viability. The same was true for 
MEC1 and Daudi cells, regardless of whether the cells were cultured under serum-
free or serum-rich conditions. This latter experiment was necessary because Sp1 
transcribes many genes involved in the cell cycle [176], and is itself regulated by cell 
cycle genes such as E2F1 and CDK4, among others [257]. Thus, we observed that 
maximal reduction of PKCβII mRNA levels in both cell lines and in CLL cells were 
achieved using a concentration of 200 nM mithramycin. This similarity in response 
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suggested that MEC1 and Daudi cells could be used to model the behaviour of in 
vitro-cultured CLL cells. 
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 Figure 3.8: Mithramycin inhibits PKCβII mRNA levels in B lymphoid cell lines and 
in CLL cells in a dose dependent manner. CLL cells (1x107/ml) or B lymphoid cell 
lines (MEC1 and Daudi) (2x106/ml) were cultured for 24 h in the absence (UT) or 
presence (MIA) of the indicated concentrations of mithramycin (nM). A) PKCβII 
mRNA levels in CLL cells taken from different six patients (mean±SE). B) Effect of 
Mithramycin (200 nM) on PKCβII mRNA levels in CLL cells from a single CLL patient 
(n=3 separate biological replicates) (mean±SE). C) and D) PKCβII mRNA levels in 
MEC1 and Daudi cell lines, respectively, cultured under serum free (SF) or serum 
rich (FCS) medium conditions. This experiment illustrates (n=3) separate biological 
replicates (mean±SE) and the relative mRNA to RNA Polymerase II for each replicate 
was measured by qRT-PCR as triplicates. Statistical analysis for all parts of this figure 
was performed using a student’s t-test for paired data.      
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3.2.7 Mithramycin inhibition of PKCβ gene transcription in MEC1 and 
CLL cells results in a time-dependent decrease in PKCII mRNA levels  
200 nM of mithramycin was determined optimal for the inhibition of PKC gene 
expression because PKCβII mRNA levels were quantitatively reduced in treated cells 
without affecting cell viability.  I next used this concentration to investigate the 
kinetics of this reduction. Figure 3.9 shows that PKCβII mRNA levels began to drop 
in MEC1 and CLL cells after 3 h incubation with mithramycin, and maximal effect 
was observed after 12 h. The half-life of PKCβII mRNA in these cells is estimated to 
be between 6-9 h. Because mithramycin does not affect cell viability under these 
conditions, I used a 24 h incubation period for all subsequent experiments.  
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Figure 3.9:  Change in PKCβII mRNA levels in MEC1 and CLL cells treated with 
mithramycin. MEC1 cells (2x106/ml) or CLL cells (1x107/ml) were cultured in the 
absence (UT) or presence of 200 nM mithramycin (MIA) for 24 h. Every 3 h a sample 
of cells was taken and the expression of PKCβ mRNA relative to RNA Polymerase II 
was measured by qRT-PCR. A) PKCβ mRNA levels in MEC1 cells. B) PKCβ mRNA 
levels in CLL cells from three different patients. All the experiments in this figure 
illustrate (n=3) separate biological replicates, and values are presented as mean±SE. 
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3.2.8 Mithramycin inhibits Sp1 gene expression in MEC1, Daudi and 
CLL cells    
It was reported that Sp1 gene expression is auto-regulated by Sp1 binding to its 
promoter [257]. I next asked the question whether mithramycin treatment of the 
cells used in the present study also affected Sp1 mRNA levels. Indeed, similar to the 
effect of mithramycin on PKCβII mRNA levels, 200 nM of mithramycin also caused 
marked inhibition of Sp1 mRNA expression in MEC1, Daudi and CLL cells after 24 h 
treatment (Figure 3.10). This result suggested two questions for investigation. The 
first question is that mithramycin can affect many genes, so it should be 
determined whether there are specific effects on other genes. Secondly, my earlier 
observations indicated a close correlation between expression of Sp1 and that of 
PKCII, indicating that a reduction in Sp1 expression potentially affects PKC gene 
transcription. Therefore, clarification of a direct role for Sp1 in PKC gene 
transcription needs to be established. 
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Figure 3.10: Effect of mithramycin on Sp1 mRNA levels in MEC1, Daudi and CLL 
cells. A) MEC1, B) Daudi (each 2x106/ml) and C) CLL (1x107/ml) cells were cultured 
for 24 h in the absence (UT) or presence of 200 nM mithramycin (MIA). MEC1 and 
Daudi cells were cultured under serum free (SF) or serum rich (FCS) conditions. Sp1 
mRNA levels in each cell type was determined by qRT-PCR and is expressed relative 
to RNA Polymerase II. Each illustration represents 3 separate biological replicates 
(mean±SE). In part C, CLL cells from 3 different patients were used. Statistical 
analysis for all parts of this figure was performed using a student’s t test for paired 
data.  
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3.2.9 Mithramycin treatment does not change BCL10 mRNA levels in 
MEC1 of CLL cells 
To investigate the specificity of mithramycin I used BCL10 as a negative control. Use 
of the Encyclopaedia of DNA Elements (ENCODE) reveals that this gene contains 
CpG islands and a single Sp1 binding site. This suggests that expression of BCL10 is 
potentially affected by mithramycin. Figure 3.11 shows that treatment of either 
MEC1 or CLL cells with 200 nM mithramycin do not affect the expression of BCL10. 
This result indicates that mithramycin selectively affects the expression of some 
genes, and, therefore, suggests that the drop in Sp1 and PKCβ mRNA levels in 
treated MEC1 and CLL cells is because of targeted disruption of gene expression by 
this drug. 
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Figure 3.11: Effect of mithramycin on BCL10 mRNA levels in MEC1 and CLL cells. 
BCL10 mRNA levels were determined by qRT-PCR and are shown relative to RNA 
Polymerase II. A) MEC1 cells (2x106/ml) and B) CLL cells (1x107/ml) were incubated 
for 24 h in the absence (UT) or presence of 200 nM mithramycin (MIA). This 
experiment illustrates n=3 separate biological replicates (mean±SE). In the case of 
CLL, cells from 3 different patients were used.  Statistical analysis for all part of this 
figure was performed by using a student’s t-test for paired data. 
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3.2.10 Sp1-specific siRNA reduces PKCβII mRNA levels in MEC1, Daudi 
cell lines and CLL cells 
The results from sections 3.2.5 and 3.2.6 suggest that Sp1 has a potential role in 
regulating the expression of PRKCB in CLL cells. Thus, to clarify this role I used 3 
different Sp1-specific siRNA oligonucleotides to reduce the levels of Sp1 protein in 
MEC1, Daudi, and CLL cells and investigated whether this also affected PKCII 
expression (Figure 3.12). The use of each specific oligonucleotide affected Sp1 
expression to a different extent in MEC1 cells, an effect that was not observed with 
the control (non-specific) oligonucleotide. It was determined that the mix of all 3 
oligos was most effective at reducing mRNA and protein levels of Sp1 in MEC1 and 
cells. Furthermore, the reduction in Sp1 protein levels was accompanied by a 
concomitant reduction in PKCβII transcript and protein levels in these cells.  
In CLL and Daudi cells, similar results were observed. Use of the siRNA mix showed 
reduction in Sp1 mRNA and protein levels, and this was accompanied by reduction 
in PKCII mRNA and protein levels (Figure 3.12G-I). Taken together, these results 
demonstrate that reduced Sp1 expression results in a reduction of PKCII gene and 
protein expression, and suggests that the effect of mithramycin is due to inhibition 
of Sp1. However, whether Sp1 directly drives the transcription of PRKCB still 
needed to be determined.     
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Figure 3.12:  Sp1-specific siRNA reduces PKCβII mRNA and protein levels in MEC1, 
Daudi and CLL cells. MEC1 and Daudi cells (2x106 each) and CLL cells (1x107) were 
nucleofected with Sp1-specific or control siRNA oligonucleotides (2 µM), and then 
cultured under the conditions specific for each cell type for 72 h. Harvested cells 
were analysed for protein expression by Western blot and for mRNA levels by qRT-
PCR measured relative to the reference gene RNA Polymerase II. A) Sp1 mRNA 
levels in MEC1 cells. B) PKCβII mRNA levels in MEC1 cells. C) Western blot analysis 
of MEC1 cell lysates for the indicated proteins.  D) Sp1 mRNA levels in Daudi cells. 
E) PKCβII mRNA levels in Daudi cells. F) Western blot analysis of Daudi cell lysates 
for the indicated proteins.  G) Sp1 mRNA levels in CLL cells. H) PKCβII mRNA levels 
in CLL cells. I) Western blot analysis of CLL cell lysates for the indicated proteins. 
Graphical data are presented as arbitrary units where each graph represents 
mean±SE of n=3 separate experiments. Where CLL cells were used, experiments 
were performed using material from different patients. -actin is used as a loading 
control for Western blots. Statistical analysis for all parts in this figure was 
performed using a student’s t-test for paired data. 
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3.2.11 Sp1 drives PRKCB promoter function  
I next performed a functional assay to investigate the role of Sp1 in driving 
expression of the PKCβ gene. This was done using the basal PRKCB promoter region 
to drive expression of luciferase (from the pGL3-pkc0.5 plasmid) in Daudi and 
MEC1 cells. Figure 3.13A shows that Daudi (top panel) and MEC1 cells (bottom 
panel) have considerable luciferase activity when transfected with the pGL3-
pkc0.5 plasmid compared to those transfected with pGL3 alone. This figure also 
shows that the presence of 200 nM mithramycin quantitatively reduces promoter 
activity in pGL3-pkc0.5-transfected Daudi and MEC1 cells to background levels. 
Thus, similar to its effect in reducing PRKCB transcription, mithramycin also 
suppresses PRKCB promoter function.  
Reduction of Sp1 expression using specific siRNA also blocked PRKCB promoter 
function in pGL3-pkc0.5-transfected Daudi and MEC1 cells, an effect that did not 
occur in cells treated with either control siRNA or had no siRNA added (Figure 
3.13B). These results clearly show a role for Sp1 in driving PRKCB promoter 
function, and, taken together with the data showing the effect of Sp1 knockdown 
on PKCII mRNA levels, strongly suggest that Sp1 may drive PKC expression in vivo.  
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Figure 3.13: Sp1 drives PRKCB promoter activity. 2x106 Daudi (top panels) and 
MEC1 (bottom panels) cells were transfected with pGL3-pkcβ-0.5 and pRL according 
to the procedure outlined in the materials and methods. A) Effect of mithramycin. 
Following transfection, cells were cultured for 24 h under serum-rich conditions, 
and then transferred into serum-free for a further 48 h. For the final 24 h, 200 nM 
mithramycin was added where indicated. B) Effect of Sp1 knockdown using specific 
siRNA. Daudi and MEC1 cells were co-transfected with either control or Sp1-specific 
siRNA as indicated, and then further cultured for 72 h. Luciferase assays were 
performed and results are presented as activity mean±SE of firefly (promoter 
specific) relative to renilla (reference) of n=3 experiments. Statistical analysis was 
performed using a student’s t-test for paired data.  
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3.2.12 Both Sp1 binding sites within the PRKCB promoter are 
important to its function  
The promoter of PRKCB has two binding sites for Sp1, one at position -94 (site 1) 
and a second a -63 (site 2) [4]. To clarify which of these binding sites is important 
for driving PRKCB promoter activity I used site-directed mutagenesis. Thus, I 
created mutations within the Sp1 binding sites at site 1, site 2, or both site 1 and 2 
within pGL3-pkc0.5 (Figure 3.14A). Sanger sequencing of the pGL3-pkc0.5 
plasmid containing the various mutations confirmed that they had been introduced 
(Figure 3.14A). Transfection of these pGL3-pkc0.5 plasmid mutants into Daudi cells 
showed that mutations within either of the binding sites for Sp1, or both, within the 
PRKCB promoter resulted in a profound reduction in luciferase expression (Figure 
3.14B). This finding is supported by studies of other gene promoters which show a 
requirement for multiple Sp1 binding sites for full promoter activity [258-260]. 
Importantly, this experiment demonstrates that Sp1 binding to both sites within the 
basal PRKCB promoter is required to drive activity. Because gene expression is 
reduced to background levels when Sp1 sites were mutated in the basal PRKCB 
promoter thus, this result implies that no other transcription factor is involved in 
basal promoter activity and that Sp1 is likely the main driver of PKC gene 
expression in vivo. 
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Figure 3.14: Effect of Sp1 binding site mutation on PRKCB promoter-driven 
luciferase expression. The Sp1 binding sites within the basal PRKCB promoter of 
pGL3-pkc0.5 were mutated by site-directed mutagenesis and validated by Sanger 
sequencing. A) Sanger sequences of pGL3-pkc0.5 comparing the basal PRKCB 
promoter region containing the Sp1 binding sites. The sequence enclosed by the 
red box shows those with mutations compared to unaltered sequences enclosed 
within the purple box. B) Daudi cells (2x106) were transfected with wt pGL3-pkcβ-
0.5, or with pGL3-pkcβ-0.5 containing mutations within Sp1 binding site 1, site 2, or 
site 1 and 2 (sequence changes are denoted in green). Luciferase assays were 
performed following 72 h culture of the cells under serum-rich conditions, and are 
reported relative to renilla expression. The data are shown as mean±SE of three 
independent experiments. Statistical analysis was performed using a student’s t-
test for paired data.   
 
 
3.2.13 Sp1 binds directly to the PRKCB promoter in CLL and MEC1 cells 
To further investigate the direct role of Sp1 in regulating PKCβII gene expression I 
used Chromatin immunoprecipitation (ChIP). Here, I compared the binding of this 
transcription factor to the PRKCB promoter in both CLL cells and normal B cells.  
Figures 3.15A and B show that Sp1 binds the PRKCB promoter in CLL cells to a 
significantly greater extent than in normal B cells. In addition, I found that Sp1 is 
also associated with the PRKCB promoter sequence in MEC1 cells (Figure 3.15C). All 
these experiments included a negative control where a non-specific antibody was 
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used. Moreover, as a positive control the DHFR gene promoter was used because 
this gene is known to be controlled by Sp1 [261] (Figure 3.15D). Thus, Sp1 binds 
directly to the PRKCB promoter sequence. 
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Figure 3.15: Sp1 binds to the PRKCB promoter sequence in CLL and MEC1 cells. CLL 
and normal B cell extracts were prepared for ChIP analysis, and Sp1, or a non-
specific antibody was used for immunoprecipitation. The PRKCB promoter 
sequences associated with Sp1 were detected by qPCR, and are presented as fold 
enrichment compared to the PRKCB promoter sequences associated with the non-
specific IgG immunoprecipitation control. A) Shows the results of each single 
experiment for different CLL patient’s samples and three samples of purified normal 
B cells. B) Shows the summary (mean±SE) of the experiments displayed in part A. 
Statistical analysis was performed using a Mann-Whitney U-test. C) Shows Sp1 
association with the PRKCB promoter sequence in MEC1 cells. The data represents 
mean±SE of three independent experiments. D) Shows Sp1 binding to the DHFR 
gene promoter, a positive control for amplification of Sp1 association with a specific 
sequence in a promoter region of a gene. 
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3.2.14 Mithramycin displaces Sp1 from its cognate binding sequence 
within the PRKCB promoter in CLL and MEC1 cells   
I next employed ChIP to investigate the mechanism mithramycin employs to 
suppress PKC expression in CLL and MEC1 cells. Figure 3.16 shows that Sp1 
association with the PRKCB promoter sequence in both CLL and MEC1 cells is 
eliminated by the presence of 200 nM mithramycin. This result, taken together with 
my experiments demonstrating the role of Sp1 in driving PRKCB promoter function, 
show that mithramycin inhibits PKC gene expression by limiting the access of Sp1 
to its binding sites. These results also suggest that Sp1 is the main driver of PRKCB 
transcription in CLL cells.  
Interestingly, my experiments with CLL cells showed that Sp1 association with the 
PRKCB promoter specific sequence decreased in CLL cells after 24 h culture (Figure 
3.16A). This reveals a potential regulation of PKC gene expression through control 
of Sp1 association with the promoter. This aspect is further investigated in a 
subsequent chapter of this thesis.  
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Figure 3.16: Mithramycin displaces Sp1 from the PRKCB promoter sequence. CLL 
cells (1x107) and MEC1 cells (2x106) were incubated for 24 h in the absence (UT) or 
presence of 200 nM mithramycin (MIA). Sp1 was immunoprecipitated from 
prepared extracts, and the presence of Sp1 binding to the PRKCB promoter was 
detected using qPCR. The results are presented as fold enrichment of the PRKCB 
promoter sequences associated with Sp1 compared to the IgG immunoprecipitation 
control. A) Data derived using CLL cells from (n=3) different patients. T0 represents 
CLL cells used directly after thawing. B) Data derived from MEC1 cells and 3 
biological replicates. The data presented illustrates the mean±SE of the replicates 
used. Statistical analysis was performed using a student’s t-test for paired data. 
 
3.1.3 Discussion 
At the beginning of this work it was unclear how PKC gene expression was 
regulated. Two early studies characterised the basal promoter region of PRKCB, and 
showed that they had potential binding sites for a number of transcription factors 
[4, 161]. However, these studies did not investigate the individual contribution of 
these factors in regulating PKCβ gene expression, or whether their role is direct or 
not. Later studies showed that PKC gene expression could be regulated by 
mechanisms involving PKCII activity [1, 164, 262], but these studies also did not 
investigate the role of individual transcription factors. Therefore, in this chapter I 
investigated the role of Sp1. I present data clearly showing that overexpressed 
PKC gene expression in CLL cells is regulated by this transcription factor. This 
finding is consistent with the function of Sp1 because the promoter region of PRKCB 
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is reported to be TATA-less [4, 161], and genes regulated by Sp1 are mostly of this 
type [176, 263]. Thus, I provide insight into the regulation of PKC gene expression, 
insight which is important to our understanding of the pathobiology of CLL cells, 
and also of the malignant cells of other neoplasms where PKCβII is overexpressed 
[149-152, 264]. Furthermore, this finding also provides insight into the effect of 
malignant B cells on stromal microenvironment because of a recent paper by Lutzny 
et al., [144] showing that CLL cells induce the expression of PKCβII in adjacent 
microenvironmental stromal cells. 
The results I present in this chapter strongly suggest that overexpression of Sp1 
plays a major role in overexpression of PKCβII in CLL cells. My finding that Sp1 is 
overexpressed in CLL cells compared to normal B cells agrees with those of another 
study which used an RNA microarray to identify overexpressed Sp1 in CLL cells 
[265]. Thus, I demonstrate that Sp1 protein levels strongly correlate with PKCβII 
mRNA levels in CLL cells, and that Sp1 association with the PRKCB promoter drives 
expression of the gene. This finding is important because it suggests that 
overexpression of Sp1 in CLL cells may be linked to their pathophysiology. Sp1 is a 
pleiotropic transcription factor regulating the expression of many genes [176]. 
Overexpression of PKCII is a phenotypic feature that distinguishes CLL cells from 
other B cell malignancies [1]. The relationship between Sp1 and PKCII 
overexpression therefore suggests that Sp1 may be regulating the overexpression 
of other genes important to the phenotype of CLL cells. For example, TCL1, Lyn and 
Syk are all overexpressed in CLL cells, particularly in patients with progressive 
disease, and with disease at a late stage [266-268]. The promoter regions of these 
genes all have Sp1 binding sites, and, in particular, TCL1 and Syk are known to be 
regulated by Sp1 [269]. This suggests that regulation of PRKCB may be taken as a 
model to understand the phenotype of CLL cells, and possibly other tumours types, 
such as those associated with the lung, where increased Sp1 expression has been 
shown to contribute to disease progression [194].  
Many of the experiments I present in this chapter use B cell lines to model the 
behaviour of CLL cells. MEC1 cells were derived from a patient with CLL where the 
malignant lymphocytes were undergoing prolymphocytic transformation [241]. 
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MEC1 cells retain many of the phenotypic features of CLL cells; for example, these 
cells are CD5 and CD19 positive, and have been used to model certain aspects of 
CLL cell behaviour [270-272]. Importantly, for the purposes of this Chapter, PKCII 
is highly expressed in this cell line. In contrast, Daudi cells were derived from a 
patient with Burkitt’s lymphoma and maintain a different phenotype to CLL and 
MEC1 cells. These cells express less PKCII than do MEC1 cells, however, they are 
still useful because they are easily transfected. In terms of the experiments I 
perform in this Chapter, these cell lines behave in a highly similar way to CLL cells. 
Thus, PKC gene expression is suppressed in MEC1, Daudi and CLL cells by 
mithramycin and Sp1-specific siRNA. Increasing concentrations of mithramycin in 
cultures of CLL, Daudi and MEC1 cells showed similar and proportional reductions in 
Sp1 and PKCβII mRNA levels in these cells. Mixed pool of siRNA nucleotides used to 
knockdown Sp1 expression also showed similar and proportional reductions in Sp1 
and PKCβII mRNA levels in MEC1 cells, justifying the use of the mixed pool of siRNA 
oligos to knockdown Sp1 expression in Daudi and CLL cells. Further evidence of the 
similarity of MEC1 and CLL cells was gained from ChIP analysis of Sp1 association 
with the promoter region of PRKCB. These experiments showed that Sp1 is 
associated with this promoter, and can be displaced by treatment of these cells 
with mithramycin. Importantly, MEC1 and Daudi cells were highly useful for 
studying PRKCB promoter function within a luciferase assay. This type of 
experiment cannot be easily done using CLL cells. Taken together, these data 
provide a strong foundation for using MEC1 and Daudi cells to model PKC 
regulation in primary CLL cells. This is important for the results presented in 
subsequent chapters of this thesis. 
The results presented in this Chapter show that Sp1 is likely to be the major driver 
of PRKCB transcription in CLL cells, and thereby brings insight to previous studies 
characterising the basal promoter region of PRKCB [4, 161]. During the preparation 
of the data for this Chapter, a paper by Hagiwara et al. investigating the regulation 
of PKC gene expression in HeLa cells was published. This paper used mithramycin, 
Sp1 siRNA as well as ChIP to show a role for Sp1 in regulating PKCβII expression in 
these cells [5]. Thus, many of the findings I present in this Chapter are confirmed by 
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Hagiwara study. However, I additionally show a more direct role for Sp1 in 
regulating PRKCB promoter function.  Mutation of the Sp1 binding sites results in 
complete suppression of promoter function, suggesting a dominant role for this 
transcription factor in regulating PKC gene expression. Similar dominant roles for 
Sp1 in regulating gene expression are reported for other genes in different cellular 
contexts [273, 274]. In particular, I demonstrate the importance of both Sp1 binding 
sites for PRKCB promoter function, a finding which is similar to that reported for the 
control of cholesterol acetyltransferase gene expression in HepG2 cells [275]. 
Finally, my study of PKC gene regulation is the first to demonstrate linkage 
between Sp1 and PKCII expression in primary cells. The study by Hagiwara et al. 
was performed only using a cell line.  
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 Chapter Four: Investigating the potential roles of 
other transcription factors in regulating the expression 
of PKCβ in CLL cells 
4.1 Introduction and aims   
The results of Chapter 3 clearly show a role for Sp1 in regulating PKC gene 
expression in CLL cells. However, other transcription factors such as Sp3, MITF, 
RUNX1, and STAT3 have been reported to be involved in regulating the expression 
of the PKC gene [5-8]. In addition, the basal promoter region also contains two E-
box motifs [4], and therefore could be regulated by transcription factors involved in 
mitosis such as c-Myc. This has basis in a study by Weidong et al., showing that 
MAPK pathway activation stimulated PKC expression in a colon cancer cell line 
[164]. Therefore, the aim of this chapter is to investigate the role of these factors in 
regulating the transcription of PRKCB in CLL cells. 
 
4.2 Results 
4.2.1 The role of Sp3  
4.2.1.1 Sp3 protein levels in CLL and normal B cells 
Sp3 can compete with Sp1 for binding to GC-regions of target genes and repress 
transcription [176]. Considering that CLL cells overexpress Sp1, it seemed logical 
that Sp3 expression might be underexpressed. Thus, to investigate this notion, I 
examined normal B and CLL cells for Sp3 expression by Western blot. Figure 4.1 
shows that Sp3 protein is expressed at higher levels in CLL compared to normal B 
cells. This is an unexpected result, and suggests that Sp3 is not acting to suppress 
PKCβ gene expression. I next investigated the potential role of Sp3 by manipulating 
its expression with siRNA. 
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Figure 4.1: Sp3 protein levels in normal B and CLL cells. CLL and normal B cells 
were purified by positive selection and analysed for Sp3 protein expression by 
Western blot. Lysates of CLL and normal B cells were prepared and 10 µg protein 
was separated by SDS-PAGE (10% acrylamide gel) and transferred to PVDF 
membrane. The membranes were probed for the indicated antibodies. β-actin was 
used as a loading control. 
 
 
4.2.1.2 Sp3-specific siRNA reduces PKCβII mRNA and protein levels in 
Daudi cells 
In this section I used Daudi cells to investigate the role of Sp3 in PKC gene 
expression. Figure 4.2A shows that Sp3 mRNA and protein levels are reduced when 
cells are treated with Sp3-specific siRNA. Examination of PKC mRNA and protein 
levels in these treated cells also showed reduction (Figure 4.2B). These results 
suggest a potential role of Sp3 in promoting transcription of PRKCB.  
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Figure 4.2: Sp3-specific siRNA reduces PKCβII mRNA and protein levels in Daudi 
cells. 2x106 Daudi cells were nucleofected with 2 µM Sp3-specific or control siRNA, 
and then cultured for 72 h. Harvested cells were analysed for protein expression by 
Western blot, and for mRNA levels by qRT-PCR. The mRNA levels were measured 
relative to the reference gene RNA Polymerase II and expressed as arbitrary units. 
Whole cell lysates were prepared and 10 g protein separated by SDS-PAGE and 
transferred to PVDF membrane for detection with the indicated antibodies. A) Sp3 
mRNA levels (top panel) and protein levels (bottom panel). B) PKCII mRNA levels 
(top panel) and protein levels (bottom panel). Results for mRNA analysis are 
presented as mean±SE of n=3 separate replicates. Statistical analysis was 
performed using a student’s t-test for paired data. 
 
4.2.1.3 Sp3 reduces PRKCB promoter activity in Daudi cells  
I next investigated a more direct role for Sp3 in driving PRKCB promoter function 
using a luciferase assay. Daudi cells were transfected with pGL3-PKC-0.5 (the 
minimal promoter region of PRKCB coupled to a luciferase gene) and with Sp3-
specific siRNA. Figure 4.3 shows that knockdown of Sp3 results in profound 
reduction in PRKCB promoter activity. Taken together with the results present in 
section 4.2.1.2, these results support a direct role for Sp3 in driving PKC gene 
expression.  
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Figure 4.3: Knockdown of Sp3 expression with siRNA inhibits PRKCB promoter 
activity. 2x106 Daudi cells were transfected with pGL3-pkcβ-0.5 (2 g) and pRL (0.1 
g) according to the procedure outlined in the materials and methods. Cells were 
cultured for 24 h under serum-rich conditions, and then transferred into serum-free 
for a further 48 h. In addition, the cells were co-transfected with either Sp3-specific 
or control siRNA (2 M each). Luciferase assays were performed on harvested cells. 
The data are presented as mean±SE of three independent experiments. Statistical 
analysis was performed using a student’s t-test for paired data. 
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4.2.1.4 Sp3 does not bind to the PRKCB promoter in CLL cells  
To confirm a direct role of Sp3 in regulating PRKCB transcription I performed ChIP 
analysis for its binding to the GC-region of the PRKCB promoter where Sp1 binds. 
Figure 4.4 shows that Sp3 does not bind the PRKCB promoter in either normal B, 
CLL cells, or MEC1 cells. In contrast, a positive control shows direct binding of Sp3 
to the DHFR gene promoter [276]. Thus, although gene expression analysis and 
promoter function assays suggest a clear role of Sp3 in driving PKC gene 
expression, my results using ChIP indicate that this role is not direct.  
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 Figure 4.4: Sp3 does not bind to the PRKCB promoter sequence in normal B, CLL 
and MEC1 cells. Chromatin was prepared from 2x106 MEC1 cells or from 1x107 CLL 
and normal B cells. Sp3 was immunoprecipitated using a specific antibody, and DNA 
sequences associated with Sp3 were detected by qPCR amplification of the PRKCB 
or DHFR promoter. Results are presented as fold enrichment within Sp3 
immunoprecipitates compared to non-specific IgG immunoprecipitation controls. A) 
Shows the summary (mean±SE) of Sp3 ChIP analysis with the PRKCB promoter in 
CLL cells (n=7) and normal B cells (n=3). B) Shows the summary (mean±SE) of Sp3 
ChIP analysis with the PRKCB promoter in MEC1 cells (n=3). C) Shows Sp3 ChIP 
analysis with the DHFR promoter in MEC1 cells (n=1, positive control).  
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 4.2.1.5 Reverse effect of Sp3/Sp1-specific siRNAs on Sp3 and Sp1 
mRNAs levels in Daudi cells  
It has been reported that Sp1 and Sp3 are involved in regulating the expression of 
each other [277, 278], and that Sp3 can associate with the Sp1 gene promoter 
[278]. I next investigated whether Sp3 could influence Sp1 expression within my 
system, thereby explaining an indirect role of Sp3 in driving PKC gene expression. 
Reduction of Sp3 with siRNA resulted in a reduction of Sp1 mRNA and protein 
(Figure 4.5A), indicating that Sp3 is involved in regulating expression of Sp1 in B 
cells. I also investigated the effect of Sp1 knockdown on Sp3 expression. Figure 4.5B 
shows that treatment of Daudi cells with siRNA targeting Sp1 results in increased 
Sp3 mRNA expression and protein expression. Thus, it is likely that Sp3 regulates 
PRKCB transcription in CLL cells by modulating the expression of Sp1. 
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Figure 4.5: Reverse effect of Sp3/Sp1-specific siRNA on Sp1/Sp3 mRNA levels in 
Daudi cells. 2x106 Daudi cells were nucleofected with 2 µM Sp3-specific, Sp1-
specific or control siRNA, and then cultured for 72 h. Harvested cells were analysed 
for protein expression by Western blot and mRNA levels by qRT-PCR. The mRNA 
levels were measured relative to the reference gene RNA Polymerase II and 
expressed as arbitrary units. Whole cell lysates were prepared and 10 g protein 
separated by SDS-PAGE and transferred to PVDF membrane for detection with the 
indicated antibodies. A) Sp1 mRNA levels (top panel) and protein levels (bottom 
panel) in Daudi cells transfected with Sp3 siRNA. B) Sp3 mRNA levels (top panel) 
and protein levels (bottom panel) in Daudi cells transfected with Sp1 siRNA. In this 
figure the results are presented as mean±SE of n=3 separate replicates. Statistical 
analysis for all parts in this figure was performed using a student’s t-test for paired 
data.  
 
4.2.2 The Role of RUNX1 
4.2.2.1 RUNX1 does not associate with the PRKCB promoter sequence 
in CLL cells 
A previous paper showed that RUNX1 regulates PRKCB transcription in U937 cells 
by directly binding to the promoter of this gene [6]. In order to investigate whether 
this finding is similar within a CLL cell context, I performed ChIP analysis for RUNX1 
binding to the PRKCB promoter in CLL, normal B, and MEC1 cells. Within this 
analysis, I used primers that amplified the section of DNA containing the RUNX1 
 101 
 
binding site described in Hug et al., [6]. I found that RUNX1 does not bind to the 
PKCβ gene promoter in normal B, CLL, or MEC1 cells (Figure 4.6A and B). As a 
positive control I used RUNX1 binding to the EVI1 promoter [279], and Figure 4.6C 
shows clear association of this transcription factor to this promoter in MEC1 cells. 
This indicates that RUNX1 likely does not play a role in the regulation of PRKCB 
transcription in CLL.  
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Figure 4.6:  RUNX1 does not bind to the PRKCB promoter sequence in normal B, 
CLL and MEC1 cells. Chromatin was prepared from 2x106 MEC1 cells or from 1x107 
of purified CLL and normal B cells. RUNX1 was immunoprecipitated using a specific 
antibody, and DNA sequences associated with RUNX1 were detected by qPCR 
amplification of the PRKCB or EVI1 promoter. Results are presented as fold 
enrichment within RUNX1 immunoprecipitates compared to non-specific IgG 
immunoprecipitation controls. A) Shows the summary (mean±SE) of RUNX1 ChIP 
analysis within the PRKCB promoter in CLL cells (n=7) and normal B cells (n=3). B) 
Shows the summary (mean±SE) of RUNX1 ChIP analysis within the PRKCB promoter 
in MEC1 cells (n=3). C) Shows RUNX1 ChIP analysis within the EVI1 promoter in 
MEC1 cells (n=1, positive control). 
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4.2.3 The Role of MITF 
4.2.3.1 Protein expression of MITF in normal B, CLL, and cell lines 
In 2006 Park et al., suggested that MITF is involved in regulating the expression of 
PRKCB [7]. However, this observation may be cell type-specific because MITF is 
primarily found in melanocytes [7]. Thus, I first examined my cell system (normal B, 
CLL, MEC1 and Daudi cells) for MITF expression. Figure 4.7 shows Western blot 
analysis of MITF protein expression in these cells compared to a melanoma cell line 
used as a positive control. A dominant band is observed at approximately 52kD in 
all lanes, and is consistent with the predicted molecular weight of MITF. A weaker 
secondary band was also observed in most of the lanes, including the positive 
control, and could potentially be a proteolytic cleavage product [280]. In general, 
these results show that there is relatively little difference in MITF protein 
expression level between normal B and CLL cells. Thus, MITF is expressed in CLL 
cells, and could potentially play a role in regulating transcription of PRKCB in these 
cells.    
 
 
 
 
 
 103 
 
MW
(kD)
50
37
75
β-actin 50
MITF
3
3
4
2
N.B Primary CLL
37
3
3
4
3
1
7
4
7
3
3
4
0
2
6
8
6
2
0
9
4
3
3
3
6
D
au
d
i
M
EC
1
M
el
an
o
m
a 
2
.9
1
Cell lines
A)
B)
0
5
10
15
20
25
30
35
40
45
M
IT
F/
β
-a
ct
in
 
Figure 4.7: MITF protein expression in CLL, normal B, MEC1 and Daudi cells. A) 
Western blot analysis of cell lysates prepared from purified CLL and normal B cells, 
as well as from Daudi and MEC1 cells, and the melanoma 2.91 cell line used as a 
positive control. 10 µg of protein was separated on 10% acrylamide SDS-PAGE gels, 
and transferred to PVDF membranes, which were then probed with antibodies to 
MITF and β-actin. B) Graphical representation of the data presented in part A.  
 
 
4.2.3.2 MITF binds within the PRKCB promoter sequence in CLL cells 
but not in normal B cells 
MITF belongs to the basic helix-loop-helix/leucine zipper transcription factor group 
that recognizes and binds to E-box sequences within target promoters [214]. There 
are two potential E-box sequences within the minimal region of the PRKCB 
promoter (Figure 4.8A) [4]. To investigate whether MITF could interact with these 
sequences, I performed ChIP analysis. Figure 4.8B compares MITF binding to the 
minimal region of the PRKCB promoter in CLL or normal B cells. There appeared to 
be greater association of MITF to this region in CLL cells, but this was not significant. 
Nevertheless, it was considered that any MITF binding to this region was not 
responsible for driving PKC gene expression because mutation of the Sp1 binding 
sites within the basal promoter region eliminated promoter activity (Figure 3.14B). 
The notion that MITF is not responsible for driving PKC gene expression is in 
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agreement with the findings of Park et al., [7] who show that overexpressed MITF 
does not result in enhanced basal promoter function.   
However, the paper by Park et al., suggested that overexpressed MITF could drive 
expression of a larger PRKCB promoter sequence [7]. To identify potential binding 
sites for MITF within this larger sequence, I used the PROMO3 web tool to analyse a 
1kB region of the PRKCB promoter upstream of the transcriptional start site (TSS). I 
found that there is an E47 sequence that could also be recognized by MITF (Figure 
4.8A). I performed ChIP for MITF targeting this region of the PRKCB promoter and 
found that MITF is strongly and significantly associated with this distal region of the 
PKCβ gene promoter in CLL cells compared to that in normal B cells (Figure 4.8C). 
This shows that MITF binds directly to the PRKCB promoter, but whether MITF has a 
direct role in regulating PKCβ gene expression in CLL cells remains undetermined.  
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Figure 4.8: Comparison of MITF binding in distal and proximal region within 
PRKCB promoter sequence in CLL and normal B cells. 1x107 CLL or normal B cell 
extracts were prepared and MITF was immunoprecipitated using a specific MITF 
ChIP-grade antibody. The PRKCB promoter sequences associated with MITF were 
detected by qPCR and are presented as fold enrichment compared to the PRKCB 
promoter sequences associated with a non-specific IgG immunoprecipitation 
control. A) Schematic diagram of the PRKCB promoter 1kB upstream of the 
transcriptional start site. The E box and E47 sequences are highlighted in green 
colour to show their relationship to other potential drivers of transcription. B) 
Shows the results of MITF ChIP using primers to detect the E box sequences within 
the proximal region of the PRKCB promoter. C) Shows the results of MITF ChIP using 
primers to detect the E47 sequences within the distal region of the PRKCB 
promoter. Statistical analysis for parts B and C was performed using a Mann-
Whitney U-test. 
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4.2.3.3 MITF-specific siRNA does not reduce PKCβ mRNA levels in 
MEC1 cells 
To elucidate the specific role of MITF in regulating PKCβ gene expression, I used 
specific siRNA to examine how knockdown of MITF expression affected PKC mRNA 
levels in MEC1 cells. Figure 4.9 shows that reduction of MITF expression in these 
cells did not result in reduction of PKCβ mRNA levels. Interestingly, and seemingly 
in contrast to the observations of Park et al, a reduction in MITF expression in my 
system resulted in an increase in PKC mRNA. The degree to which PKC mRNA 
levels where changed, seemed related to the ability of the different oligos I used to 
knockdown MITF expression. Thus, Oligo 3 > Oligo 1 > Oligo 2 in ability to 
knockdown MITF expression, and Oligo 3 > Oligo 1 > Oligo 2 in ability to increase 
PKC mRNA levels. I also used a mixture of oligos 1, 2 and 3 to knockdown MITF 
expression, and although this was effective in reducing MITF expression, PKC 
mRNA levels remained similar to those in the control sample. The reason for this 
discrepancy is unclear, but could be the result of off-target effects. Nevertheless, 
these results indicate that MITF likely plays no role in promoting PKC gene 
expression. 
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Figure 4.9: MITF-specific siRNA does not reduce the expression of PKCβ mRNA 
levels in MEC1 cells. 2x106 MEC1 cells were transfected with 500 nM MITF-specific 
siRNA oligonucleotides or siRNA-negative control. Following 72 h culture the cells 
were harvested and analysed for mRNA levels by qRT-PCR. A) MITF mRNA levels 
measured by qRT-PCR. B) PKC mRNA levels measure by qRT-PCR. The mRNA levels 
for MITF and PKC were measured relative to the reference gene RNA Polymerase 
II, and expressed in arbitrary units as mean±SE of n=3 separate replicates. Statistical 
analysis for all parts in this figure was performed using a student’s t-test for paired 
data.     
 
 
4.2.3.4 MITF associates with Sp1 in MEC1 cells 
Park et al., [7] suggested that MITF may work with other factors to modulate 
expression of PKC within their system. Since my work has so far demonstrated a 
clear role for Sp1 in regulating PKC gene expression, it seemed logical to 
investigate whether MITF co-associated with this latter transcription factor. Figure 
4.10 shows that immunoprecipitation of MITF from MEC1 cell lysates resulted in co-
immunoprecipitation of Sp1. However, the ChIP data presented in Figure 4.8A 
indicate no significant difference in MITF association with the basal promoter 
region of PRKCB in CLL and normal B cells despite the much higher levels of Sp1 
associated with this region (Figure 3.15B). These data indicate that although MITF 
may co-associate with Sp1, this association likely does not take place in the context 
of the PRKCB promoter, or that the PRKCB promoter is organised in a non-linearized 
fashion to promote MITF association with Sp1.   
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Figure 4.10: MITF associates with Sp1 in MEC1 cells. 1x107 MEC1 cells were lysed 
with RIPA buffer, and lysates were immunoprecipitated with IgG control or MITF-
specific antibodies. Immunoprecipitates were separated by SDS-PAGE alongside 
10g whole cell lysate used as an input control. Western blots were developed 
using Sp1 antibodies.  
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4.2.4 The Role of c-Myc 
4.2.4.1 Expression of c-Myc in normal B and CLL cells 
E-box sequences within gene promoters can bind c-Myc and become activated for 
transcription [281]. Moreover, it is known that c-Myc can contribute to the 
pathobiology of CLL cells, particularly those cases experiencing BCR engagement 
[282]. Finally, work by Cejas et al., has demonstrated a role for mitogenic signalling 
in the regulation of PKC gene expression [262]. To investigate whether c-Myc 
played a role in regulating PKC expression I first compared protein expression of 
this transcription factor in B and CLL cells. Figure 4.11 shows, as expected, that CLL 
cells generally expressed more c-Myc protein than did normal B cells. Therefore, c-
Myc may have a potential role in regulating PRKCB transcription in CLL cells.   
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Figure 4.11: c-Myc protein expression in normal B and CLL cells. Western blot 
analysis of cell lysates prepared from purified CLL and normal B cells. A) 10 µg of 
protein was separated on 10% acrylamide SDS-PAGE gels, and transferred to PVDF 
membranes, which were then probed with antibodies to c-Myc and β-actin as 
loading control. B) Graphical representation of the data presented in part A. 
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4.2.4.2 The c-Myc inhibitor 10058-F4 reduces PKCβ mRNA levels in 
MEC1 and Daudi cells 
To characterise the potential role of c-Myc in regulating PRKCB transcription, I 
initially used the specific c-Myc inhibitor 10058-F4.  Figures 4.12A and B show PKCβ 
mRNA levels were reduced following treatment of MEC1 and Daudi cells with 
10058-F4 regardless of whether the cells were cultured under serum rich or serum 
free conditions. These results indicate that c-Myc has a potential role in regulating 
PKCβ gene expression, but two issues need to be clarified: Firstly, whether the 
effect of 10058-F4 is specific or not, and, secondly, whether the role of c-Myc is 
direct or indirect. 
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Figure 4.12: c-Myc inhibitor inhibits PKCβII mRNA levels in MEC1 and Daudi cells. 
2x106 were cultured under serum free (SF) or serum rich (FCS) medium conditions 
for 24h in absence (UT) or presence of 60 nM c-Myc inhibitor(c-Myci). A) PKCβII 
mRNA levels in MEC1 cells. B) PKCβII mRNA levels in Daudi cells. This experiment 
illustrates the mean ± SE of three separate biological replicates. The PKCβ mRNA 
level was measured relative to RNA Polymerase II by qRT-PCR and is represented as 
arbitrary units.  
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4.2.4.3 c-Myc-Specific siRNA decreases PKCβII mRNA levels in MEC1 
and Daudi cells 
To investigate the specificity of 10058-F4 in targeting c-Myc I used siRNA to 
knockdown expression of the transcription factor in MEC1 and Daudi cells.  Figure 
4.13 shows that knockdown of c-Myc expression results in reduction of PKC mRNA 
levels whereas treatment of MEC1 or Daudi cells with control siRNA has no effect. 
In addition, Figures 4.13C and D show that knockdown of c-Myc with siRNA reduced 
Sp1 protein expression. Taken together with the data generated using 10058-F4, 
these results suggest that c-Myc regulates PRKCB transcription, but whether the 
regulatory mechanism is direct or not still needs to be examined.  
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Figure 4.13: c-Myc-specific siRNA reduces PKCβII mRNA in MEC1 and Daudi cells. 
MEC1 and Daudi cells (2x106) were nucleofected with 100 nM of c-Myc-specific or 
control siRNA oligonucleotides. The cultured cells were harvested after 72 h and 
were analysed for protein expression by Western blot, and for mRNA levels by qRT-
PCR. The PKCβ mRNA levels were measured relative to the reference gene RNA 
Polymerase II and presented as arbitrary units. A) PKCβII mRNA levels in MEC1 cells. 
B) PKCβII mRNA levels in Daudi cells. C) and D) Western blot analysis of MEC1 and 
Daudi cell lysates for the indicated proteins, respectively. Graphical data are 
presented as arbitrary units where each graph represents mean±SE of n=3 separate 
experiments. β-actin is used as a loading control for Western blots. Statistical 
analysis for parts A and B was performed using a student’s t-test for paired data. 
 
 
4.2.4.4 c-Myc does not bind to the PRKCB promoter in MEC1 cells  
c-Myc is a member of the helix-loop-helix/leucine zipper family of nuclear 
transcription factors that recognize and bind to E-box sequences in target gene 
promoters [283]. The PRKCB promoter has two potential E-box binding sites in its 
minimal region (Figure 4.9A) [4]. Thus, to examine whether c-Myc binds to these E-
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box sequences within the PRKCB promoter, I performed ChIP analysis. I found that 
c-Myc does not associate with the E-box sequences within the basal promoter of 
PRKCB (Figure 4.14A) in MEC1 cells. To ensure that my assay was working I analysed 
c-Myc binding to the Nucleolin gene promoter which also contains E-box sequences 
[284]. This experiment showed clear association of c-Myc with this gene promoter 
(Figure 4.14B). My analysis of the PRKCB promoter with the PROMO3 web tool 
showed that c-Myc had no other potential binding sites within the proximal or 
distal regions. Therefore, it is likely that this transcription factor does not have a 
direct role in regulating transcription of PRKCB. However, the results using the c-
Myc inhibitor and c-Myc-specific siRNA suggests an indirect role for c-Myc, which is 
investigated in the next section. 
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Figure 4.14:  c-Myc does not associate with the PRKCB promoter in MEC1 cells. 
Chromatin extracts were prepared from 2x106 MEC1 cells, and were 
immunoprecipitated using a specific antibody for c-Myc. c-Myc association to the E-
box sequences within the PRKCB promoter was detected using qPCR. The results 
are presented as fold enrichment compared to PRKCB promoter sequences 
associated with a non-specific IgG immunoprecipitation control. A) Shows the 
results of c-Myc ChIP within PRKCB promoter. B) Shows the results of c-Myc ChIP 
within the Nucleolin promoter region covering the c-Myc binding site. 
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4.2.5 The Role of E2F1  
4.2.5.1 Protein expression of E2F1 in normal B and CLL cells 
The PROMO3 web tool I used to analyse the promoter region of PRKCB identified 
two E2F1 binding sites within the 1kB region upstream of the transcription start 
site. Expression of E2F1 can be regulated by c-Myc [285], and this warranted further 
investigation of its potential role in regulating PKC gene expression. Therefore, to 
investigate this role I began by examining the expression of E2F1 protein levels in 
normal B and CLL cells by Western blot analysis. Figure 4.15 shows that E2F1 
protein is expressed in CLL, but is barely detected in normal B cells.  
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Figure 4.15: E2F1 protein expression in normal B and CLL cells. Western blot 
analysis of the cell lysate prepared from purified CLL and normal B cells. A) 10 µg of 
protein was separated on 10% acrylamide SDS-PAGE gels, and transferred to PVDF 
membranes, which were then probed with antibodies to E2F1 and β-actin. A 
nonspecific band appeared above E2F1 and is labelled as N.S B) Graphical 
representation of the data presented in part A. 
 
4.2.5.2 E2F1-Specific siRNA inhibits the expression of Sp1 and PKCβII 
mRNA and protein levels in MEC1 and CLL cells 
To investigate the specific role of E2F1 in regulating the expression of the PKCβ 
gene I used E2F1-specific siRNA oligonucleotides to decrease E2F1 protein levels in 
MEC1 and CLL cells. Figures 4.16A and D show that PKC mRNA levels are reduced 
in, respectively MEC1 and CLL cells, treated with E2F1 siRNA in comparison to those 
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treated with control siRNA. This suggested a role for E2F1 in regulating PKC gene 
expression. However, E2F1 is also known to regulate Sp1 expression[257] and it was 
therefore necessary to investigate whether this was happening in my system. 
Figures 4.16B and E show that knockdown of E2F1 resulted in reduction of Sp1 
mRNA in MEC1 and CLL cells. For completeness, I also analysed protein expression 
of E2F1, Sp1 and PKCII in the treated cells. Figures 4.16C and F show that E2F1 
siRNA eliminated E2F1 protein expression, and also of Sp1 protein. PKCII protein 
expression was also reduced, with a greater effect being observed in MEC1 cells 
than in CLL cells. These results strongly suggest that E2F1 has a role in regulating 
PRKCB transcription in CLL cells, but it is unclear whether this role is direct owing to 
the role E2F1 may in regulating Sp1 expression. Nevertheless, figures 4.13C and D 
show that knockdown of c-Myc with siRNA also reduces Sp1 protein expression 
[285]; an observation that, taken together with the data presented in this section 
with the known role of c-Myc in regulating E2F1 expression, provides a possible 
explanation of why knockdown of c-Myc reduces PKC mRNA levels.  
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Figure 4.16: E2F1-specific siRNA reduces Sp1 and PKCβII mRNA and protein levels 
in MEC1 and CLL cells. 2x106 MEC1 or 1x107 CLL cells were nucleofected with 100 
nM E2F1-specific or control siRNA oligonucleotides. The cultured cells were 
harvested after 72 h and were analysed for protein expression by Western blot and 
for mRNA levels by qRT-PCR. Measured mRNA levels are relative to RNA 
Polymerase II, reference gene, and presented as arbitrary units. A) PKCβ mRNA 
levels in MEC1 cells. B) Sp1 mRNA levels in MEC1. D) PKCβ mRNA levels in CLL cells. 
E) Sp1 mRNA levels in CLL cells. C) and F) Western blot analysis of MEC1 and CLL cell 
lysates for the indicated proteins. Graphical data are presented as arbitrary units 
where each graph represents mean±SE of n=3 separate experiments. β-actin is used 
as a loading control for Western blots. Statistical analysis for parts A, B, D and E was 
performed using a student’s t-test for paired data. 
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4.2.5.3 E2F1 binds to the PRKCB promoter sequence in CLL cells 
I next investigated whether E2F1 could bind directly to the PRKCB promoter using 
ChIP. Figure 4.17 shows that E2F1 associates strongly with the PRKCB promoter in 
MEC1 cells as well as in CLL cells, and that this binding in CLL cells was significantly 
higher than that observed in normal B cells. As a positive control E2F1 binding to 
the DHFR promoter was used [286]. 
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Figure 4.17: E2F1 associates with the distal region of the PRKCB promoter 
sequence. Chromatin extracts from MEC1 cells (2x106) or from purified CLL and 
normal B cells (1x107 each) were prepared, and E2F1 was immunoprecipitated using 
a specific antibody. E2F1 association within the distal region of PRKCB promoter 
was detected by using qPCR and primers that covered the identified E2F1 binding 
sequences within the promoter. The results are presented as fold enrichment 
compared to PRKCB promoter sequences associated with a non-specific IgG 
immunoprecipitation control. A) E2F1 association with the PRKCB promoter in 
MEC1 cells. B) E2F1 association with the DHFR promoter region in MEC1 cells, used 
as a positive control. C) Comparison of E2F1 association with the PRKCB promoter 
in eight different cases of CLL cells and three cases of normal B cells. Statistical 
analysis was performed using a Mann-Whitney U-test. 
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4.2.6 The Role of total STAT3 
4.2.6.1 STAT3 represses PRKCB promoter activity in MEC1 cells 
The final transcription factor I consider in this Chapter is STAT3. As a driver for the 
expression of many genes that play key roles in the pathophysiology of CLL cells 
[243, 287, 288], STAT3, therefore, deserves consideration. This is particularly 
relevant because a recent study identified four potential binding sites for STAT3 
within the distal promoter region of PRKCB ([8] and Figure 4.18), and also showed 
that one of these sites (site 4), was important for the repression of gene expression 
during monocyte differentiation. Thus, to understand the role of STAT3 in 
regulating PKCβ gene expression in CLL cells, I first compared the activity associated 
with the basal PRKCB promoter (pGL3-pkcβ0.5kb) with that associated with larger 
promoter containing the STAT3 binding sites (pGL3-pkcβ1.2kb) in MEC1 cells. Figure 
4.19A shows that the basal PRKCB promoter was significantly more active than the 
pGL3-pkcβ1.2kb construct containing the STAT3 binding sites. This finding agreed 
with those of previous studies [4, 8, 161], and suggested a potential of STAT3 
binding to the PRKCB promoter in CLL cells. I next compared the role of each STAT3 
binding site within the PRKCB promoter by site-directed mutagenesis to alter these 
sites so that STAT3 could no longer bind. Thus, mutation of sites 1 or sites 2 plus 3 
had no effect on promoter activity, whereas mutation of site 4 resulted in 
significantly increased promoter activity (Figure 4.19B). However, this increase did 
not reach the activity of the basal promoter (Figure 4.19A), suggesting that other 
repressive elements are present. Taken together, these results indicate that STAT3 
acts as a repressor for the transcription of PRKCB by binding to its gene promoter.  
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Figure 4.18: Schematic diagram of the PRKCB promoter showing the STAT3 
binding sites. This schematic drawing shows the binding sites for STAT3 within the 
PRKCB promoter in relation to the binding sites of the other transcription factors 
discussed in this Chapter. The transcription start site is labelled by red arrow and 
the translational start site labelled as ATG in red. The sequences for the STAT3 
binding sites within the PRKCB promoter are shown within the inset red box. 
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Figure 4.19: STAT3 suppresses PRKCB promoter activity. MEC1 cells 2x106 were co-
transfected with (0.1 µg) pRL and (2 µg each) of wt pGL3-pkcβ-1.2kb, wt PGL3-pkcβ-
0.5kb, or different mutants of STAT3 binding sites within pGL3-pkcβ-1.2kb 
constructs. STAT3 binding sites within PRKCB promoter were altered by site-
directed mutagenesis. A) Shows the constructs activities of wt pGL3-pkcβ-0.5, wt 
pGL3-pkcβ-1.2kb, or pGL3-pkcβ-1.2kb containing mutations within STAT3 binding 
site 4. B) Shows the constructs activities of wt pGL3-pkcβ-1.2 kb or mutant for 
STAT3 binding; sites 1, site 2+3, or site 4; within pGL3-pkcβ-1.2kb.Luciferase assays 
were performed following 72 h culture of the cells under serum-rich conditions, and 
are reported relative to renilla expression. The data represented mean±SE of three 
independent experiments. Statistical analysis was performed using a student’s t-
test for paired data.  
  
 
4.2.6.2 STAT3 binds to PRKCB promoter in normal B and CLL cells 
I next examined STAT3 binding to the PRKCB promoter in primary CLL cells by ChIP. 
Here, I examined STAT3 binding specifically to site # 4 within the promoter region 
isolated from CLL cells, and compared this to the binding observed for the same 
region isolated from B cells. Figure 4.20A shows that STAT3 binds to the distal 
region of the PRKCB promoter in normal B and CLL cells. The binding of STAT3 to 
this region in normal B cells appeared similar in the three cases tested, however, 
variability was observed with respect to the CLL cell samples. Some cases showed 
high levels of STAT3 association with the PRKCB promoter, whereas others showed 
little or no association. To ensure that this observation was not a technical artefact I 
used STAT3 association to the c-Fos gene promoter as a positive control [289] 
(Figure 4.20C). Those cases of CLL where STAT3 binding to the PRKCB promoter was 
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observed to be low or absent, showed STAT3 binding to the c-Fos gene promoter. 
This indicates that the immunoprecipitation reaction worked, and validates the 
variability of STAT3 binding to the PRKCB promoter in CLL cells. Nevertheless, 
comparison of STAT3 binding to this region in CLL with normal B cells showed no 
significant difference when analysed either with Mann-Whitney U-test, or Fischer’s 
exact test (Figure 4.20B). Thus, these results indicate that STAT3 binds to the PRKCB 
promoter in CLL cells, but raises the question of the cause for the observed 
variability in binding. This I partially address in the next section.  
 
 
 
 
 
 
 
 
 123 
 
B)
C)
0
2
4
6
8
10
12
14
16
18
Ig
G
N
.B
 3
3
4
2
N
.B
 3
3
4
3
N
.B
 3
3
4
6
C
LL
 2
7
2
7
C
LL
 2
7
0
4
C
LL
 1
8
7
4
C
LL
 1
7
6
3
C
LL
 3
3
5
4
C
LL
 3
1
4
4
C
LL
 3
3
6
5
C
LL
 3
3
2
5
Fo
ld
 E
n
ri
ch
m
e
n
t
0
2
4
6
8
10
12
Ig
G
N
.B
 3
3
4
2
N
.B
 3
3
4
3
N
.B
 3
3
4
6
C
LL
 2
7
2
7
C
LL
 2
7
0
4
C
LL
 1
8
7
4
C
LL
 1
7
6
3
C
LL
 3
3
5
4
C
LL
 3
1
4
4
C
LL
 3
3
6
5
C
LL
 3
3
2
5
Fo
ld
 E
n
ri
ch
m
e
n
t
A)
 
Figure 4.20: STAT3 associates with the PRKCB promoter in CLL and normal B cells. 
Chromatin extracts from 1x107 purified CLL or normal B cells were prepared, and 
STAT3 was immunoprecipitated using a specific antibody. STAT3 association within 
the PRKCB promoter distal region was detected by using qPCR and primers covering 
the STAT3 binding site. The results are presented as fold enrichment compared to 
the same PRKCB promoter sequences associated with a non-specific IgG 
immunoprecipitation control. A) Shows the results of each single experiment for 
eight different CLL patient’s samples, and three samples of purified normal B cells. 
B) Shows the summary (mean±SE) of the experiments displayed in part A. Statistical 
analysis was performed using a Mann-Whitney U-test. C) Shows STAT3 ChIP within 
the c-Fos gene promoter region, use as a positive control for the results presented 
in part A. 
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4.2.6.3 STAT3 association with the PRKCB promoter of CLL cells 
increases after 24 hours culture  
Previous work from this Department showed that PKC mRNA levels decrease in 
CLL cells that are cultured overnight [143]. Other work showed that such culture 
resulted in an increase in phospho-STAT3 [243]. Therefore, it seemed plausible that 
any repressive role for STAT3 in regulating PKC gene expression might be due to 
its activation. I next examined the effect of overnight culture of CLL cells on the 
association of STAT3 to the PRKCB promoter. Figure 4.21 shows that such overnight 
culture of CLL cells results in significantly increased STAT3 binding to the PRKCB 
promoter.  This observation potentially explains why PKC mRNA levels decrease in 
CLL cells that are cultured overnight, and this mechanism will be investigated in a 
subsequent Chapter of this thesis. 
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Figure 4.21:  Increased STAT3 association with the PRKCB promoter of CLL cells 
after culturing overnight. Chromatin extracts from 1x107 CLL cells at T0 (time zero, 
just after thawing) and after culturing for 24 h were prepared, and STAT3 was 
immunoprecipitated using a specific antibody. STAT3 association within the distal 
region of PRKCB promoter was detected by using qPCR and primers covered STAT3 
binding site within PRKCB promoter. The results are presented as fold enrichment 
compared to PRKCB promoter sequences associated with the non-specific IgG 
immunoprecipitation control. Results show a summary of 4 experiments (mean±SE) 
using four different CLL patient samples. Statistical analysis was performed using a 
student’s t-test for paired data.   
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4.8 Discussion 
In chapter 3 I clearly showed that Sp1 is the main driver for the transcription of 
PRKCB in CLL cells. However, other studies have shown roles for Sp3, MITF, RUNX1, 
and STAT3 in regulating the expression of this gene in different cellular contexts [5-
8]. Therefore, it was necessary to investigate the role of these factors in CLL cells. I 
also investigated the involvement of c-Myc and E2F1 in regulating the expression of 
PKC. With the exception of STAT3, none of the transcription factors I investigate in 
this Chapter play direct roles in regulating the transcription of PRKCB in CLL cells. 
These data are important because they support the main regulatory role of Sp1 in 
driving overexpression of PKCβII in CLL.  
Transcription factors interact with DNA to generate three potential outcomes, 
activation or repression of gene expression, or stasis where transcription factor 
binding neither stimulates nor suppresses gene expression. Such static interaction 
of transcription factors with DNA is often observed within intronic sequences of 
genes, or, in some cases, also within the regulatory regions important for gene 
expression [290].   
With regard to gene activation/repression, this could potentially be influenced by 
expression level of a particular transcription factor, and this has direct relevance to 
the current study because I show a correlation between Sp1 protein and PKC gene 
expression. A potential competitor of Sp1 function is Sp3 because of the similarity 
of the zinc finger domains which comprise the binding sites for the cognate regions 
of DNA they recognise [170]. Thus, many of the genes driven by Sp1 could also be 
affected by Sp3 [291]. In many respects Sp3 is described as a repressor of Sp1 
function [292-295], and because Sp1 is overexpressed in CLL cells, I hypothesized 
that Sp3 may be underexpressed in order to generate the high expression levels of 
PKCII. However, I found that Sp3 is overexpressed in CLL compared to normal B 
cells, indicating that Sp3 is likely not acting to repress PKC expression within this 
context. An alternative explanation could be that Sp3 can compete with Sp1 to 
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drive promoter function as is described for other genes [296, 297], particularly if, 
like the promoter region of PRKCB, there are multiple Sp1 binding sites [174, 296]. 
My experiments using Sp3 knockdown with siRNA suggested that this transcription 
factor may be driving PRKCB promoter activity in CLL cells, but were not supported 
by ChIP analysis which indicated that Sp3 did not interact directly with the PRKCB 
promoter. Instead, my results indicated that Sp3 played an indirect role in PKC 
gene expression by regulating the expression of Sp1 because knockdown of Sp3 
resulted in decreased expression of Sp1 mRNA and protein. This conclusion is 
supported by a previous report which showed that Sp3 binds to the Sp1 promoter 
to regulate its expression [278]. My finding is important because it suggests that 
overexpression of Sp1 in CLL cells is potentially be due to the overexpression of Sp3. 
Previous to this thesis two transcription factors that bind to the PRKCB promoter 
were recognised; RUNX1 [6] and STAT3 [8]. With respect to RUNX1, Hug et al. used 
ChIP analysis to demonstrate interaction of this transcription factor with the 
promoter region of PRKCB in U937 cells, a myeloid cell line [6]. However, I could not 
demonstrate this in CLL cells despite clear evidence of RUNX1 association with the 
EVI1 promoter, which is a known direct target for RUNX1 [279] and the positive 
control for my experiments with CLL. A possible explanation for these contradictory 
results could be related to the cellular context; RUNX1 is reported overexpressed in 
U937 cells, which are, in turn, used as a cell model for studying RUNX1 functions 
[298, 299]. It is not clear whether RUNX1 is overexpressed in CLL cells, the antibody 
I used for ChIP analysis was not efficient at detecting endogenous levels of RUNX1 
by Western blot. It could be that RUNX1 expression levels are important for 
interaction with the PRKCB promoter. If this notion is true, the relative role of this 
transcription in CLL cells is less important than Sp1 because elimination of the 
RUNX1 binding within the PRKCB promoter does not eliminate activity of this 
promoter [6], whereas elimination of the Sp1 binding site does.   
With respect to STAT3, this transcription factor plays a key pathophysiological role 
in CLL cells as a driver of genes such as MCL1, among others, which are important 
for their survival [243, 288, 300]. A recent study identified 4 potential STAT3 
binding sites within the PRKCB promoter, of which one, site 4, is particularly 
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important in suppressing PKC gene expression in myeloid cells undergoing 
differentiation [8]. The results I present in this Chapter show that there is no 
significant collective difference in STAT3 association with the PRKCB promoter 
between normal B and CLL cells, but do identify individual CLL cases where 
association is clearly observable. This could be due to variation in STAT3 activation 
between CLL cases [243, 288]. Importantly, my data show that overnight culture of 
CLL cells results in significant increase in association of STAT3 to the PRKCB 
promoter, and this corresponds to a decrease in PKC mRNA levels within CLL cells. 
In previous work from this Department, overnight culture of CLL cells had the effect 
of inducing activating phosphorylation of STAT3 through a mechanism involving 
release of autocrine IL-6 and activation of PKC [243]. This indicates a potential 
regulatory role for STAT3 in CLL cells in suppressing PKC gene expression, the 
nature of which is more fully explored in Chapter 6. 
An early study of melanocytes showed a potential role for MITF in regulating PRKCB 
transcription [7]. However, this study did not show direct binding of this 
transcription factor to the promoter region of PRKCB, and relied on luciferase 
assays where MITF was co-transfected with luciferase genes which were under the 
control of a 1.4kB region of the PRKCB promoter. Expression of MITF is highest in 
melanocytes [301], but expression in tissues such as lymphocytes has not been 
characterised. Therefore, I first determined that MITF is expressed in CLL, normal B, 
MEC1 and Daudi cells, which suggested that it may have a role in regulating the 
expression of PRKCB in these cells. Typically, MITF binds to E-box and E47 
sequences of gene promoters, and the promoter of PRKCB has these sequences; an 
E-box within the basal promoter region and an E47 sequence within the more distal 
region. ChIP analysis of these regions showed that MITF binds strongly to the E47 
sequence within the distal region, but not to the E-box sequences within the basal 
promoter. As a potential driver of PRKCB transcription, this binding of MITF to the 
PRKCB promoter is consistent with the results of Park et al., who show that co-
transfection of MITF stimulates the activity of a 1.4kB PRKCB promoter, but not a 
0.5kB basal PRKCB promoter construct [7]. However, knockdown of MITF 
expression within my system does not result in decreased levels of PKC mRNA; 
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rather, levels of this mRNA species are slightly increased. This suggests that MITF 
could be operating as a transcriptional repressor, a role that has been described 
when MITF is in association with the STAT3 inhibitor PIAS3 [302] and is consistent 
with the suggestion made by Niino et al., who implicated repressive factors in 
regulating PRKCB [161].  
I next investigated a role for c-Myc in regulating PKC gene expression. This is 
because overexpressed c-Myc and activation of the MAPK pathway can drive 
expression of the PKC gene [262, 303, 304]. However, these studies have not 
shown the mechanism behind this relationship, and this may be important within a 
CLL cell context because activated c-Myc is often observed in the malignant cells 
associated with progressive disease [305, 306]. Like MITF, c-Myc binds to E-Box 
sequences to regulate transcription of target genes, and ChIP analysis of c-Myc 
binding to the E box sequences within the basal promoter of PRKCB in CLL and 
MEC1 cells shows no association despite clear association with a positive control. 
This would indicate that c-Myc does not drive PRKCB promoter activity, but 
inhibition of c-Myc either by knockdown with specific siRNA or using an inhibitor 
compound (10058-F4) causes a profound reduction in PKCβ gene expression. This 
suggests an indirect role of c-Myc, possibly through its role in regulating expression 
of a protein involved in PRKCB transcription. Thus, analysis of the effects of c-Myc 
inhibition on Sp1 expression revealed a profound reduction in the levels of this 
latter protein. Importantly, there is no obvious binding site within the promoter 
region of the Sp1 gene for c-Myc to influence transcription, suggesting that a gene 
which c-Myc regulates must come in between. It is known that Sp1 expression can 
be regulated by transcription factors involved in the cell cycle, and an important 
example is E2F1 [138, 175]. My data show that E2F1 is overexpressed in CLL 
compared to normal B cells, and ChIP analysis indicates that this transcription factor 
binds the PRKCB promoter at higher levels in CLL than in normal B cells. However, a 
direct role for E2F1 could not be demonstrated because siRNA knockdown of E2F1 
in CLL and MEC1 cells caused down-regulation of Sp1 expression, a result  
consistent with a report that shows Sp1 expression is regulated by E2F1 [180]. 
Ultimately, this question can only be answered in luciferase assays where the E2F1 
 129 
 
binding site within the PRKCB promoter is mutated to eliminate binding. 
Considering the dominant role of Sp1 in regulating PRKCB transcription, it is likely 
that E2F1 plays only a minor role.  
Taken together, these results from this chapter suggest that many of the additional 
transcription factors that bind the PRKCB promoter in CLL cells likely have a static 
function, neither directly promoting nor suppressing transcription of this gene. I 
have identified potential repressor functions for STAT3 and MITF, the former of 
which is further investigated in Chapter 6.  
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 Chapter Five: Role of epigenetic modifications in 
regulating PRKCB gene expression in CLL cells 
 
5.1 Introduction and aims 
In this thesis I have so far described the role of transcription factors in regulating 
gene expression of PKCII. However, factors which influence transcription factor 
access to gene promoters also play roles in gene expression [307-309]. The 
chromatin landscape and its structural alterations, which are known as epigenetic 
modifications, are important for tissue-specific expression of particular genes[310]. 
These epigenetic modifications are under enzymatic control of chromatin-
remodelling enzymes, thereby creating a second tier through which heritable gene 
expression is maintained in a tissue-specific way [37]. Importantly, epigenetic 
control of gene expression is a key to cellular differentiation, and in cancer cells 
such epigenetic control is often lost [311-313]. CLL cells are no different from other 
cancer cells in this respect, thus, the aim of this Chapter is to describe the role of 
epigenetics in the regulation of PKC gene expression in these cells.  
Epigenetic modifications can silence gene transcription by different mechanisms 
[314]; miRNA disruption of translation or destabilisation of mRNA[20], histone 
modifications controlling chromatin condensation [18] and gene methylation [17]. 
miRNAs expression in CLL has so far not identified species involved in regulating 
PKC gene expression. Therefore, I focussed on the latter two epigenetic 
phenomenons.  
 
5.2 Results 
5.2.1 The PRKCB promoter is unmethylated in CLL cells 
CpG islands within DNA sequences are targets for DNA methyltransferases, which 
target the cytosine residues within the CpG dinucleotides at these islands [315]. 
Gene expression is silenced when these islands are located within regulatory 
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regions of genes, and the methylation of cytosine within the CpG islands either 
interferes with the binding of transcription factors to their consensus sequences, or 
by recruiting chromatin silencing complexes [21]. Previous characterization of the 
PRKCB promoter showed that it is enriched with CpG dinucleotides; more than 70% 
of the 1kB region upstream of the transcription start site contains such motifs [4]. 
Importantly, gene methylation catalysed by PROX1 has been shown to influence 
PRKCB transcription in a HeLa cell model system [5]. Therefore, it was necessary to 
examine the methylation status of the PRKCB promoter in CLL cells and compare 
this to that in normal B cells. These experiments assessed the methylation status of 
the CpG Island located near the Sp1 binding sites of the promoter in normal B and 
CLL cells (Figure 5.1). We found that this region was virtually unmethylated and 
markedly similar in CLL and normal B cells (p=0.84, Mann-Whitney U-test, Table 
5.1). Therefore, these results show clearly that methylation status does not play a 
role in influencing Sp1 binding to the PRKCB promoter in CLL cells.  
CCCTGGGCACATCTCCTGAACGCAGCCCCGGGGGCCGAGGACGGGGTGGGGTGG
GGGGCGAGGCTCGGGTCCGACGACCCCGGGCTGCGGTCCCGGCGCTGCAGAGCT
GCGGCTGTGCACGCTTAGCCGCGAGGCCCGCGGTAGCCCGGGCGCCGATATGTAA
AGCAGCTGGCAGCGCTGGGCGGGGCCTGGGCGCGATGCAAATGAGGAGGG
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Figure 5.1: GC-rich region in PRKCB promoter. Schematic drawing of PRKCB 
promoter show the GC-rich region adjacent to Sp1 binding sites. The sequence 
underneath the drawing shows the CpG dinucleotides (green) adjacent to Sp1 
binding site in italic font and the primers that used for methylation studies (red). 
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Table 5.1: PRKCB promoter methylation in normal B and CLL cells. Normal B and 
CLL cells were each purified from 5 healthy donors or CLL patients, respectively. 
Genomic DNA was isolated from these cells, and methylation of the PRKCB 
promoter was determined as described in the materials and methods. % 
methylation is reported as the mean average methylation of 8 CpGs within the 
analysed sequence. A dash within the % purity of the cells indicates the cell purity 
was not assessed following purification. 
Sample ID B-CLL / Normal B % purity 
Mean % 
methylation 
2649 
Normal B 
96.12 3.49 
2667 97.12 2.22 
2668 93.15 2.3 
2675 - 1.73 
2063 
B-CLL 
99.79 3.32 
2064 - 4.51 
2226 - 2.31 
2262 93.03 1.05 
2458 91.09 0.8 
2536 99.33 3.16 
 
 
 
 
5.2.2 PRKCB chromatin is enriched with permissive histone marks in 
CLL cells  
Acetylation of lysine 9 and 14 within histone H3 (collectively known as H3Ac), as 
well as tri-methylation of lysine 4 residues (H3K4me3), are modifications associated 
with transcriptionally active promoters and are therefore known as permissive 
histone marks [316]. I used ChIP to compare the status of these permissive marks 
approximately 500bp upstream and downstream of the transcription start site of 
PRKCB in CLL and normal B cells. These regions were chosen as it has been 
demonstrated that transcriptionally active genes are enriched for these marks 
within these locations [317, 318]. Figure 5.2 shows that both H3Ac and H3K4me3 
marks are associated with the PRKCB promoter in CLL and normal B cells, and that 
the extent of this association is significantly higher in the former compared to the 
latter. Figure 5.2 also shows that these marks are present on PRKCB chromatin 
500bp up- and downstream of the transcriptional start site, and that the level of 
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association is greater in CLL compared to normal B cells. These results clearly show 
that the H3Ac and H3K4me3 marks are enriched on PRKCB chromatin in CLL cells. 
Because these marks are associated with chromatin relaxation consistent with 
active transcription, these results suggest that increased access of Sp1 to the PRKCB 
promoter in CLL cells may be the result of such chromatin relaxation. 
 
B)A)
C) D)
 
Figure 5.2: PRKCB chromatin is enriched with permissive histone marks as an 
indicator of active transcription status of its promoter in CLL cells. Chromatin was 
prepared from 1x107 purified normal B and CLL cells, and the permissive Histone 
marks (H3Ac and H3k4me3) were immunoprecipitated using specific antibodies. 
The association of H3Ac and H3K4me3 were detected by qPCR and primers covering 
the region upstream and downstream of the TSS of PRKCB promoter. The results 
are presented as fold enrichment compared to PRKCB promoter sequences 
associated with the non-specific IgG immunoprecipitation control. A) and C) Show 
comparison of H3Ac association upstream and downstream of TSS within PRKCB 
promoter in normal B and CLL cells respectively. B) and D) Show comparison of 
H3K4me3 association upstream and downstream of TSS within PRKCB promoter in 
normal B and CLL cells respectively. Statistical analysis was performed using a 
Mann-Whitney U-test.  
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5.2.3 Expression of p300 in normal B and CLL cells 
p300 is a histone acetyltransferase (HAT) that is important for acetylating lysine 
residues in histone3 [319]. I next examined the protein levels of p300 in CLL and 
normal B cells using Western blot. Figure 5.3 shows that p300 protein levels are 
generally higher in CLL compared to normal B cells. Some cases, such as #1873 and 
#1872 seem to overexpress p300 at very high levels. Considering that p300 is 
recruited to chromatin by co-association with transcription factors such as Sp1 
[320, 321], it seemed logical to explore whether p300 played a role in regulation of 
PRKCB transcription.  
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Figure 5.3: p300 protein expression in normal B and CLL cells. Western blot 
analysis of cell lysates prepared from purified CLL and normal B cells. 10 µg of 
protein was separated on 10% acrylamide SDS-PAGE gels, and transferred to PVDF 
membranes, which were then probed with antibodies to p300 and β-actin. A) 
Shows p300 protein expression in normal B (n=3) and CLL (n=10) cells. B) 
Quantitative analysis of p300 protein expression in CLL and normal B cells depicted 
in part A. Statistical analysis was performed using a Mann-Whitney U-test. 
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5.2.4 Inhibition of p300 decreases H3Ac and H3K4me3 marks 
associated with PRKCB chromatin in CLL cells, and suppresses PKC 
gene expression 
C646 is a HAT inhibitor that specifically targets p300 [310]. I used this compound in 
combination with ChIP analysis to examine how treatment of CLL cells with C646 
affected the H3Ac and H3K4me3 marks. Figure 5.4 shows that treatment of CLL 
cells with this inhibitor resulted in a decrease of H3Ac and H3K4me3 chromatin 
marks associated with PRKCB either upstream or downstream of the transcriptional 
start site. I next examined how this decrease of H3Ac and H3K4me3 chromatin 
marks associated with PRKCB affected transcription. Figure 5.5A shows that 
treatment of CLL cells with C646 resulted in a reduction of PKC mRNA levels. This 
reduction in PKC mRNA correlated with decreased association of Sp1 to the PRKCB 
promoter in treated CLL cells as analysed by ChIP (Figure 5.5B). Finally, Sp1 and 
PKCβII protein levels in CLL cells remained unaffected by treatment with C646 
(Figure 5.5C). Taken together, these data show that inhibition of p300 with C646 
suppresses PKC gene expression, and suggest that the mechanism of this 
suppression is through alteration of the chromatin marks that are permissive of 
transcription.   
The next logical step would be to examine how knockdown of p300 affected PRKCB 
transcription. Figure 5.6 shows that treatment of MEC1 cells with siRNA targeting 
p300 resulted in a reduction of p300 mRNA and protein and PKC mRNA and 
protein. However, Sp1 protein and mRNA levels were also reduced by knockdown 
of p300, a result that indicates that the reduction in PKC gene expression observed 
in this experiment is as a result of suppressed Sp1 expression.  
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Figure 5.4: C646 decreases H3Ac and H3K4me3 associated with PRKCB promoter 
in CLL cells. Chromatin extracts from 1x107 CLL cells at T0 (time zero, just after 
thawing), or from cells cultured for 24 h in the presence of 10 µM C646 or DMSO 
vehicle control (UT) were prepared. Then, H3Ac and H3K4me3 were 
immunoprecipitated using specific antibodies. PRKCB promoter 500bp upstream 
and downstream of the TSS associated with H3Ac and H3K4me3 were detected 
using qPCR and specific primers covering these regions. The results are presented 
as fold enrichment compared to PRKCB promoter sequences associated with the 
non-specific IgG immunoprecipitation control. Results show a summary of single 
experiments using two different CLL patient samples.  
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Figure 5.5: Effect of C646 on PKCβ mRNA levels, Sp1 association within PRKCB 
promoter and Sp1 protein levels in CLL cells. 1x107 CLL cells were cultured in 
absence (UT) or presence of DMSO vehicle control or 10 µM C646. Cell lysates, 
chromatin and mRNA extracts were prepared from harvested cells after 24 h 
culturing in addition to samples taken at T0 (time directly after thawing). PKCβ 
mRNA levels were measured using qRT-PCR relative to the reference gene RNA 
Polymerase II and presented as arbitrary units. 10µg of protein were separated by 
SDS-PAGE and were transferred to PVDF membranes and blot for Sp1, PKCβII, and 
β-actin as loading control. Sp1 was immunoprecipitated using specific antibodies. 
PRKCB promoter associated with Sp1 was detected using qPCR and specific primers 
covering Sp1 binding regions. The results are presented as fold enrichment 
compared to PRKCB promoter sequences associated with the non-specific IgG 
immunoprecipitation control. A) Shows PKCβ mRNA levels. B) Shows Sp1 
association with PRKCB promoter. C) Shows PKCβII and Sp1 protein levels. This 
experiment illustrates n=3 separate biological replicates and the results presented 
as (mean±SE) for parts A from two different CLL patients. Results show a summary 
of single experiments using two different CLL patient samples for part B.  
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Figure 5.6: Effect of p300-specific siRNA on p300, PKCβII, and Sp1 mRNA and 
protein levels in MEC1 cells. 2x106 MEC1 cells were nucleofected with 2 µM of 
p300-specific or control siRNA oligonucleotides and then cultured under the 
conditions described in the materials and methods. Harvested cells after 72h were 
analysed for protein expression by Western blot and mRNA levels by qRT-PCR. All 
the mRNA levels were measured relative to the reference gene RNA Polymerase II 
and expressed as arbitrary units. A) Shows p300 mRNA levels. B) Shows PKCβ mRNA 
levels. C) Shows Sp1 mRNA levels. D) Shows the protein levels for p300, PKCβII, Sp1, 
and β-actin. 10 µg of the prepared whole cell lysates were separated by SDS-PAGE 
and transferred into PVDF membranes, and then were immunobloted for the 
indicated antibodies. The mRNA levels in parts A, B, and C presented as the 
mean±SE of n=3 separate replicates. Statistical analysis for parts A, B, and C in this 
figure was performed using a student’s t-test for paired data. 
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5.2.5 HDAC inhibitor increases H3Ac and H3K4me3 enrichment 
associated with PRKCB promoter in CLL cells 
Chromatin remodelling is also catalysed by HDAC enzymes, which silence gene 
expression by altering the chromatin structure to a state which is less permissive of 
transcription by removing acetyl groups from lysine residues in histones [322]. 
Romidepsin is a class I HDAC inhibitor, and I used this compound to investigate its 
effect on CLL cells. ChIP analysis of H3Ac and H3K4me3 associated with the PRKCB 
promoter ±500bp from TSS showed that these marks increased in CLL cells treated 
with romidepsin (Figure 5.7). However, similar to C646, treatment of CLL cells with 
romidepsin also decreased PKC mRNA levels and Sp1 association with the PRKCB 
promoter (Figure 5.8A and B) without affecting Sp1 protein expression (Figure 
5.8C). These results show that HDAC inhibition in CLL cells results in changes to 
chromatin that is potentially permissive of transcription, but does not lead to 
increased PKC gene expression.  
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Figure 5.7: Romidepsin increases acetylation H3 and tri-methylation on lysine 4 of 
H3 associated with PRKCB promoter in CLL cells. Chromatin extracts from 1x107 
CLL cells at T0 (time zero, just after thawing), or from cells cultured for 24 h in 
absence of Romidepsin (UT) or in presence of Romidepsin (Romi) (6 nM) were 
prepared. Then, H3Ac and H3K4me3 were immunoprecipitated using specific 
antibodies. The association of H3Ac and H3k4me3 within the A) -500bp and B) 
+500pb of the TSS regions of PRKCB promoter were detected by using qPCR and 
primers covering the indicated regions within PRKCB promoter. The results are 
presented as fold enrichment compared to PRKCB promoter sequences associated 
with the non-specific IgG immunoprecipitation control. Results show a summary of 
single experiments using for two different CLL patient samples. 
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Figure 5.8: Effect of Romidepsin on PKCβ mRNA levels, Sp1 association within 
PRKCB promoter and Sp1 protein levels in CLL cells. 1x107 CLL cells were cultured 
in the absence (UT) or presence of DMSO vehicle control or 6 nM Romidepsin 
(Romi). Cell lysates, chromatin and mRNA extracts were prepared from harvested 
cells after 24 h culturing in addition to samples taken at T0 (time directly after 
thawing). PKCβ mRNA levels were measured using qRT-PCR relative to the 
reference gene RNA Polymerase II and presented as arbitrary units. 10 µg of protein 
were separated by SDS-PAGE and were transferred to PVDF membranes and then 
blotted for Sp1, PKCβII, and β-actin as loading control. Sp1 was immunoprecipitated 
using specific antibodies. PRKCB promoter associated with Sp1 was detected using 
qPCR and specific primers covering Sp1 binding regions. The results are presented 
as fold enrichment compared to PRKCB promoter sequences associated with the 
non-specific IgG immunoprecipitation control. A) Shows PKCβ mRNA levels. B) 
Shows Sp1 association to PRKCB promoter. C) Shows Sp1 and PKCβII protein levels. 
This experiment illustrates n=3 separate biological replicates and the results 
presented as (mean±SE) for parts A from two different CLL patients. Results show a 
summary of single experiments using two different CLL patient samples for part B. 
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5.3 Discussion 
Epigenetic control of gene expression is important for maintaining cell phenotype, 
allowing heritable expression of particular genes without changing nucleotide 
sequences in DNA [113]. In cancer this process can be deregulated to allow 
over/under expression of particular genes that are important for the neoplastic 
behaviour of the malignant cell [323, 324]. Therefore, studying this phenomenon 
and its regulatory mechanisms is key to gaining insight into cancer cell 
pathophysiology. In this Chapter I present data which shows that chromatin 
containing the PKC gene in CLL cells is more highly associated with 
transcriptionally permissive histone marks than that in normal B cells. Furthermore, 
my data also suggest that the presence of these histone marks allows greater 
accessibility of Sp1 because treatment of CLL cells with HAT inhibitors reduces the 
level of transcriptionally permissive histone marks and Sp1 association with the 
PRKCB promoter. These data, for the first time, implicate a role of chromatin 
structure in the regulation of PKC gene expression.  
Epigenetic control of gene expression is principally mediated by three different 
mechanisms [314]; changes in the status of gene promoter methylation [17], 
histone modifications controlling chromatin condensation [18] and by miRNA 
disruption of translation or destabilisation of mRNA [20]. In the first instance, we 
investigated PRKCB promoter methylation in CLL and normal B cells and we showed 
that it is similar and unmethylated in these two cell types. The CLL cell epigenome 
has been investigated and shown to be generally hypomethylated, specifically for 
genes that play key roles in the pathogenesis of these malignant cells [162, 325]. 
This implies that overexpression of these genes is the result of hyopmethylation of 
their promoter regions as is suggested as a mechanism for how DNA methylation 
affects gene expression [326, 327]. For the purposes of the current study it was 
important to study methylation of the PRKCB promoter because it is known to 
contain CpG islands, which are the target of the DNA methyltransferases and 
demethylases that are responsible for DNA methylation status [326]. Also, 
promoter methylation status affects the ability of Sp1 to access gene promoters 
[186, 328], and this is important regarding my results which indicate that Sp1 drives 
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PKC gene expression. And finally, a recent study by Hagiwara et al. showed that 
the PRKCB promoter is a target of PROX1, a DNA methyltransferase, in a HeLa cell 
model system where it limits access of Sp1 to its consensus binding sequence in the 
PRKCB promoter due to hypermethylation [5]. That the methylation status of the 
PRKCB promoter in CLL and normal B cells is unmethylated indicates that PROX1 
likely does not play a role in regulating PKC gene expression in CLL cells, and that 
the increased access of Sp1 to this promoter in CLL cells is not the result of changes 
to gene methylation. In this regard, control of PRKCB transcription in CLL is similar 
to that controlling PRKCE (the gene coding for PKCε) in breast cancer cells; 
expression of this gene is also driven by Sp1, but although its promoter can be 
methylated it remains unmethylated between normal and breast cancer cells [329]. 
With regard to histone modifications, I studied H3Ac and H3K4me3 which are 
permissive histone marks of euchromatin and are generally associated with gene 
promoters where active transcription is taking place [42, 316]. In particular, the 
H3K4me3 mark promotes the recruitment of enzymes which facilitate the 
formation of an “open” structure of chromatin that is conducive to increased access 
of transcription factors and induction of transcription [316]. The data I present in 
this Chapter clearly show that the PRKCB promoter in CLL cells has these permissive 
histone marks to a greater extent than that in normal B cells. Interestingly, recent 
reports have indicated that expression of the class of enzymes responsible for 
regulating histone acetylation, known as HDACs and HATs [330, 331], are 
deregulated in CLL cells, and may relate to disease prognosis and pathogenesis 
[332-334]. p300 is an example of a HAT protein that transfers an acetyl group to 
histone proteins, and, in particular to histone H3 at lysine residues. I found the 
p300 was more highly expressed in CLL compared to normal B cells, suggesting that 
this enzyme might catalyse the more permissive transcriptional environment 
observed in the former cell type. C646 is a drug that was developed to specifically 
inhibit the activity of p300 [245]. In this Chapter I used this drug to explore how 
p300-mediated histone modification affected PKC gene expression in CLL cells. I 
found that inhibition of p300 in CLL cells with C646 lead to reduced levels of H3Ac 
and H3K4me3, as well as Sp1 associated with the PRKCB promoter. Thus, the 
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presence of C646 inhibited the expression of PKC in CLL cells, and because this 
compound had no effect on Sp1 protein levels the proposed mechanism of 
downregulated PKC gene expression is due to chromatin condensation caused by 
inhibition of p300. I attempted to confirm this conclusion by knocking down p300 
expression in MEC1 cells with siRNA. Such knockdown resulted in a profound 
reduction in PKCβ mRNA levels, but this could be caused by reduced Sp1 expression 
because knockdown of p300 in these cells also resulted in attenuation of mRNA and 
protein levels of this transcription factor. The reason for this discrepancy could be 
because I used CLL cells to test the effects of C646 and MEC1 cells to test the effects 
of p300 knockdown. Nevertheless, although I cannot directly demonstrate a role for 
p300 in regulating PKC gene expression, the data presented do suggest that 
chromatin structure is important. 
HDAC enzymes are antagonistic to HATs, and remove acetyl groups from histone 
and other proteins. HDACs are a family of enzymes that are divided into four 
different classes [322], and inhibiting these enzymes using pan or specific inhibitors 
leads to increased acetylation of lysine residues within proteins. When this happens 
within histones this result in relaxation of chromatin and allows more accessibility 
for transcription factors [308, 335]. I have examined histone marks associated with 
PRKCB chromatin in romidepsin-treated and untreated CLL cells. I found that 
culture of CLL cells with romidepsin results in an increase in the H3Ac and H3K4me3 
marks associated with the PRKCB promoter. However, the increased association of 
these marks with the PRKCB promoter did not result in increased PKCβ gene 
transcription, nor increased Sp1 association with the PRKCB promoter. The failure 
of romidepsin-treated CLL cells to upregulate PKC gene expression in the presence 
of relaxed chromatin was not due to changes in Sp1 protein levels as was suggested 
by others using MS-275, another class I HDAC inhibitor [336]. Alternatively, because 
HDACs also catalyse removal of acetyl from other proteins such as transcription 
factors [337], it could be that Sp1 in CLL cells became acetylated and this inhibited 
its function. This notion is supported by studies showing that such modification of 
Sp1 inhibits the ability of this transcription factor to bind its target genes [191, 338, 
339].      
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Taken together, the findings of this Chapter show that PRKCB in CLL cells is more 
permissive for transcription than that in normal B cells. Future work will need to 
determine the nature of the enzymes catalysing the permissive environment, and, 
in particular, focus on the potential role of p300.  
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 Chapter Six: Role of vascular endothelial growth 
factor (VEGF) and Bryostatin in regulating 
transcription of PRKCB expression in CLL cells 
 
6.1 Introduction and aim 
So far in this thesis I have focussed on the role of two cell-intrinsic factors, 
transcription factors and epigenetic modifications, in regulating PKCβ gene 
expression in CLL cells. An additional level of regulation can occur through 
stimulation of gene expression by extrinsic factors such as growth factors. This is 
important with respect to PKC because a previous report from this Department 
has shown that PRKCB transcription in CLL cells is stimulated by VEGF [143], whilst 
another has demonstrated that expression of this gene can be inhibited by the PKC 
agonist Bryostatin [137]. However, these studies have not addressed the 
mechanism by which PRKCB transcription is stimulated/inhibited by these factors. 
The previous work of this thesis identified Sp1 as the major driver of PRKCB 
transcription, and the work of Farren et al., [8] shows that STAT3 can suppress 
expression of this gene. Therefore, the aim of this chapter is to investigate how 
VEGF and Bryostatin regulate Sp1/STAT3 interaction with the PRKCB promoter in 
CLL cells.  
 
6.2 Results 
6.2.1 VEGF stimulates the expression of PKCβII gene in CLL cells 
To begin this investigation I repeated the findings reported by Abrams et al., [143]. 
Figure 6.1 shows confirmation of these findings. PKC mRNA levels decrease in CLL 
cells that have been cultured overnight, whilst inclusion of VEGF in these cultures 
results in PKC mRNA levels being maintained or further increased. Considering the 
role of Sp1 in driving PKC gene expression, I next examined the effect of VEGF on 
association of this transcription factor with the PRKCB promoter. 
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Figure 6.1: VEGF stimulates PKCβ gene expression in CLL cells. 1x107 CLL cells were 
cultured for 24 h in the absence (UT) or presence of 100 ng/mL VEGF, or with 
200nM mithramycin, and then mRNA was harvested. T0 indicates cells from which 
mRNA was extracted just after thawing (time zero). PKCβ mRNA level was 
measured by qRT-PCR and presented relative to the reference gene RNA 
Polymerase II in arbitrary units. The data are presented as mean ± SE of n=3 
experiments using CLL cells from a single patient. These data are representative of 
the results generated using cells from three different CLL patient samples. 
Statistical analysis for this figure was performed using a student’s t-test for paired 
data. 
 
 
2.6.2 VEGF stimulates Sp1 association with the PRKCB promoter in CLL 
cells 
To investigate the notion that VEGF may modulate the association of Sp1 to the 
PRKCB promoter I performed ChIP analysis. Figure 6.2 shows that CLL cells 
stimulated with VEGF have significantly increased levels of Sp1 in association with 
the PRKCB promoter than do either unstimulated CLL cells, or CLL cells that have 
had chromatin extracted from them directly after thawing. In these experiments 
mithramycin was included as a control to displace Sp1 from the PRKCB promoter. 
Taken together with the data showing that VEGF stimulates PKC gene expression, 
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these results show clearly that the stimulation of PRKCB transcription in CLL cells by 
VEGF is due to induction of Sp1 binding to the promoter of this gene.  
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Figure 6.2: VEGF stimulates Sp1 association with the PRKCB promoter in CLL cells. 
1x107 CLL cells were cultured for 24 h in the absence (UT) or presence of VEGF 
(100ng/ml), or with MIA (200 nM). Following harvest of these cells chromatin 
extracts were prepared, and Sp1 was immunoprecipitated using specific antibody. 
T0 indicates cells from which chromatin was extracted just after thawing (time 
zero). The association of Sp1 to the PRKCB promoter was detected using qPCR and 
primers which covered the Sp1 binding site within this promoter. The results are 
presented as fold enrichment compared to PRKCB promoter sequences associated 
with the non-specific IgG immunoprecipitation control. Results are presented as 
mean ± SE of n=3 independent experiments using cells from a single CLL patient 
sample. These results are representative of similar experiments performed using 
cells from three different CLL patient samples. Statistical analysis for this figure was 
performed using a student’s t-test for paired data. 
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2.6.3 VEGF decreases association of STAT3 to the PRKCB promoter 
after 24h of culturing with CLL cells  
In Chapter 4 I showed that STAT3 association with the PRKCB promoter was 
induced after overnight culture of CLL cells. Considering the role of STAT3 in 
suppression of PKC gene expression [8], it seemed necessary to investigate 
whether there is a relationship between STAT3 and Sp1 in relation to VEGF. Figure 
6.3A shows, as in Figure 4.21, that overnight culture of CLL cells resulted in 
induction of STAT3 association with the PRKCB promoter in CLL cells. Figure 6.3A 
also shows that when VEGF is present, this induction is blocked and the level of 
STAT3 association with the PRKCB promoter remains similar to that observed using 
fresh cells.  
To explore whether STAT3 suppresses PRKCB promoter activity I next used MEC1 
cells where I transfected pGL3-pkcβ-1.2kb and assayed for luciferase.  Figure 6.3B 
shows that VEGF stimulates PRKCB promoter activity in line with its ability to 
stimulate PKC gene expression in CLL cells (Figure 6.1). Similarly, treatment of 
MEC1 cells with an inhibitor of STAT3 which blocks its ability to interact with DNA 
also results in increased PRKCB promoter activity. In contrast, stimulation of MEC1 
cells with IL-6 or IL-21 (which both activate STAT3), or with LY333531 (an inhibitor 
of PKC and of the ability of VEGF to stimulate PKC gene expression [143]) 
suppressed PRKCB promoter activity (Figure 6.3B). Taken together, these results 
suggest that STAT3 also functions as a suppressor of PKC gene expression in CLL 
cells. Furthermore, when considered in combination with the ChIP data showing 
regulated association of STAT3 and Sp1 with the PRKCB promoter in CLL cells, these 
results further suggest that STAT3 works to influence the ability of Sp1 to associate 
with the PRKCB promoter through a mechanism involving VEGF-stimulated 
activation of PKC. 
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Figure 6.3: Effect of VEGF on STAT3 association with the PRKCB promoter in CLL 
cells. A) STAT3 association with the PRKCB promoter. 1x107 CLL cells were cultured 
for 24 h in the absence (UT) or presence of 100 ng/ml VEGF. T0 refers to cells used 
just after thawing. Chromatin extracts were prepared from harvested cells and 
STAT3 was immunoprecipitated using specific antibodies. The association of STAT3 
within the PRKCB promoter were detected using qPCR and primers covering the 
STAT3 binding site region. The results are presented as fold enrichment compared 
to PRKCB promoter sequences associated with the non-specific IgG 
immunoprecipitation control, and as a mean±SE summary of three experiments 
using different CLL patient samples. Statistical analysis for this figure was 
performed using a student’s t-test for paired data.  B) Effect of different stimulators 
and inhibitors on PRKCB promoter activity in MEC1 cells. 2x106 MEC1 cells were co-
transfected with 0.1 µg pRL and 2 µg wt pGL3-pkcβ-1.2kb (WT), and were either left 
untreated, or were treated with 100 nM LY333531, 0.5 µM STAT3 inhibitor VII, 100 
ng/ml VEGF , 150 ng/ml IL-6, or with 50 ng/ml IL-21. Luciferase assays were 
performed following 24 h culture of the cells under serum-rich conditions, and are 
reported relative to renilla expression. This is a single experiment.  
 
 
2.6.4 Bryostatin inhibits PKCβII mRNA and protein levels in CLL cells 
Abrams et al. [143] and the experiments with LY333531 (Figure 6.3B) show that 
PKCII activity is important for the induction of PRKCB transcription. Bryostatin is a 
PKC agonist, and as such, treatment of CLL cells with this agent should stimulate 
PKC gene expression. However, work from our department and others shows that 
treatment of CLL cells with Bryostatin inhibits transcription of PRKCB and 
expression of PKCII protein [137, 340]. Figure 6.4 shows confirmation of these 
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results; PKCβII transcript and protein levels in CLL cells were reduced by treatment 
with Bryostatin relative to untreated or control (DMSO vehicle) samples.  
Previous work in this thesis has shown that a reduction of Sp1 protein levels in CLL 
cells leads to a reduction in PRKCB transcription. However, Figure 6.5A shows that 
Sp1 protein levels remain similar between control and Bryostatin-treated CLL cells. 
Since Bryostatin stimulates CLL differentiation [341] it seemed necessary to 
investigate how this agent affected the presence of permissive transcription marks 
associated with the PRKCB promoter. Treatment of CLL cells with Bryostatin 
induced an increase in permissive H3Ac histone marks associated with the PRKCB 
promoter (Figure 6.5B), indicating that epigenetic changes are not responsible for 
the suppression of PKC gene expression. Thus, the suppressive effects of 
bryostatin must be mediated by regulation of transcription factor access to the 
PRKCB promoter. I investigate this notion in the next section.  
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Figure 6.4: Bryostatin inhibits PKCβII mRNA and protein levels in CLL cells. 1x107 of 
CLL cells were cultured in absence (UT) or presence of Bryostatin (Bryo) (50 nM).  
Cell lysate for Western blot analysis and PKCβ mRNA was prepared from CLL cells 
harvested after 24 h culturing or at T0 (time zero, just after thawing). PKCβ levels 
were measured by qRT-PCR relative to the reference gene RNA Polymerase II and 
presented as arbitrary units. For Western blot analysis 10 µg of protein was 
separated on 10% acrylamide SDS-PAGE gels, and transferred to PVDF membranes, 
which were then probed with antibodies to PKCβII and β-actin. A) Shows PKCβ 
mRNA levels. B) Shows protein levels. The results in this figure presents n=1 
experiment in two different CLL patients samples. 
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Figure 6.5: Effect of Bryostatin on Sp1 protein levels and H3Ac associated with the 
PRKCB promoter in CLL cells. 1x107 of CLL cells were cultured in absence (UT) or 
presence of Bryostatin (Bryo) (50 nM) for 24 h. T0 refers to cells used just after 
thawing. A) Sp1 protein levels Sp1.  Cell lysates were prepared from harvested cells, 
and 10µg of protein was separated on 10% acrylamide SDS-PAGE gels, and 
transferred to PVDF membranes, which were then probed with antibodies to Sp1 
and β-actin. B) H3Ac levels increases in the treated CLL cells with bryostatin. 
Chromatin was prepared and H3Ac was immunoprecipitated using specific 
antibodies. The association of H3Ac with the PRKCB promoter were detected by 
using qPCR and primers covered -500bp region from TSS of PRKCB promoter. The 
results are presented as fold enrichment compared to PRKCB promoter sequences 
associated with the non-specific IgG immunoprecipitation control in two different 
CLL patient samples. The results for part B in this figure presents single experiment 
in two different CLL patients samples. 
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2.6.5 Bryostatin decreases Sp1 and increases STAT3 association with 
the PRKCB promoter in CLL cells 
To explore whether Bryostatin changes transcription factor accessibility to the 
PRKCB promoter in CLL cells I used ChIP and analysed for Sp1 and STAT3. Treatment 
of CLL cells with Bryostatin results in decreased Sp1 association with the PRKCB 
promoter, and increased STAT3 association (Figure 6.6). Considering the role of 
STAT3 in suppressing PKC gene expression, these results suggest that the 
mechanism through which Bryostatin acts to inhibit PKC gene expression is 
through activation of STAT3 binding to the promoter and consequent block of Sp1 
access.  
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Figure 6.6: Bryostatin increase Sp1 and decrease STAT3 association within PRKCB 
promoter in CLL cells. 1x107 CLL cells were cultured in absence of (UT) or the 
presence of Bryostatin (50 nM) (Bryo).Chromatin extracts were prepared from 
harvested cells after 24 h culturing or at T0 (time zero, just after thawing) then, Sp1 
or STAT3 were immunoprecipitated using specific antibodies. The association of Sp1 
or STAT3 within PRKCB promoter were detected by using qPCR and primers covered 
Sp1 or STAT3 binding site region within PRKCB promoter. The results are presented 
as fold enrichment compared to PRKCB promoter sequences associated with the 
non-specific IgG immunoprecipitation control in two different CLL patient samples.  
 
6.3 Discussion 
Earlier studies showed that VEGF stimulates [143] while Bryostatin inhibits [137, 
340] PKCβ gene expression in CLL cells. These findings deserved investigation 
because of the apparent contradiction of result despite a common mechanism of 
activation; both VEGF and bryostatin activate PKC, and PKC activity is known to 
play a role in stimulating PRKCB transcription [143, 164, 262].  In this Chapter I 
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investigated how these two cell extrinsic factors stimulated PRKCB expression at 
the transcriptional level. I found that these factors principally affected the ability of 
Sp1 to drive and STAT3 to inhibit PKC gene expression. These findings are 
important because they provide further insight into the mechanisms that are 
responsible for the overexpression of PKCβII in CLL cells.  
It is well established that VEGF plays a key role in survival and development of 
cancer cells, and this also includes CLL cells [342, 343]. A key player in the signal 
transduction pathway stimulated by VEGF is PKC [143], and it is established that 
active PKCβII can auto-stimulate expression of its gene [143, 164, 262]. Previous 
work from this Department showed that the activity of PKCII in CLL cells decreased 
with overnight culture, and that this activity could be maintained by including VEGF 
within these cultures [143]. The decreased activity of PKCII corresponded with a 
drop in PKC mRNA levels that were maintained in cells stimulated with VEGF. Here 
I show that these changes in PKC mRNA levels correlate with decreased or 
increased association of Sp1 to the PRKCB promoter. These results therefore 
suggest that PKCII activity must regulate the ability of Sp1 to associate with the 
promoter region of PRKCB and induce transcription. However, my results also show 
that the changes in PKC mRNA levels I observe in CLL cells cultured in the presence 
or absence of VEGF also correlate with decreased or increased association of STAT3 
to the PRKCB promoter. A previous report by another group showed that STAT3 
operated as a repressor of PRKCB transcription [8]. Thus, there appears to be a 
relationship between STAT3 and Sp1 whereby Sp1 access to the PRKCB promoter is 
governed by the presence of STAT3. This would then mean that PKCII activity must 
influence STAT3 association with the PRKCB promoter, and that this is involved in 
the mechanism governing the ability of Sp1 to stimulate PKC gene expression.  
The ability of active PKCII to influence STAT3 and Sp1 regulation of PKC gene 
expression deserved further modelling. Here, I used MEC1 cells and transfected 
them with a PRKCB promoter construct that included the STAT3 and Sp1 binding 
sites. Stimulation of these transfected cells with either IL-6 or IL-21, which both 
stimulates STAT3 activity; result in inhibition of promoter activity. In contrast, 
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treatment of CLL cells with STAT3 inhibitor VII (which blocks the ability of STAT3 to 
interact with DNA) results in induction of promoter activity. These results, when 
taken together with those presented in Figure 4.19B showing that mutations of the 
STAT3 binding sites within the promoter construct that I used lead to increased 
promoter activity, strongly suggest a predominant role of STAT3 as a repressor of 
PKC gene expression. A role for active PKCII within this system is implied when 
transfected MEC1 cells are treated with LY333531, which when used at 100 nM is 
highly specific for the inhibition of PKC and  [344]. Such inhibition of PKC leads 
to suppressed PRKCB promoter activity within my system. Finally, stimulation of 
transfected MEC1 cells with VEGF generated increased promoter activity of a 
similar magnitude observed when cells were treated with STAT3 inhibitor VII. This 
implies that VEGF-stimulated PKC activity removes the suppressive effects of 
STAT3 on the promoter.  
The above findings are consistent with those reported by Farren et al., who showed 
that there is a relationship between PKCβII activity and the block of suppressor 
function of STAT3 on the PRKCB promoter [8]. The mechanism proposed to explain 
this effect is that active PKCβII causes a reduction in the expression of receptors for 
VEGF on the surface of undifferentiated myeloid cells. This explanation, however, 
does not apply to CLL cells because PKCβII is active in these cells, and VEGF 
receptors are both expressed and functional [143].  
Bryostatin is a PKC agonist which can activate classical PKC isoforms[345]. I used 
this compound to stimulate CLL cells, and found that bryostatin inhibited PKCII 
expression both at the protein and at the mRNA levels. While it could be expected 
that bryostatin treatment leads to increase degradation of PKCβII protein as it was 
described before [111, 159, 346] the effect on PKC gene expression required 
further investigation. Thus, I used ChIP analysis to show that bryostatin treatment 
of CLL cells leads to reduced levels of Sp1 and increased levels of STAT3 association 
with the PRKCB promoter. Bryostatin is a potent inducer of differentiation in CLL 
[165, 347], and I demonstrate that such treatment relaxes the chromatin structure 
surrounding the promoter of PRKCB to potentially make it more permissive of Sp1 
association and transcription. Therefore, decreased association of Sp1 with the 
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PRKCB promoter in bryostatin-treated CLL cells is not because of chromatin 
landscape changes. Importantly, it is likely the increased association of STAT3 to the 
PRKCB promoter results in suppression of gene expression. STAT3 is likely to have 
become activated by CLL cell stimulation with bryostatin due to autocrine 
stimulation by secreted factors as is described by Battle and Frank [165]. 
Interestingly, Obeid et al. [4] showed that stimulation of cells transfected with the 
basal region of the PRKCB promoter with phorbol ester, another PKC agonist, leads 
to hyperactivation of promoter activity. Assuming that PKC protein expression 
within the cell system used by Obeid et al. [4] would be decreased by phorbol ester 
treatment in a similar way as is observed in CLL cells, it is therefore likely that PKC 
activity is required for modulating STAT3 association with the promoter rather than 
with simulating Sp1 association. Future work will need to address this proposition.  
Taken together, these findings are of importance because they show a new 
relationship between STAT3 and Sp1 in the regulation of PKC gene expression, and 
provide further insight into the role of VEGF in the pathophysiology of CLL cells. 
Within proliferation centres it is reasonable to assume that CLL cells would be 
exposed to factors such as IL-6 [348-350]and IL-21 [351, 352] which would stimulate 
and activate STAT3, to possibly suppress PKC expression. VEGF is also present 
within proliferation centres [353], and its function is to modulate the suppressive 
effects of STAT3 activation by IL-6/IL-21 and promote the high PKCII expression 
that is observed. Potentially, VEGF-stimulation of PKCII activity inhibits STAT3 
suppression of PRKCB transcription. The mechanism how is mediated now needs 
further investigation.  
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 Chapter Seven: General Discussion and conclusions 
 
PKCβII overexpression is a hallmark feature of CLL cells. At the beginning of this 
work there were few studies investigating the regulation of PRKCB, the gene 
encoding PKCβII. The earliest of these studies described the basal promoter of the 
PRKCB gene, and gave hints regarding the factors which drove activity of this 
promoter [4, 161]. Subsequent studies identified roles for RUNX1 [6], MITF [7] and 
STAT3 [8], but the binding sites for these transcription factors are outside of the 
basal promoter region of PRKCB and do not majorly contribute to driving 
transcription of this gene. Additionally, epigenetic factors were also taken into 
consideration because the PRKCB promoter region is rich in CpG islands making it a 
candidate for methylation [4], as were cell extrinsic factors such as VEGF and 
Bryostatin which were shown to respectively stimulate or inhibit PKC gene 
expression [143, 340]. None of these studies identified the central transcription 
factor regulating PRKCB transcription. Thus, a clear and full understanding of the 
mechanisms regulating this gene was missing.  
The main aim of this thesis was to provide insight into the regulatory mechanisms 
of PRKCB expression in CLL cells. I found that the overexpression of PKCβII in CLL 
cells is derived mainly by Sp1-mediated transcription of PRKCB. Importantly, the 
result I present in Figure 3.7 shows that Sp1 is overexpressed in CLL cells and 
correlates with PKCII mRNA levels, suggesting that these factors are linked and 
potentially contribute to the pathophysiology of these malignant cells. PKCβII is 
known to be overexpressed in other cancer cell types such as lung and colorectal 
cells and this is correlated with disease progression [304, 354]. Interestingly, these 
malignant cells also show overexpression of Sp1 [355-357]. Thus, the 
overexpression of PKCβII in these cells may be due to deregulated expression of Sp1 
in a similar way to my findings in CLL cells. Importantly, in CLL cells there are a 
number of genes such as Bcl2 [191], TCL-1 [269], and LEF1 [358] that are 
overexpressed, and which have Sp1 binding sites within their promoters. It is 
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therefore possible that overexpression of Sp1 in CLL cells may lead to deregulated 
expression of these genes as well. 
 
Sp1 is a ubiquitous transcription factor regulating the expression of many genes. It 
can act to stimulate transcription of genes with TATA or TATA-less promoters [59, 
143], and Sp1-driven expression of some genes has been found to play an 
important role in the pathogenesis of epithelial cancers [359, 360]. With respect to 
PRKCB, the promoter which governs expression of this gene is TATA-less [4]. This is 
important for the reliance of PRKCB on Sp1 to mediate transcription. The TATA box 
of gene promoters is responsible for coordinating assembly of the machinery 
responsible for gene transcription [361-363]. In the case of Sp1, the protein 
structure of this transcription factor is able to recruit this machinery to effect 
transcription from genes which lack the TATA box [364-370].  The studies describing 
the basal promoter of PRKCB suggested two potential binding sites for Sp1 based 
on recognition of consensus binding sites [4]. In Chapter 3 I show clearly that Sp1 is 
the major driver of PRKCB expression in CLL cells. Importantly, I show that both Sp1 
binding sites are required for transcription to occur, mutation of either Sp1 binding 
site results in complete suppression of promoter activity. This finding is consistent 
with a model of how Sp1 mediates transcription from TATA-less gene promoters, 
such promoters tend to have multiple Sp1 binding sites where each plays a role in 
driving transcription of the gene [369, 371].  
The reliance of PRKCB in CLL cells on Sp1 to mediate transcription is further 
supported by my studies demonstrating a relationship between Sp1 binding to the 
PRKCB promoter and PKC mRNA. This relationship partially explains the 
mechanism of how VEGF mediates PKC gene expression in CLL cells. Thus, work 
presented in this thesis and by others in this Department [143] show that PKC 
mRNA levels decrease in CLL cells that are cultured overnight. Stimulation of 
cultured CLL cells with VEGF results in maintenance or increased PKC mRNA levels. 
The work I present in this thesis shows that Sp1 binding to the PRKCB promoter in 
CLL cells decreases with overnight culture of unstimulated CLL cells, and increases 
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in cells that have been stimulated with VEGF. This data suggests that Sp1 binding to 
the PRKCB promoter for induction of transcription can be regulated by cell-extrinsic 
factors.  VEGF may accomplish this by inducing post-translational modification of 
Sp1 to change its ability to associate with DNA. Indeed, Sp1 can be modified by 
phosphorylation, acetylation, ubiquitination and sumoylation [49, 176, 372]. 
However, the role of each of these modifications on Sp1 function seems specific to 
particular promoters and cells lines, and has not been clearly delineated owing to 
the ubiquitous role of Sp1 in transcribing many genes and a lack of appropriate 
molecular tools.  
In Chapter 4 I addressed the role of other potential transcription factors in 
regulating the expression of PRKCB in CLL cells. I investigated RUNX1, Sp3, MITF, 
E2F1 and c-Myc as well as STAT3 because of the reported role of these transcription 
factors in regulating the expression of this gene [158, 162-164]. In the first instance 
I found that RUNX1 does not associate with the PRKCB promoter in primary CLL 
cells. My cell line model, MEC1, showed expression of RUNX1, but ChIP analysis 
showed no association with the PRKCB promoter in these cells although association 
could be demonstrated with EVI1, used as a positive control. Therefore, it is highly 
unlikely that RUNX1 contributes to PKC overexpression in CLL cells.  
Investigation of MITF and E2F1 showed that these transcription factors were static 
with respect to transcription of PRKCB. Thus, MITF and E2F1 bound the promoter of 
PRKCB at higher levels in CLL than in normal B cells, but they did not appear to have 
a direct role in gene transcription. Knockdown of MITF resulted in a slight increase 
in PKC gene expression, whereas knockdown of E2F1 resulted in decreased PKC 
gene expression due to a reduction in Sp1 expression. These results suggest a 
passive role for MITF and E2F1, and it is possible that the increased binding 
observed in CLL compared to normal B cells could be due to the increased 
euchromatin surrounding PRKCB observed in the former cells. Alterations in 
chromatin structure play a role in regulating MITF access to and activation of gene 
promoters [373]. With respect to PRKCB the relaxation of chromatin structure 
allows MITF access to the promoter, but transcription does not occur for reasons 
unknown. A potential role for c-Myc is also included because it is expressed in CLL 
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cells from patients with progressive disease [374], and because these cells are likely 
to contain high levels of PKCII [1]. However, c-Myc was not observed in association 
with the E-Box sites of the PRKCB promoter in either primary CLL cells or MEC-1 
cells. Nevertheless, knockdown of c-Myc induced downregulation of PKC gene 
expression, and further analysis revealed a potential mechanism explaining this 
effect involving c-Myc regulation of E2F1, which, in turn, regulates Sp1 expression. 
Support for this mechanism is provided by studies showing that c-Myc regulates the 
expression of E2F1 [285], and that E2F1 can regulated the expression of Sp1 [257]. 
The consensus sequence that Sp1 and Sp3 bind to in DNA is very similar, and many 
genes show binding of Sp1 and Sp3 to their promoter regions [375-378]. Because of 
this similarity in consensus binding sequence, Sp3 is suggested to be a suppressor of 
Sp1 function particularly in the promoters which have more than one Sp1 binding 
sites [176, 276, 293]. Therefore, it was important to examine the potential role of 
Sp3 in PRKCB transcription. Importantly, Sp3 seems overexpressed in CLL compared 
to normal B cells. This implies that increased association of Sp1 with the PRKCB 
promoter is not the result of decreased Sp3 expression resulting in reduced 
competition for the binding sites. Indeed, ChIP analysis of Sp3 showed that it does 
not associate with the PRKCB promoter. Nevertheless, knockdown of Sp3 resulted 
in decreased levels of PKC mRNA indicating an indirect role for Sp3 in expression 
of PRKCB. This role was defined in experiments showing that knockdown of Sp3 
reduced Sp1 expression in CLL and MEC1 cells. This notion is supported by studies 
showing that Sp3 regulates Sp1 gene expression [278], and is consistent with the 
observation that Sp3 shows higher levels of expression in CLL cells. Thus, high 
expression of Sp3 contributes to high expression of Sp1 and, effectively, PKCII. 
High expression of Sp3 has been observed in other cancers where overexpression of 
Sp1 has also been observed [291, 379, 380]. Potentially, deregulation of Sp3 
expression could contribute to the behaviour of the malignant cells in these 
diseases. 
Analysis of the role STAT3 plays in regulating PRKCB transcription in CLL cells was 
important for two reasons; firstly, STAT3 was shown to suppress PRKCB promoter 
activity in a myeloid cell system [8], and, secondly, STAT3 is known to be 
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constitutively active in CLL cells [238]. Therefore, it is highly likely that STAT3 plays a 
role in regulating PKC gene expression in CLL cells. Indeed, examination of PRKCB 
promoter activity in MEC1 cells shows that STAT3 binding is important because 
mutation of the binding site results in increased activity. Moreover, incubation of 
MEC1 cells bearing the wt promoter construct with VEGF or with IL-6/IL-21 
respectively shows increased and suppressed promoter activity. This role of STAT3 
is echoed in experiments with primary CLL cells which showed increased association 
of STAT3 with the PRKCB promoter in cells cultured overnight in unstimulated 
conditions known to result in increased levels of pY-STAT3 [243], and decreased 
association of STAT3 in cells cultured in the presence of VEGF. Previous work from 
this Department showed that VEGF induced PKC gene expression through 
stimulation of PKCII activity. In my experiments, inhibition of PKCII activity 
blocked PRKCB promoter activity in transfected MEC1 cells. This suggests a 
potential role of PKCII in regulating the suppressive effects of STAT3 on the PRKCB 
promoter. Further work is now necessary to clarify how PKCII mediates its effect 
on STAT3, and whether this occurs when STAT3 is maximally activated by cytokines 
such as IL-6 and IL-21. The proliferation centres where CLL cells survive and expand 
contain high levels of VEGF, IL-6 and IL-21 as well as other stimuli [348-353]. PKCII 
protein levels in CLL cells within this environment is shown to be high [143], 
suggesting that VEGF may override the suppressive effects of STAT3. 
This work could potentially clarify the relationship between STAT3 and Sp1 on the 
PRKCB promoter. My experiments show that VEGF induces the association of Sp1 
whilst decreasing the accessibility for STAT3 to PRKCB. Conversely, in unstimulated 
cells, the increased binding of STAT3 sees reduction of Sp1 association with the 
promoter. It seems logical from these experiments that STAT3 binding to the PRKCB 
promoter may limit the accessibility of Sp1, and this would be the mechanism by 
which STAT3 mediates its suppression function. How this is achieved could be due 
to cooperation with MITF, which I have also shown interacts with the PRKCB 
promoter. This cooperation between STAT3 and MITF could involve the 
participation of a third protein known as Protein inhibitor of activated STAT3 
(PIAS3). This protein is known to interact with both MITF and STAT3 to limit their 
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transcriptional activity [381, 382]. In particular, IL-6 is demonstrated to stimulate 
co-association of STAT3, PIAS3 and MITF [383]. PIAS3 is potentially a target of PKC, 
and VEGF stimulation of CLL cells may influence the ability of IL-6 to stimulate 
STAT3-PIAS3-MITF complex formation. The ensuing result is STAT3 is unable to bind 
the PRKCB promoter and Sp1 is free to bind and upregulate expression of the gene. 
Support for this notion is suggested by my experiment where I knockdown 
expression of MITF and see a slight upregulation in PKC gene expression.  
Access of Sp1 to the PRKCB promoter in CLL cells is not only regulated by STAT3, but 
also by epigenetic factors. During the course of this thesis a paper by Higawara et 
al. showed that Sp1 binding to PRKCB could be blocked by hypermethylation of its 
binding site by the gene product of PROX1 [5]. However, my studies show that the 
PRKCB promoter in CLL cells is similar to that in normal B cells and is unmethylated. 
This indicates that gene methylation does not play a role in overexpression of 
PKCII in CLL. Instead, my results suggest that the greater access of Sp1 to the 
PRKCB promoter in CLL cells is likely due to enrichment of H3Ac and H3K4me3 
which are histone marks both connected with euchromatin [42]. This appears to be 
an active process in CLL because treatment of CLL cells with an inhibitor of HATs 
reduces the H3Ac and H3K4me3 histone marks and Sp1 association with the PRKCB 
promoter. The role of chromatin structure in regulating CLL cell phenotype and 
malignant cell behaviour is largely unexplored. 
In conclusion, I demonstrate a clear role for Sp1 as a major driver of PKCβII 
overexpression in CLL cells. This role appears to be the result of changes in 
chromatin structure leading to increased access of Sp1 to the PRKCB promoter, 
increased expression of Sp1 itself (potentially driven by high expression of Sp3) and 
decreased ability of STAT3 to suppress PRKCB transcription caused by cell extrinsic 
factors which affect CLL survival and growth in proliferation centres (Figure 7.1). 
Sp1 regulates the expression of many genes within cells, and potentially the 
findings I present in this thesis could provide insight into the mechanism controlling 
the overexpression of other genes that define the malignant cell phenotype of CLL. 
Moreover, there is a well-established bidirectional relationship between CLL cells 
and their microenvironmental support cells where the latter provides survival 
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signals. Recently, Lutzny et al., have shown that CLL cells induce expression of 
PKCβII in microenvironmental stromal cells leading to NFκB activation and ultimate 
support of the malignant cells in this system [131]. My findings may explain the 
mechanism how CLL cells and other neoplastic B cells stimulate the expression of 
PKCβII in supportive stromal cells.  
 
:Sp1 :Sp1 binding site :Histones :STAT3 binding site 
:STAT3
Nuclear membrane 
Plasma membrane 
1 2
A)
Nuclear membrane 
Plasma membrane 
1 2
C)
VEGF
Nuclear membrane 
Plasma membrane 
1 
B)
2
 
Figure 7.1: Model summary for the transcription of PRKCB in CLL cells. This Model 
represents the transcription of PRKCB in CLL cells. A) Represents basal promoter 
transcription driven mainly by Sp1. B) Represents inactive promoter status where 
binding of STAT3 suppresses transcription. C) Represents stimulation of PRKCB 
transcription by VEGF whereby STAT3 binding is reduced and Sp1 binding is 
increased.   
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-Appendix A: 
Clinical data of CLL patients used in this study 
Sample ID Gender IgVH 
mutation 
P53 
status 
CD38 
(%) 
Disease stage 
(Binet/Rai) 
Cytogenetic 
abnormalities 
3340 Male 3.44% NK NK IV/ C NK 
3336 Female NK NK NK II/C NK 
2329 Male NK WT NK NK Normal 
3052 Male 3.44% NK NK NK NK 
2172 Female NK NK NK NK NK 
3041 Male NK NK NK A NK 
2823 Male NK NA NK NK NK 
2155 Female 0 C NK NK NK 
2294 Female NK NK NK NK NK 
2354 Female NK NK NK NK NK 
2264 Female NK Normal NK NK Normal 
2532 Male NK NK NK NK NK 
3026 Female NK NK NK NK NK 
2027 Male 2.05% WT NK NK NK 
2437 Male NK B NK B NK 
3105 Male NK NK 95.8% NK NK 
1874 Male NK NK 5% A/0 Normal 
3144 Female NK NK NK C NK 
1786 Female NK NK NK B/IV NK 
2724 Female NK NK NK B NK 
3354 Female NK NK NK B/I NK 
3365 Female NK NK NK C/0 NK 
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NK: Not known 
 
 
 
 
 
 
 
 
 
 
 
 
3325 Female 5.21% NK NK C/IV Del17p13 (77%) 
3244 Male 0.00% NK NK B NK 
3028 Female NK NK NK A NK 
2727 Male NK WT NK A NK 
1767 Female NK NK NK B NK 
2686 Female NK NK NK NK NK 
3347 Female NK NK NK III NK 
2683 Male NK NK NK NK NK 
3221 Male NK NK NK NK NK 
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-Appendix B: 
-Mycoplasma Test protocol: 
The mycoplasma infection test was applied for the recent passaged cultured cell 
lines. The cells were suspended with 100µl of sterile PBS after washing them twice. 
Subsequently the cell suspension was vortexed for 5-10sec after heating for 10min 
at 95ᴼC. Then, the supernatant was collected in sterile eppendorff after spin down 
the cells at 13,000 RPM for 2min and kept in ice until it was used for the test. The 
next PCR step in the mycoplasma test protocol was done by the lab technicians. 
Briefly, 10µl of the cell supernatant was added as a PCR template to each e-MycoTM 
Mycoplasma PCR detection kit (v.2.0) (Intro Biotechnologies, Korea) tube and were 
suspended with another 10µl of sterile water to give a total volume of 20µl of PCR 
reaction. Simultaneously, another 20µl of a negative control, sterile water only, and 
a positive control were running alongside the tested samples in the PCR reaction. 
The following thermal profile was used for the PCR reaction an initial denaturation 
step at 94ᴼC for 1min. followed by 35 cycles of denaturation at 94ᴼC for 30 sec, 
annealing at 60ᴼC for 20sec, and extension at 72ᴼC for 1min. The reaction was 
further extended for one cycle at 72ᴼC for 5min.Finally, the PCR products beside the 
DNA leader were run in 2% agarose gel. The samples consider infected if they 
showed a similar band size like the positive control. 
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-Appendix C:  
Sequence and the optimized conditions of qRT-PCR and ChIP primers 
Sequence of primers and techniques that used for Temperature of 
A) primers were used in qPCR for mRNA expression  Annealing  Collecting data 
PKCβ 
For:  (5’- TGGGGTGACACCCAAGACATTC-3') 
Rev: (5’- GCTGGATCTCTTTGCGTTCAAG-3')           
58ᴼC 81ᴼC 
Sp1 
For:  (5'-GACGTTGATGCCACTGTTG-GCAAG-3')  
Rev: (5' -TCAAGACCCACCAGAATAAGAAGGGAG-3') 
64ᴼC 80ᴼC 
Sp3 
For:5'-CAGGAGGAACAACGCTTATC-3' 
Rev:5'-TCTCATTTCCAGAAACTGTGAC-3’ 
57ᴼC 80ᴼC 
MITF 
For:  (5'-CTCACAGCGTGTATTTTTCCCACAG-3')  
Rev: (5' -TGGTTCCCTTGTTCCAGCGCATG-3') 
64ᴼC 80ᴼC 
p300 
For:  (5'-CGCTTTGTCTACACCTGCAA-3')  
Rev: (5'-TGCTGGTTGTTGCTCTCATC-3') 
57ᴼC 80ᴼC 
BCL10 
For:  (5'-CCCGCTCCGCCTCCTCTCCTT-3')  
Rev: (5'-GGCGCTTCTTCCGGGTCCGG-3') 
65ᴼC 80ᴼC 
B) Primers were used in qPCR ChIP analysis for the PRKCB promote and the Positive controls primers 
PRKCB promoter proximal region  
For:  (5’-GCACGCTTAGCCGCGAGG-3')  
Rev: (5’-AGCTGCTGCCGCTCGTCC-3') 
56ᴼC 85ᴼC 
PRKCB promoter distal region 
For: (5’-TATTGATCTACTGAAATCCTTCCTC-3')  
Rev: (5'-ATCCCATTGGTCATTCTGCA-3') 
58ᴼC 85ᴼC 
+500bp region of PRKCB Promoter TSS 
For:  (5'-ACTTCATCTGGTGAGCGCGC-3') 
Rev: (5’-AGGACTGTCCATCCGGGAGT-3') 
72ᴼC 85ᴼC 
-500bp region of PRKCB Promoter TSS 
For:  (5'-ACTTCATCTGGTGAGCGCGC-3') 
Rev: (5’-AGGACTGTCCATCCGGGAGT-3') 
64ᴼC 85ᴼC 
DHFR promoter Sp1/Sp3/E2F1 positive primer 
For:  (5’- TCGCCTGCACAAATAGGGAC-3’) 
Rev: (5’-AGAACGCGCGGGTCAAGTTT-3’) 
60ᴼC 85ᴼC 
Nucleolin promoter c-Myc positive primer 
For:  (5’- TTGCGACGCGTACGAGCTGG-3’) 
Rev: (5’-ACTCCGACTAGGGCCGATAC-3’) 
65ᴼC 85ᴼC 
EVI1 promoter RUNX1 positive primer 
For:  (5’- TCACTTCGGACAGTTTCCTG-3’) 
Rev: (5’-CCCGGCTTAGCAACGTAGA-3’) 
58ᴼC 81ᴼC 
c-Fos promoter STAT3 positive primer (Cell Signalling, 
Technology, USA) 
60ᴼC 85ᴼC 
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-Appendix D: 
List of antibodies using in Western blot and ChIP analysis 
Antibody Source dilution Application 
Anti-PKCβII rabbit polyclonal Santa Cruz Biotechnology, Inc, USA 1:20000 W.B 
ChIPAb+
TM
Sp1 rabbit polyclonal MerckMillipore, Watford, UK 1:10000 
5µg 
W.B 
ChIP 
ChIPAb+ Acetyl-Histone H3 rabbit 
polyclonal 
MerckMillipore, Watford, UK 5µg ChIP 
ChIPAb+ Trimethyl- Histone H3 
(Lys4) rabbit monoclonal 
MerckMillipore, Watford, UK 3µL ChIP 
Anti-Sp3 rabbit polyclonal MerckMillipore, Watford, UK 1:5000 
5µg 
W.B 
ChIP 
Anti-c-Myc (N-262)rabbit 
polyclonal 
Santa Cruz Biotechnology, Inc, USA 5µg ChIP 
Anti-c-Myc monoclonal rabbit Cell signalling Technology, USA 1:1000 W.B 
Anti-E2F1 rabbit polyclonal (C-20) Santa Cruz Biotechnology, Inc, USA 1:1000 
2µg 
W.B 
ChIP 
Anti-MITF ChIP grade (ab122982) 
rabbit polyclonal 
Abcam, Cambridge,  UK 1:1000 
1:200 
W.B 
ChIP 
Anti-P300 (N-15) rabbit polyclonal Santa Cruz Biotechnology, Inc, USA 1:1000 
7µl 
W.B 
ChIP 
BCL2 rabbit polyclonal Cell signalling Technology, USA 1:1000 W.B 
ERK1/2 mouse monoclonal Santa Cruz Biotechnology, Inc, USA 1:2000 W.B 
Anti-RUNX1 rabbit polyclonal Calbiochem, UK 5µg ChIP 
 
 
 
 
